<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>HMG CoA reductase inhibitors (statins) for dialysis patients - Palmer, SC - 2013 | Cochrane Library</title> <meta content="HMG CoA reductase inhibitors (statins) for dialysis patients - Palmer, SC - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004289.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="HMG CoA reductase inhibitors (statins) for dialysis patients - Palmer, SC - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004289.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004289.pub5" name="dc.identifier" scheme="DOI"/> <meta content="HMG CoA reductase inhibitors (statins) for dialysis patients" name="citation_title"/> <meta content="Suetonia C Palmer" name="citation_author"/> <meta content="University of Otago Christchurch" name="citation_author_institution"/> <meta content="Sankar D Navaneethan" name="citation_author"/> <meta content="Glickman Urological and Kidney Institute, Cleveland Clinic" name="citation_author_institution"/> <meta content="Jonathan C Craig" name="citation_author"/> <meta content="David W Johnson" name="citation_author"/> <meta content="Princess Alexandra Hospital" name="citation_author_institution"/> <meta content="Vlado Perkovic" name="citation_author"/> <meta content="The George Institute for Global Health" name="citation_author_institution"/> <meta content="Sagar U Nigwekar" name="citation_author"/> <meta content="Harvard Medical School" name="citation_author_institution"/> <meta content="Jorgen Hegbrant" name="citation_author"/> <meta content="Diaverum Renal Services Group" name="citation_author_institution"/> <meta content="Giovanni FM Strippoli" name="citation_author"/> <meta content="strippoli@negrisud.it" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD004289.pub5" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/09/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004289.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004289.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004289.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Renal Dialysis; Cardiovascular Diseases [etiology, mortality, *prevention &amp; control]; Cause of Death; Cholesterol [blood]; Hydroxymethylglutaryl‐CoA Reductase Inhibitors [adverse effects, *therapeutic use]; Hyperlipidemias [*drug therapy]; Kidney Failure, Chronic [complications, *therapy]; Myocardial Infarction [prevention &amp; control]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004289.pub5&amp;doi=10.1002/14651858.CD004289.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="bzu3XIhG";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004289\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004289\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004289\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004289\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ru","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004289.pub5",title:"HMG CoA reductase inhibitors (statins) for dialysis patients",firstPublishedDate:"Sep 11, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=bzu3XIhG&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004289.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004289.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004289.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004289.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004289.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004289.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004289.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004289.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004289.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004289.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3231 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004289.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/full#CD004289-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/full#CD004289-sec-0082"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/full#CD004289-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/full#CD004289-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/full#CD004289-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/full#CD004289-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/full#CD004289-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/full#CD004289-sec-0076"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/appendices#CD004289-sec-0087"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/table_n/CD004289StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/table_n/CD004289StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">HMG CoA reductase inhibitors (statins) for dialysis patients</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/information#CD004289-cr-0002">Suetonia C Palmer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/information#CD004289-cr-0003">Sankar D Navaneethan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/information#CD004289-cr-0004">Jonathan C Craig</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/information#CD004289-cr-0005">David W Johnson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/information#CD004289-cr-0006">Vlado Perkovic</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/information#CD004289-cr-0007">Sagar U Nigwekar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/information#CD004289-cr-0008">Jorgen Hegbrant</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004289.pub5/information#CD004289-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Giovanni FM Strippoli</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/information/en#CD004289-sec-0093">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 September 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004289.pub5">https://doi.org/10.1002/14651858.CD004289.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004289-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004289-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004289-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004289-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD004289-abs-0002">繁體中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004289-abs-0001" lang="en"> <section id="CD004289-sec-0001"> <h3 class="title" id="CD004289-sec-0001">Background</h3> <p>People with advanced kidney disease treated with dialysis experience mortality rates from cardiovascular disease that are substantially higher than for the general population. Studies that have assessed the benefits of statins (HMG CoA reductase inhibitors) report conflicting conclusions for people on dialysis and existing meta‐analyses have not had sufficient power to determine whether the effects of statins vary with severity of kidney disease. Recently, additional data for the effects of statins in dialysis patients have become available. This is an update of a review first published in 2004 and last updated in 2009. </p> </section> <section id="CD004289-sec-0002"> <h3 class="title" id="CD004289-sec-0002">Objectives</h3> <p>To assess the benefits and harms of statin use in adults who require dialysis (haemodialysis or peritoneal dialysis). </p> </section> <section id="CD004289-sec-0003"> <h3 class="title" id="CD004289-sec-0003">Search methods</h3> <p>We searched the Cochrane Renal Group's Specialised Register to 29 February 2012 through contact with the Trials' Search Co‐ordinator using search terms relevant to this review. </p> </section> <section id="CD004289-sec-0004"> <h3 class="title" id="CD004289-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) and quasi‐RCTs that compared the effects of statins with placebo, no treatment, standard care or other statins on mortality, cardiovascular events and treatment‐related toxicity in adults treated with dialysis were sought for inclusion. </p> </section> <section id="CD004289-sec-0005"> <h3 class="title" id="CD004289-sec-0005">Data collection and analysis</h3> <p>Two or more authors independently extracted data and assessed study risk of bias. Treatment effects were summarised using a random‐effects model and subgroup analyses were conducted to explore sources of heterogeneity. Treatment effects were expressed as mean difference (MD) for continuous outcomes and risk ratios (RR) for dichotomous outcomes together with 95% confidence intervals (CI). </p> </section> <section id="CD004289-sec-0006"> <h3 class="title" id="CD004289-sec-0006">Main results</h3> <p>The risk of bias was high in many of the included studies. Random sequence generation and allocation concealment was reported in three (12%) and four studies (16%), respectively. Participants and personnel were blinded in 13 studies (52%), and outcome assessors were blinded in five studies (20%). Complete outcome reporting occurred in nine studies (36%). Adverse events were only reported in nine studies (36%); 11 studies (44%) reported industry funding. </p> <p>We included 25 studies (8289 participants) in this latest update; 23 studies (24 comparisons, 8166 participants) compared statins with placebo or no treatment, and two studies (123 participants) compared statins directly with one or more other statins. Statins had little or no effect on major cardiovascular events (4 studies, 7084 participants: RR 0.95, 95% CI 0.88 to 1.03), all‐cause mortality (13 studies, 4705 participants: RR 0.96, 95% CI 0.90 to 1.02), cardiovascular mortality (13 studies, 4627 participants: RR 0.94, 95% CI 0.84 to 1.06) and myocardial infarction (3 studies, 4047 participants: RR 0.87, 95% CI 0.71 to 1.07); and uncertain effects on stroke (2 studies, 4018 participants: RR 1.29, 95% CI 0.96 to 1.72). </p> <p>Risks of adverse events from statin therapy were uncertain; these included effects on elevated creatine kinase (5 studies, 3067 participants: RR 1.25, 95% CI 0.55 to 2.83) or liver function enzymes (4 studies, 3044 participants; RR 1.09, 95% CI 0.41 to 1.25), withdrawal due to adverse events (9 studies, 1832 participants: RR 1.04, 95% CI 0.87 to 1.25) or cancer (2 studies, 4012 participants: RR 0.90, 95% CI 0.72 to 1.11). Statins reduced total serum cholesterol (14 studies, 1803 participants; MD ‐44.86 mg/dL, 95% CI ‐55.19 to ‐34.53) and low‐density lipoprotein cholesterol (12 studies, 1747 participants: MD ‐39.99 mg/dL, 95% CI ‐52.46 to ‐27.52) levels. Data comparing statin therapy directly with another statin were sparse. </p> </section> <section id="CD004289-sec-0007"> <h3 class="title" id="CD004289-sec-0007">Authors' conclusions</h3> <p>Statins have little or no beneficial effects on mortality or cardiovascular events and uncertain adverse effects in adults treated with dialysis despite clinically relevant reductions in serum cholesterol levels. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004289-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004289-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD004289-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD004289-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004289-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004289-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD004289-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD004289-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004289-abs-0003" lang="en"> <h3>Does statin therapy improve survival or reduce risk of heart disease in people on dialysis? </h3> <p>Adults with severe kidney disease who are treated with dialysis have high risks of developing heart disease. Statin treatment reduces risks of death and complications of heart disease in the general population. </p> <p>In 2009 we identified 14 studies, enrolling 2086 patients, and found that while statins were generally safe and reduced cholesterol levels, they did not prevent death or clinical cardiac events in people treated with dialysis. This latest update analysed a total or 25 studies (8289 patients), and included the results from two new large studies. We found that statins lowered cholesterol in people treated with dialysis but did not prevent death, heart attack, or stroke. </p> <p>Evidence for side‐effects was incomplete, and potential harms from statin therapy remain uncertain. Current study data did not address whether statin treatment should be stopped when a person starts dialysis, although the benefits associated with continued treatment are likely to be small. Limited information was available for people treated with peritoneal dialysis, suggesting that more research is needed in this setting. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004289-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004289-sec-0082"></div> <h3 class="title" id="CD004289-sec-0083">Implications for practice</h3> <section id="CD004289-sec-0083"> <p>Statins have little or no effect on mortality or major cardiovascular outcomes in adults treated with dialysis and cannot be routinely recommended to prevent cardiovascular events in this population. The body of included evidence did not address whether statin treatment should be stopped when a person commences dialysis, although the benefits associated with continued treatment are likely to be small. Risks of adverse events for statins on muscle and liver dysfunction and cancer with statin treatment remain uncertain. Insufficient data are available to understand whether treatment effects differ in the clinical setting of haemodialysis compared to peritoneal dialysis or the effect of statin therapy in patients with established vascular disease or recent vascular event. </p> </section> <h3 class="title" id="CD004289-sec-0084">Implications for research</h3> <section id="CD004289-sec-0084"> <p>Statin therapy consistently provides little or no benefit for people treated with dialysis. Despite some limitations, the evidence is generally moderate to high quality according to GRADE recommendations (<a href="./references#CD004289-bbs2-0065" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [MEDLINE: 18436948] ">Guyatt 2008</a>), indicating further large studies may have an important impact on our confidence in the estimate of effect. Additional data for people treated with peritoneal dialysis would improve our confidence in the effects of therapy in this clinical setting. Well‐designed RCTs of other interventions to reduce cardiovascular morbidity and death in people on dialysis are now required. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004289-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004289-sec-0022"></div> <div class="table" id="CD004289-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Statin versus placebo or no treatment for dialysis patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with chronic kidney disease </p> <p><b>Settings:</b> dialysis </p> <p><b>Intervention:</b> statin therapy </p> <p><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk/year/1000 treated</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk/year/1000 treated</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Statin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major cardiovascular events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000 (7 fewer)</b> <br/> (132 to 155) (18 fewer to 5 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> (0.88 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7804 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>192 per 1000 (8 fewer)</b> <br/> (176 to 208) (24 fewer to 8 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> (0.90 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4705 (13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕</p> <p><b>moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>94 per 1000 (6 fewer)</b> <br/> (82 to 105) (18 fewer to 5 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> (0.84 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4627 (13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕<br/> <b>moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Absolute approximate events rates of outcomes per year were derived from previously observational cohort studies. Absolute numbers of people on dialysis with cardiovascular or mortality events avoided or incurred per 1000 treated were estimated using these assumed risks together with the estimated relative risks and 95% confidence intervals (<a href="./references#CD004289-bbs2-0066" title="HerzogC A , MaJ Z , CollinsA J . Poor long‐term survival after acute myocardial infarction among patients on long‐term dialysis. New England Journal of Medicine1998;339(12):799‐805. [MEDLINE: 9738087] ">Herzog 1998</a>; <a href="./references#CD004289-bbs2-0079" title="TrivediH , XiangQ , KleinJ P . Risk factors for non‐fatal myocardial infarction and cardiac death in incident dialysis patients. Nephrology Dialysis Transplantation2009;24(1):258‐66. [MEDLINE: 18682489] ">Trivedi 2009</a>; <a href="./references#CD004289-bbs2-0081" title="WeinerD E , TabatabaiS , TighiouartH , ElsayedE , BansalN , GriffithJ , et al. Cardiovascular outcomes and all‐cause mortality: exploring the interaction between CKD and cardiovascular disease. American Journal of Kidney Diseases2006;48(3):392‐401. [MEDLINE: 16931212] ">Weiner 2006</a>; <a href="./references#CD004289-bbs2-0082" title="WetmoreJB , ShiremanTI . The ABCs of cardioprotection in dialysis patients: a systematic review. American Journal of Kidney Diseases2009;53(3):457‐66. [MEDLINE: 19022545] ">Wetmore 2009</a>) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004289-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004289-sec-0023"></div> <section id="CD004289-sec-0024"> <h3 class="title" id="CD004289-sec-0024">Description of the condition</h3> <p>Although cardiovascular mortality is decreasing, events among dialysis patients remains 20‐ to 30‐times higher than for the general population (<a href="./references#CD004289-bbs2-0063" title="FoleyRN , CollinsAJ . End‐stage renal disease in the United States: an update from the United States Renal Data System. Journal of the American Society of Nephrology2007;18(10):2644‐8. [MEDLINE: 17656472] ">Foley 2007</a>; <a href="./references#CD004289-bbs2-0067" title="HerzogCA , AsingerRW , BergerAK , CharytanDM , DíezJ , HartRG , et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International2011;80(6):572‐86. [MEDLINE: 21750584] ">Herzog 2011</a>; <a href="./references#CD004289-bbs2-0080" title="United States Renal DataSystem . USRDS 2011 Annual Data Report. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. http://www.usrds.org/2011/pdf/v2_ch04_11.pdf (accessed 24 July 2013). ">USRDS 2011</a>). Elevated circulating lipid levels is one of several factors, that also include hypertension, diabetes, and smoking, that have been implicated in the increased cardiovascular risk associated with chronic kidney disease (CKD) (<a href="./references#CD004289-bbs2-0064" title="GaneshSK , StackAG , LevinNW , Hulbert‐ShearonT , PortFK . Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. Journal of the American Society of Nephrology2001;12(10):2131‐8. [MEDLINE: 11562412] ">Ganesh 2001</a>; <a href="./references#CD004289-bbs2-0070" title="JungersP , MassyZA , KhoaTN , FumeronC , LabrunieM , LacourB , et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrology Dialysis Transplantation1997;12(12):2597‐602. [MEDLINE: 9430858] ">Jungers 1997</a>; <a href="./references#CD004289-bbs2-0072" title="MallamaciF , ZoccaliC , TripepiG , FermoI , BenedettoFA , CataliottiA , et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney International2002;61(2):609‐13. [MEDLINE: 11849403] ">Mallamaci 2002)</a>. </p> </section> <section id="CD004289-sec-0025"> <h3 class="title" id="CD004289-sec-0025">How the intervention might work</h3> <p>Clinical studies conducted in the general population, and in people with established cardiovascular disease, have found a strong, consistent and independent association between lipid lowering, primarily low‐density lipoprotein (LDL) cholesterol, and the risk of all‐cause and cardiovascular mortality (<a href="./references#CD004289-bbs2-0071" title="LawMR , WaldNJ , ThompsonSG . By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?. BMJ1994;308(6925):367‐72. [MEDLINE: 8043072] ">Law 1994</a>; <a href="./references#CD004289-bbs2-0078" title="RossouwJE , LewisB , RifkindBM . The value of lowering cholesterol after myocardial infarction. New England Journal of Medicine1990;323(16):1112‐9. [MEDLINE: 2215579] ">Rossouw 1990</a>). A linear proportional reduction in the risk of major vascular events equal to approximately 20% per 1 mmol/L (39 mg/dL) reduction in LDL cholesterol has been reported (<a href="./references#CD004289-bbs2-0060" title="BaigentC , KeechA , KearneyPM , BlackwellL , BuckG , PollicinoC , et al. Efficacy and safety of cholesterol‐lowering treatment: prospective meta‐analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet2005;366(9493):1267‐78. [MEDLINE: 16214597] ">Baigent 2005</a>). Optimal lowering of serum lipid levels has been anticipated to lower cardiovascular and overall mortality for people treated with dialysis. </p> </section> <section id="CD004289-sec-0026"> <h3 class="title" id="CD004289-sec-0026">Why it is important to do this review</h3> <p>Study data for the benefits of lipid lowering in people on dialysis are increasingly conflicted. Our previous review (<a href="./references#CD004289-bbs2-0085" title="NavaneethanSD , NigwekarSU , PerkovicV , JohnsonDW , CraigJC , StrippoliGF . HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD004289.pub4] ">Navaneethan 2009a</a>) identified little or no benefit from statin therapy on mortality, although one study reported fewer major cardiovascular events in people with diabetes on dialysis (<a href="./references#CD004289-bbs2-0001" title="DrechslerC , KraneV , GrootendorstDC , RitzE , WinklerK , MarzW , et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrology Dialysis Transplantation2009;24(10):3151‐7. [MEDLINE: 19474272] DrechslerC , KraneV , RitzE , MarzW , WannerC . Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation2009;120(24):2421‐8. [MEDLINE: 19948978] DrechslerC , KraneV , WinklerK , DekkerFW , WannerC . Increasing adiponectin is associated with cardiovascular events and mortality in diabetic patients on hemodialysis [abstract]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):727A. KraneV , BergerM , LilienthalJ , WinklerK , SchambeckC , WannerC , et al. Antibodies to platelet factor 4‐heparin complex and outcome in hemodialysis patients with diabetes. Clinical Journal of The American Society of Nephrology: CJASN2010;5(5):874‐81. [MEDLINE: 20185595] KraneV , HeinrichF , MeesmannM , OlschewskiM , LilienthalJ , AngermannC , et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clinical Journal of The American Society of Nephrology: CJASN2009;4(2):394‐400. [MEDLINE: 19158371] KraneV , KrieterDH , OlschewskiM , MaerzW , MannJFE , RitzE , et al. Impact of dialyzer membrane characteristics on outcome in type 2 diabetic patients on maintenance hemodialysis: results of the 4D study [abstract]. Journal of the American Society of Nephrology2006;17(Abstracts):22A. KraneV , MaerzW , RufG , RitzE , WannerC . Atorvastatin in Type 2 diabetic patients on hemodialysis (4D‐study): baseline characteristics and 1st interim analysis [abstract]. Journal of the American Society of Nephrology2003;14(Nov):496A. KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. American Journal of Kidney Diseases2009;54(5):902‐11. [MEDLINE: 19781835] KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International2008;74(11):1461‐7. [MEDLINE: 18818679] MarzW , GenserB , DrechslerC , KraneV , GrammerTB , RitzE , et al. Atorvastatin and low‐density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN2011;6(6):1316‐25. [MEDLINE: 21493741] WannerC , KraneV , MarzW , OlschewskiM , AsmusHG , KramerW , et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney &amp; Blood Pressure Research2004;27(4):259‐66. [MEDLINE: 15316128] WannerC , KraneV , MärzW , OlschewskiM , MannJF , RufG , et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine2005;353(3):238‐48. [MEDLINE: 16034009] WannerC , KraneV , RufG , MarzW , RitzE . Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney International ‐ Supplement1999;56(Suppl 71):S222‐6. [MEDLINE: 10412782] ">4D Study 2004</a>). The Study for Heart and Renal Protection (<a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a>, completed since our last review update), which included 3023 people on dialysis, reported that benefits for lipid‐lowering therapy extended to people with advanced kidney disease on dialysis, whereas the <a href="./references#CD004289-bbs2-0005" title="FellstromB , HoldaasH , JardineAG , RoseH , SchmiederR , WilpshaarW , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney &amp; Blood Pressure Research2007;30(5):314‐22. [MEDLINE: 17671394] FellstromB , HoldaasH , JardineAG , SchmiederRE , HolmeI , ZannadF . Normalisation of CRP and LDL‐C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:218a. FellstromB , JardineAG , HoldaasH , SchmiederR , GottlowM , JohnssonE , et al. Effect of rosuvastatin versus placebo on cardiovascular outcomes in patients with end‐stage renal disease on hemodialysis ‐ results of the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , ArmstrongJ , et al. A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events ‐ the AURORA study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):713. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , RoseH , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients ‐ Design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine2005;6:9. [EMBASE: 2005487466] FellstromBC , JardineAG , SchmiederRE , HoldaasH , BannisterK , BeutlerJ , et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine2009;360(14):1395‐407. [MEDLINE: 19332456] HoldaasH , FellstromB , HolmeI , SchmiederRE , ZannadF , JardineAG . Rosuvastatin and LDL cholesterol in diabetic patients receiving hemodialysis ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:12A. HoldaasH , HolmeI , SchmiederRE , JardineAG , ZannadF , NorbyGE , et al. Rosuvastatin in diabetic hemodialysis patients. Journal of the American Society of Nephrology2011;22(7):1335‐41. [MEDLINE: 21566054] HoldaasH , JardineAG , SchmiederR , GottlowM , JohnssonE , ZannadF , et al. Effect of rosuvastatin on cardiovascular outcomes in diabetic patients receiving hemodialysis ‐ results from the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. JardineAG , FellstromB , HoldaasH , GottlowM , JohnssonE , ZannadF , et al. Risk factors for cardiovascular events in patients receiving haemodialysis ‐ post hoc analyses of the AURORA study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. ">AURORA Study 2005</a> (A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events) conducted with 2776 adults on haemodialysis, found no clear benefit for statin therapy in this population. An advisory committee to the US Food and Drug Administration that considered <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a> study data did not recommend lipid‐lowering using simvastatin/ezetimibe in people on dialysis, citing insufficient evidence (<a href="./references#CD004289-bbs2-0062" title="SmithJP . Clinical Briefing Document. Endocrinologic and Metabolic Drugs Advisory Committee Meeting. November 2, 2011. New Drug Application 21‐687/S‐039:Vytorin (ezetimibe/simvastatin). New Drug Application 21‐445/S‐033:Zetia (ezetimibe). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM277649.pdf (accessed 24 July 2013). ">FDA 2011</a>). </p> <p>In light of conflicting information on the benefits of statin therapy to inform clinical practice and policy in people on dialysis, together with new study data, we conducted an update of our earlier review (<a href="./references#CD004289-bbs2-0085" title="NavaneethanSD , NigwekarSU , PerkovicV , JohnsonDW , CraigJC , StrippoliGF . HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD004289.pub4] ">Navaneethan 2009a</a>) to evaluate the benefits and harms of statin therapy in people on dialysis. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004289-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004289-sec-0027"></div> <p>To evaluate the benefits (reductions in all‐cause mortality, cardiovascular mortality, major cardiovascular events, myocardial infarction and stroke) and harms (liver or muscle damage, or cancer) of statins compared with placebo, no treatment, or another statin in adults who require dialysis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004289-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004289-sec-0028"></div> <section id="CD004289-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004289-sec-0030"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCT) and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable method) of at least 8 weeks' duration that evaluated the benefits and harms of statins in adults treated with haemodialysis or peritoneal dialysis were included. The first periods of randomised cross‐over studies were also included. Studies of fewer than eight weeks' duration were excluded because they were unlikely to enable detection of mortality or cardiovascular outcomes related to statin therapy (<a href="./references#CD004289-bbs2-0061" title="BrielM , SchwartzGG , ThompsonPL , deLemosJA , BlazingMA , vanEsGA , et al. Effects of early treatment with statins on short‐term clinical outcomes in acute coronary syndromes: a meta‐analysis of randomized controlled trials. JAMA2006;295(17):2046‐56. [MEDLINE: 16670413] ">Briel 2006</a>). </p> </section> <section id="CD004289-sec-0031"> <h4 class="title">Types of participants</h4> <section id="CD004289-sec-0032"> <h5 class="title">Inclusion criteria</h5> <p>Adults treated with dialysis (haemodialysis and peritoneal dialysis) irrespective of pre‐existing cardiovascular disease or statin therapy were included. </p> </section> <section id="CD004289-sec-0033"> <h5 class="title">Exclusion criteria</h5> <p>Studies in children were excluded. Studies including adults with CKD not treated with dialysis and recipients of a kidney transplant are the subject of other related reviews (<a href="./references#CD004289-bbs2-0073" title="NavaneethanSD , PansiniF , PerkovicV , MannoC , PellegriniF , JohnsonDW , et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD007784] ">Navaneethan 2009b</a>; <a href="./references#CD004289-bbs2-0074" title="NavaneethanSD , PerkovicV , JohnsonDW , NigwekarSU , CraigJC , StrippoliGF . HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD005019.pub3] ">Navaneethan 2009c</a>; updates in press (<a href="./references#CD004289-bbs2-0076" title="PalmerSC , NavaneethanSD , CraigJC , JohnsonDW , PerkovicV , HegbrantJ , et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews2013, Issue in press. ">Palmer 2013a</a>; <a href="./references#CD004289-bbs2-0077" title="PalmerSC , NavaneethanSD , CraigJC , PerkovicV , JohnsonDW , NigwekarSU , et al. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database of Systematic Reviews2013, Issue in press. ">Palmer 2013b</a>)). </p> </section> </section> <section id="CD004289-sec-0034"> <h4 class="title">Types of interventions</h4> <p>We included studies that compared statins with placebo, no treatment or standard care, or another statin. We excluded studies that compared a statin with a second non‐statin regimen, including fibrate therapy. </p> </section> <section id="CD004289-sec-0035"> <h4 class="title">Types of outcome measures</h4> <section id="CD004289-sec-0036"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD004289-list-0001"> <li> <p>Major cardiovascular events</p> </li> <li> <p>All‐cause mortality</p> </li> <li> <p>Cardiovascular mortality</p> </li> <li> <p>Fatal and non‐fatal myocardial infarction</p> </li> <li> <p>Fatal and non‐fatal stroke</p> </li> <li> <p>Adverse events attributable to interventions</p> <ol id="CD004289-list-0002"> <li> <p>Elevated creatine kinase</p> </li> <li> <p>Elevated liver function enzymes</p> </li> <li> <p>Withdrawal due to adverse events</p> </li> <li> <p>Cancer.</p> </li> </ol> </li> </ol> </p> </section> <section id="CD004289-sec-0037"> <h5 class="title">Secondary outcomes</h5> <p>Lipid parameters (mg/dL)</p> <p> <ol id="CD004289-list-0003"> <li> <p>Serum lipid levels</p> <ol id="CD004289-list-0004"> <li> <p>Total cholesterol</p> </li> <li> <p>LDL cholesterol</p> </li> <li> <p>Triglycerides</p> </li> <li> <p>High‐density lipoprotein (HDL) cholesterol</p> </li> </ol> </li> </ol> </p> </section> </section> </section> <section id="CD004289-sec-0038"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004289-sec-0039"> <h4 class="title">Electronic searches</h4> <section id="CD004289-sec-0040"> <h5 class="title">2013 update</h5> <p>We searched the Cochrane Renal Group's Specialised Register to 29 February 2012 through contact with the Trials' Search Co‐ordinator using search terms relevant to this review. </p> <p>The Cochrane Renal Group’s Specialised Register contains studies identified from the following sources. </p> <p> <ol id="CD004289-list-0005"> <li> <p>Quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of renal‐related journals and the proceedings of major renal conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected renal journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of the Cochrane Renal Group. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts are available in the Specialised Register section of information about the <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Renal Group</a>. </p> <p>See <a href="./appendices#CD004289-sec-0088">Appendix 1</a> for search terms used in strategies for this review. </p> </section> </section> <section id="CD004289-sec-0041"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD004289-list-0006"> <li> <p>Reference lists of relevant clinical practice guidelines, review articles and studies.</p> </li> <li> <p>Letters seeking information about unpublished or incomplete RCTs to investigators known to be involved in previous studies. </p> </li> </ol> </p> </section> </section> <section id="CD004289-sec-0042"> <h3 class="title" id="CD004289-sec-0042">Data collection and analysis</h3> <section id="CD004289-sec-0043"> <h4 class="title">Selection of studies</h4> <p>Two authors independently screened all abstracts retrieved by electronic searches to identify potentially relevant citations for detailed study in full text format. Studies that might have included relevant data or information on studies involving HMG Co‐A reductase inhibitors were retained initially. Studies published in non‐English language journals were translated before assessment for inclusion. </p> </section> <section id="CD004289-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>Two authors independently extracted data from the eligible studies using standard data extraction forms. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was included. Any further information required from the original author was requested and any relevant information obtained was included in the review. Disagreements were resolved in consultation with a third author. </p> <p>Data entry was carried out by the same two authors. Treatment effects were summarised using the random‐effects model but the fixed effects model was also analysed to ensure robustness of the model chosen and susceptibility to outliers. For dichotomous outcomes (cardiovascular events, mortality, and adverse events) treatment effects were summarised as relative risk (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used (lipid parameters), treatment effects were summarised using the mean difference (MD). </p> </section> <section id="CD004289-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by two authors using the risk of bias assessment tool (<a href="./references#CD004289-bbs2-0069" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>; <a href="./appendices#CD004289-sec-0089">Appendix 2</a>). </p> <p> <ul id="CD004289-list-0007"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study (detection bias)? </p> <ul id="CD004289-list-0008"> <li> <p>Participants and personnel</p> </li> <li> <p>Outcome assessors</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> </section> <section id="CD004289-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>Dichotomous outcomes (e.g. fatal and non‐fatal heart attack and stroke) were expressed as risk ratios (RR) with 95% confidence intervals (CI). Risk differences (RD) with 95% confidence intervals were calculated for adverse effects. Continuous outcomes were calculated as mean differences (MD) with 95% CI. </p> </section> <section id="CD004289-sec-0047"> <h4 class="title">Dealing with missing data</h4> <p>Where applicable, study authors were contacted for further information or missing data. Data obtained in this manner were included in our analyses. </p> </section> <section id="CD004289-sec-0048"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was analysed using a Chi² test on N‐1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (<a href="./references#CD004289-bbs2-0068" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity. </p> </section> <section id="CD004289-sec-0049"> <h4 class="title">Assessment of reporting biases</h4> <p>This update included all studies identified in the Cochrane Renal Group's Specialised Register, which is updated regularly with published and unpublished reports identified in congress proceedings. This reduces the risk of publication bias. All reports of a single study were reviewed to ensure that all outcomes were reported to reduce the risk of selection bias. </p> </section> <section id="CD004289-sec-0050"> <h4 class="title">Data synthesis</h4> <p>We summarised evidence quality together with absolute treatment effects for mortality and cardiovascular events based on estimated baseline risks using Grading of Recommendations Assessment Development and Evaluation (GRADE) guidelines (<a href="./full#CD004289-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./references#CD004289-bbs2-0065" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [MEDLINE: 18436948] ">Guyatt 2008</a>). Absolute numbers of people on dialysis with cardiovascular events or adverse events avoided or incurred were estimated using the risk estimate for the outcome (and associated 95% confidence interval) obtained from the corresponding meta‐analysis together with the absolute population risk estimated from previously published observational studies (<a href="./references#CD004289-bbs2-0066" title="HerzogC A , MaJ Z , CollinsA J . Poor long‐term survival after acute myocardial infarction among patients on long‐term dialysis. New England Journal of Medicine1998;339(12):799‐805. [MEDLINE: 9738087] ">Herzog 1998</a>; <a href="./references#CD004289-bbs2-0079" title="TrivediH , XiangQ , KleinJ P . Risk factors for non‐fatal myocardial infarction and cardiac death in incident dialysis patients. Nephrology Dialysis Transplantation2009;24(1):258‐66. [MEDLINE: 18682489] ">Trivedi 2009</a>; <a href="./references#CD004289-bbs2-0081" title="WeinerD E , TabatabaiS , TighiouartH , ElsayedE , BansalN , GriffithJ , et al. Cardiovascular outcomes and all‐cause mortality: exploring the interaction between CKD and cardiovascular disease. American Journal of Kidney Diseases2006;48(3):392‐401. [MEDLINE: 16931212] ">Weiner 2006</a>; <a href="./references#CD004289-bbs2-0082" title="WetmoreJB , ShiremanTI . The ABCs of cardioprotection in dialysis patients: a systematic review. American Journal of Kidney Diseases2009;53(3):457‐66. [MEDLINE: 19022545] ">Wetmore 2009</a>). </p> </section> <section id="CD004289-sec-0051"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We conducted subgroup analyses to explore potential sources of heterogeneity in modifying estimates of the effects of statins in the studies. We planned subgroup analyses according to participant type, intervention, or study‐related characteristics, when subgroups contained four or more independent studies: dialysis type (peritoneal or haemodialysis); statin type; statin dose (equivalent to simvastatin); baseline cholesterol (&lt; 230 mg/dL versus ≥ 230 mg/dL); age (≤ 55 years versus &gt; 56 years); proportion with diabetes (&gt; 20% versus &lt; 20%); adequacy of allocation concealment. Insufficient numbers of studies reporting one or more events were available to explore for publication bias using visual inspection of an inverted funnel plot or formal statistical analysis. </p> </section> <section id="CD004289-sec-0052"> <h4 class="title">Sensitivity analysis</h4> <p>Where a study's results differed considerably from other studies in a meta‐analysis, exclusion of the study was investigated to determine whether this altered the result of the meta‐analysis. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004289-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004289-sec-0053"></div> <section id="CD004289-sec-0054"> <h3 class="title">Description of studies</h3> <section id="CD004289-sec-0055"> <h4 class="title">Results of the search</h4> <section id="CD004289-sec-0056"> <h5 class="title">Initial review (2004) and first update (2009)</h5> <p>The searches identified 88 reports in 2004 and 115 reports in 2009. After title and abstract screening 67 (2004) and 97 (2009) reports were excluded. Full text assessment resulted in six studies (7 reports, 357 participants) included in our initial 2004 review and 14 studies (32 reports, 2086 participants) included in the 2009 update. Two studies reported as ongoing in 2004 and 2009 (<a href="./references#CD004289-bbs2-0005" title="FellstromB , HoldaasH , JardineAG , RoseH , SchmiederR , WilpshaarW , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney &amp; Blood Pressure Research2007;30(5):314‐22. [MEDLINE: 17671394] FellstromB , HoldaasH , JardineAG , SchmiederRE , HolmeI , ZannadF . Normalisation of CRP and LDL‐C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:218a. FellstromB , JardineAG , HoldaasH , SchmiederR , GottlowM , JohnssonE , et al. Effect of rosuvastatin versus placebo on cardiovascular outcomes in patients with end‐stage renal disease on hemodialysis ‐ results of the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , ArmstrongJ , et al. A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events ‐ the AURORA study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):713. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , RoseH , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients ‐ Design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine2005;6:9. [EMBASE: 2005487466] FellstromBC , JardineAG , SchmiederRE , HoldaasH , BannisterK , BeutlerJ , et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine2009;360(14):1395‐407. [MEDLINE: 19332456] HoldaasH , FellstromB , HolmeI , SchmiederRE , ZannadF , JardineAG . Rosuvastatin and LDL cholesterol in diabetic patients receiving hemodialysis ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:12A. HoldaasH , HolmeI , SchmiederRE , JardineAG , ZannadF , NorbyGE , et al. Rosuvastatin in diabetic hemodialysis patients. Journal of the American Society of Nephrology2011;22(7):1335‐41. [MEDLINE: 21566054] HoldaasH , JardineAG , SchmiederR , GottlowM , JohnssonE , ZannadF , et al. Effect of rosuvastatin on cardiovascular outcomes in diabetic patients receiving hemodialysis ‐ results from the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. JardineAG , FellstromB , HoldaasH , GottlowM , JohnssonE , ZannadF , et al. Risk factors for cardiovascular events in patients receiving haemodialysis ‐ post hoc analyses of the AURORA study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. ">AURORA Study 2005</a>; <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a>) have been included in our 2013 update. </p> </section> <section id="CD004289-sec-0057"> <h5 class="title">2013 review update</h5> <p>Electronic searching to February 2012 identified 71 additional records. Of these, 33 were duplicate reports of existing studies and four were ongoing studies. After full‐text assessment, a study by Joy 2008 included in our 2009 review update was considered to be a part of <a href="./references#CD004289-bbs2-0009" title="Dornbrook‐LavenderKA , JoyMS , Denu‐CioccaCJ , ChinH , HoganSL , PieperJA . Effects of atorvastatin on low‐density lipoprotein cholesterol phenotype and C‐reactive protein levels in patients undergoing long‐term dialysis. Pharmacotherapy2005;25(3):335‐44. [MEDLINE: 15843280] JoyMS , Dornbrook‐LavenderKA , ChinH , HoganSL , Denu‐CioccaC . Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients. Annals of Pharmacotherapy2008;42(1):9‐15. [MEDLINE: 18000162] JoyMS , Dornbrook‐LavenderKA , ChinH , HoganSL , Denu‐CioccaCJ . Atorvastatin can safely and effectively improve cholesterol and contemporary measures of cardiovascular risks in hemodialysis patients [abstract]. Journal of the American Society of Nephrology2004;15(Oct):615A. ">Dornbrook‐Lavender 2005</a>. We also removed <a href="./references#CD004289-bbs2-0034" title="FioriniF , PatroneE , CastelluccioA . Clinical investigation on the hypolipidemic effect of simvastatin versus probucol in hemodialysis patients. Clinica Terapeutica1994;145(9):213‐7. [MEDLINE: 7813167] ">Fiorini 1994</a> because it did not evaluate a statin versus another statin, placebo, or no treatment; and <a href="./references#CD004289-bbs2-0032" title="DograG , IrishA , ChanD , WattsG . A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. American Journal of Kidney Diseases2007;49(6):776‐85. [MEDLINE: 17533020] DograS , KanganasC , ChanD , IrishA , WattsG . Effect of statin and fibrate therapy on vascular function in chronic kidney disease (CKD) [abstract]. Nephrology2005;10(Suppl 3):A422. ">Dogra 2007</a>, because treatment duration was only six weeks. This meant that 11 unique studies were retained from the 2009 published review (<a href="./references#CD004289-bbs2-0085" title="NavaneethanSD , NigwekarSU , PerkovicV , JohnsonDW , CraigJC , StrippoliGF . HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD004289.pub4] ">Navaneethan 2009a</a>). </p> <p>After detailed assessment of the remaining reports, 25 studies (14 new eligible studies) were identified. The flow chart for the review process is shown in <a href="#CD004289-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD004289-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study selection flow diagram" data-id="CD004289-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study selection flow diagram</p> </div> </div> </div> </section> </section> <section id="CD004289-sec-0058"> <h4 class="title">Included studies</h4> <p>This review included 25 studies that involved 8289 participants. One study included relevant subsets of haemodialysis and peritoneal dialysis patient data and for purpose of the analyses have been identified as <a href="./references#CD004289-bbs2-0015" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi HD 2002</a> and <a href="./references#CD004289-bbs2-0016" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi PD 2002</a> respectively. </p> <p>There were 14 new studies included in this update (<a href="./references#CD004289-bbs2-0002" title="AhmadiFI , EslamiK , MaziarS , Lessan‐PezeshkiM , KhatamiMR , Mahdavi‐mazdehM , et al. Effect of lovastatin on high‐sensitivity C‐reactive protein and hemoglobin in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv229. AhmadiFL , EslamiK , MaziarS , Lessan‐PezeshkiM , Reza‐KhatamiM , Mahdavi‐mazdehM , et al. Effect of lovastatin on C‐reactive protein and hemoglobin in hemodialysis patients [abstract]. Nephrology2005;10(Suppl):A283‐4. ">Ahmadi 2005</a>; <a href="./references#CD004289-bbs2-0003" title="AngelJR , RojasE , delCampoFM , NavaD , Cueto‐ManzanoA . Effect of pravastatin on inflammatory status of CAPD patients: a randomized, double‐blinded, controlled and cross‐over clinical trial [abstract]. Journal of the American Society of Nephrology2007;18(Abstracts):270A. ZunigaJ , Rojas‐CamposE , delCampoFM , NavaD , Cueto‐ManzanoA . Effect of pravastatin on the inflammatory status of CAPD patients: a randomized, double‐blinded, controlled and cross‐over clinical trial [abstract]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi301. ">Angel 2007</a>; <a href="./references#CD004289-bbs2-0004" title="ArabulM , GulluluM , YilmazY , AkdagI , KahveciogluS , ErenMA , et al. Effect of fluvastatin on serum prohepcidin levels in patients with end‐stage renal disease. Clinical Biochemistry2008;41(13):1055‐8. [MEDLINE: 18571502] ">Arabul 2008</a>; <a href="./references#CD004289-bbs2-0005" title="FellstromB , HoldaasH , JardineAG , RoseH , SchmiederR , WilpshaarW , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney &amp; Blood Pressure Research2007;30(5):314‐22. [MEDLINE: 17671394] FellstromB , HoldaasH , JardineAG , SchmiederRE , HolmeI , ZannadF . Normalisation of CRP and LDL‐C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:218a. FellstromB , JardineAG , HoldaasH , SchmiederR , GottlowM , JohnssonE , et al. Effect of rosuvastatin versus placebo on cardiovascular outcomes in patients with end‐stage renal disease on hemodialysis ‐ results of the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , ArmstrongJ , et al. A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events ‐ the AURORA study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):713. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , RoseH , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients ‐ Design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine2005;6:9. [EMBASE: 2005487466] FellstromBC , JardineAG , SchmiederRE , HoldaasH , BannisterK , BeutlerJ , et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine2009;360(14):1395‐407. [MEDLINE: 19332456] HoldaasH , FellstromB , HolmeI , SchmiederRE , ZannadF , JardineAG . Rosuvastatin and LDL cholesterol in diabetic patients receiving hemodialysis ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:12A. HoldaasH , HolmeI , SchmiederRE , JardineAG , ZannadF , NorbyGE , et al. Rosuvastatin in diabetic hemodialysis patients. Journal of the American Society of Nephrology2011;22(7):1335‐41. [MEDLINE: 21566054] HoldaasH , JardineAG , SchmiederR , GottlowM , JohnssonE , ZannadF , et al. Effect of rosuvastatin on cardiovascular outcomes in diabetic patients receiving hemodialysis ‐ results from the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. JardineAG , FellstromB , HoldaasH , GottlowM , JohnssonE , ZannadF , et al. Risk factors for cardiovascular events in patients receiving haemodialysis ‐ post hoc analyses of the AURORA study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. ">AURORA Study 2005</a>; <a href="./references#CD004289-bbs2-0006" title="BurmeisterJE , MiltersteinerDR , CamposBM . Rosuvastatin in hemodialysis: short‐term effects on lipids and C‐reactive protein. Journal of Nephrology2009;22(1):83‐89. [MEDLINE: 19229822] BurmeisterJE , MiltersteinerDR , CostaMG , CamposBM . Short‐term results of rosuvastatin therapy over lipid profile and hs‐C‐reactive protein in patients on regular hemodialysis [abstract]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv472. ">Burmeister 2006</a>; <a href="./references#CD004289-bbs2-0010" title="HanSH , KangEW , YoonSJ , LeeHC , YooTH , ChoiKH , et al. Combined vascular effects of HMG‐CoA reductase inhibitor and angiotensin receptor blocker in non‐diabetic patients undergoing peritoneal dialysis. Nephrology Dialysis Transplantation2011;26(11):3722‐8. [MEDLINE: 21385862] ">Han 2011</a>; <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a>; <a href="./references#CD004289-bbs2-0018" title="SoliemaniA , NikoueinejadH , TabatabaizadeM , MianehsazE , TamadonM . Effect of hydroxymethylglutaryl‐CoA reductase inhibitors on low‐density lipoprotein cholesterol, interleukin‐6, and high‐sensitivity C‐reactive protein in end‐stage renal disease. Iranian journal of Kidney Diseases2011;5(1):29‐33. [MEDLINE: 21189431] ">Soliemani 2011</a>; <a href="./references#CD004289-bbs2-0020" title="TseKC , YungS , TangCS , TamS , LaiKN , ChanTM . Atorvastatin at conventional dose did not reduce C‐reactive protein in patients on peritoneal dialysis. Journal of Nephrology2008;21(3):283. [MEDLINE: 18587714] ">Tse 2008</a>; <a href="./references#CD004289-bbs2-0022" title="van denAkkerJM , BredieSJ , DiepenveenSH , vanTitsLJ , StalenhoefAF , vanLeusenR . Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C‐reactive protein and in vivo oxidized LDL. Journal of Nephrology2003;16(2):238‐44. [MEDLINE: 12768071] ">van den Akker 2003</a>; <a href="./references#CD004289-bbs2-0023" title="VareesangthipK , LaouthaiwattanaP , HanlakornP , SuwannatonL , LarpkitkachornR , ChuawattanaD , et al. Effects of simvastatin on the kinetics of erythrocyte sodium lithium countertransport and C‐reactive protein in hemodialysis patients [abstract]. Journal of the American Society of Nephrology2005;16:276A. ">Vareesangthip 2005</a>; <a href="./references#CD004289-bbs2-0024" title="Velickovic‐RadovanovicR , AvramovicM , MalobabicZ , DjordjevicV , KosticS , MiticB . Therapeutic effects of simvastatin on hyperlipidemia in uraemic patients on CAPD [abstract]. Nephrology Dialysis Transplantation1997;12(9):A187. ">Velickovic 1997</a>; <a href="./references#CD004289-bbs2-0025" title="VernaglioneL , CristofanoC , MuscogiuriP , ChimientiS . Does atorvastatin influence serum C‐reactive protein levels in patients on long‐term hemodialysis?. American Journal of Kidney Diseases2004;43(3):471‐8. [MEDLINE: 14981605] VernaglioneL , CristofanoC , MuscogiuriP , PennacchiottiF , ChimientiS . Analysis of the impact of atorvastatin (ATO) on c‐reactive protein (CRP) levels in haemodialysis patients (HDP) [abstract]. Journal of the American Society of Nephrology2003;14(Nov):41A. VernaglioneL , CristofanoC , PennacchiottiF , MuscogiuriP , ChimientiS . Effects of atorvastatin (ATO) on C‐reactive protein (CRP) levels in haemodialysis patients (HDP) : a prospective study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):712‐3. ">Vernaglione 2003</a>; <a href="./references#CD004289-bbs2-0026" title="YuMH , LeeJH , MinWK , ChiHS , ChangJW , YangWS , et al. Effects of ezetimibe and ezetimibe plus simvastatin (Vytorin®) on markers for inflammation and thrombogenesis in end‐stage renal disease (ESRD) patients [abstract]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi322. ">Yu 2007</a>). Of these, two (<a href="./references#CD004289-bbs2-0005" title="FellstromB , HoldaasH , JardineAG , RoseH , SchmiederR , WilpshaarW , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney &amp; Blood Pressure Research2007;30(5):314‐22. [MEDLINE: 17671394] FellstromB , HoldaasH , JardineAG , SchmiederRE , HolmeI , ZannadF . Normalisation of CRP and LDL‐C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:218a. FellstromB , JardineAG , HoldaasH , SchmiederR , GottlowM , JohnssonE , et al. Effect of rosuvastatin versus placebo on cardiovascular outcomes in patients with end‐stage renal disease on hemodialysis ‐ results of the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , ArmstrongJ , et al. A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events ‐ the AURORA study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):713. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , RoseH , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients ‐ Design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine2005;6:9. [EMBASE: 2005487466] FellstromBC , JardineAG , SchmiederRE , HoldaasH , BannisterK , BeutlerJ , et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine2009;360(14):1395‐407. [MEDLINE: 19332456] HoldaasH , FellstromB , HolmeI , SchmiederRE , ZannadF , JardineAG . Rosuvastatin and LDL cholesterol in diabetic patients receiving hemodialysis ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:12A. HoldaasH , HolmeI , SchmiederRE , JardineAG , ZannadF , NorbyGE , et al. Rosuvastatin in diabetic hemodialysis patients. Journal of the American Society of Nephrology2011;22(7):1335‐41. [MEDLINE: 21566054] HoldaasH , JardineAG , SchmiederR , GottlowM , JohnssonE , ZannadF , et al. Effect of rosuvastatin on cardiovascular outcomes in diabetic patients receiving hemodialysis ‐ results from the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. JardineAG , FellstromB , HoldaasH , GottlowM , JohnssonE , ZannadF , et al. Risk factors for cardiovascular events in patients receiving haemodialysis ‐ post hoc analyses of the AURORA study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. ">AURORA Study 2005</a>; <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a>) were identified as ongoing studies in our 2009 review. </p> <p>There were 23 studies (8166 participants) that compared statins with placebo or no treatment (<a href="./references#CD004289-bbs2-0001" title="DrechslerC , KraneV , GrootendorstDC , RitzE , WinklerK , MarzW , et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrology Dialysis Transplantation2009;24(10):3151‐7. [MEDLINE: 19474272] DrechslerC , KraneV , RitzE , MarzW , WannerC . Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation2009;120(24):2421‐8. [MEDLINE: 19948978] DrechslerC , KraneV , WinklerK , DekkerFW , WannerC . Increasing adiponectin is associated with cardiovascular events and mortality in diabetic patients on hemodialysis [abstract]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):727A. KraneV , BergerM , LilienthalJ , WinklerK , SchambeckC , WannerC , et al. Antibodies to platelet factor 4‐heparin complex and outcome in hemodialysis patients with diabetes. Clinical Journal of The American Society of Nephrology: CJASN2010;5(5):874‐81. [MEDLINE: 20185595] KraneV , HeinrichF , MeesmannM , OlschewskiM , LilienthalJ , AngermannC , et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clinical Journal of The American Society of Nephrology: CJASN2009;4(2):394‐400. [MEDLINE: 19158371] KraneV , KrieterDH , OlschewskiM , MaerzW , MannJFE , RitzE , et al. Impact of dialyzer membrane characteristics on outcome in type 2 diabetic patients on maintenance hemodialysis: results of the 4D study [abstract]. Journal of the American Society of Nephrology2006;17(Abstracts):22A. KraneV , MaerzW , RufG , RitzE , WannerC . Atorvastatin in Type 2 diabetic patients on hemodialysis (4D‐study): baseline characteristics and 1st interim analysis [abstract]. Journal of the American Society of Nephrology2003;14(Nov):496A. KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. American Journal of Kidney Diseases2009;54(5):902‐11. [MEDLINE: 19781835] KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International2008;74(11):1461‐7. [MEDLINE: 18818679] MarzW , GenserB , DrechslerC , KraneV , GrammerTB , RitzE , et al. Atorvastatin and low‐density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN2011;6(6):1316‐25. [MEDLINE: 21493741] WannerC , KraneV , MarzW , OlschewskiM , AsmusHG , KramerW , et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney &amp; Blood Pressure Research2004;27(4):259‐66. [MEDLINE: 15316128] WannerC , KraneV , MärzW , OlschewskiM , MannJF , RufG , et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine2005;353(3):238‐48. [MEDLINE: 16034009] WannerC , KraneV , RufG , MarzW , RitzE . Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney International ‐ Supplement1999;56(Suppl 71):S222‐6. [MEDLINE: 10412782] ">4D Study 2004</a>; <a href="./references#CD004289-bbs2-0002" title="AhmadiFI , EslamiK , MaziarS , Lessan‐PezeshkiM , KhatamiMR , Mahdavi‐mazdehM , et al. Effect of lovastatin on high‐sensitivity C‐reactive protein and hemoglobin in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv229. AhmadiFL , EslamiK , MaziarS , Lessan‐PezeshkiM , Reza‐KhatamiM , Mahdavi‐mazdehM , et al. Effect of lovastatin on C‐reactive protein and hemoglobin in hemodialysis patients [abstract]. Nephrology2005;10(Suppl):A283‐4. ">Ahmadi 2005</a>; <a href="./references#CD004289-bbs2-0003" title="AngelJR , RojasE , delCampoFM , NavaD , Cueto‐ManzanoA . Effect of pravastatin on inflammatory status of CAPD patients: a randomized, double‐blinded, controlled and cross‐over clinical trial [abstract]. Journal of the American Society of Nephrology2007;18(Abstracts):270A. ZunigaJ , Rojas‐CamposE , delCampoFM , NavaD , Cueto‐ManzanoA . Effect of pravastatin on the inflammatory status of CAPD patients: a randomized, double‐blinded, controlled and cross‐over clinical trial [abstract]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi301. ">Angel 2007</a>; <a href="./references#CD004289-bbs2-0004" title="ArabulM , GulluluM , YilmazY , AkdagI , KahveciogluS , ErenMA , et al. Effect of fluvastatin on serum prohepcidin levels in patients with end‐stage renal disease. Clinical Biochemistry2008;41(13):1055‐8. [MEDLINE: 18571502] ">Arabul 2008</a>; <a href="./references#CD004289-bbs2-0005" title="FellstromB , HoldaasH , JardineAG , RoseH , SchmiederR , WilpshaarW , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney &amp; Blood Pressure Research2007;30(5):314‐22. [MEDLINE: 17671394] FellstromB , HoldaasH , JardineAG , SchmiederRE , HolmeI , ZannadF . Normalisation of CRP and LDL‐C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:218a. FellstromB , JardineAG , HoldaasH , SchmiederR , GottlowM , JohnssonE , et al. Effect of rosuvastatin versus placebo on cardiovascular outcomes in patients with end‐stage renal disease on hemodialysis ‐ results of the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , ArmstrongJ , et al. A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events ‐ the AURORA study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):713. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , RoseH , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients ‐ Design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine2005;6:9. [EMBASE: 2005487466] FellstromBC , JardineAG , SchmiederRE , HoldaasH , BannisterK , BeutlerJ , et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine2009;360(14):1395‐407. [MEDLINE: 19332456] HoldaasH , FellstromB , HolmeI , SchmiederRE , ZannadF , JardineAG . Rosuvastatin and LDL cholesterol in diabetic patients receiving hemodialysis ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:12A. HoldaasH , HolmeI , SchmiederRE , JardineAG , ZannadF , NorbyGE , et al. Rosuvastatin in diabetic hemodialysis patients. Journal of the American Society of Nephrology2011;22(7):1335‐41. [MEDLINE: 21566054] HoldaasH , JardineAG , SchmiederR , GottlowM , JohnssonE , ZannadF , et al. Effect of rosuvastatin on cardiovascular outcomes in diabetic patients receiving hemodialysis ‐ results from the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. JardineAG , FellstromB , HoldaasH , GottlowM , JohnssonE , ZannadF , et al. Risk factors for cardiovascular events in patients receiving haemodialysis ‐ post hoc analyses of the AURORA study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. ">AURORA Study 2005</a>; <a href="./references#CD004289-bbs2-0006" title="BurmeisterJE , MiltersteinerDR , CamposBM . Rosuvastatin in hemodialysis: short‐term effects on lipids and C‐reactive protein. Journal of Nephrology2009;22(1):83‐89. [MEDLINE: 19229822] BurmeisterJE , MiltersteinerDR , CostaMG , CamposBM . Short‐term results of rosuvastatin therapy over lipid profile and hs‐C‐reactive protein in patients on regular hemodialysis [abstract]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv472. ">Burmeister 2006</a>; <a href="./references#CD004289-bbs2-0007" title="ChangJW , LeeMS , KinSB , YangWS , ParkSK , LeeSK , et al. Simvastatin decreased high‐sensitive c‐reactive protein (hs‐CRP) and increased serum albumin in hemodialysis (HD) patients [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):353A. ChangJW , YangWS , MinWK , LeeSK , ParkJS , KimSB . Effects of simvastatin on high‐sensitivity C‐reactive protein and serum albumin in hemodialysis patients. American Journal of Kidney Diseases2002;39(6):1213‐7. [MEDLINE: 12046033] ">Chang 2002</a>; <a href="./references#CD004289-bbs2-0008" title="BiloHJ , DiepeveenSJ , VerhoevenGH , van derPalenJ , DikkescheiBD , et al. Vitaestat 1: alpha‐tocopherol and atorvastatin in HD‐ and PD‐ patients: a short‐term, prospective randomised placebo‐controlled intervention trial [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):191A. DiepeveenSH , VerhoevenGH , van derPalenJ , DikkescheiLD , DenmackerPN , KolstersG , et al. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised‐controlled trial. Journal of Internal Medicine2005;257(5):438‐45. [MEDLINE: 15836660] DiepeveenSH , VerhoevenGH , van derPalenJ , DikkescheiLD , DenmackerPN , KolstersG , et al. Vitaestat 1: a prospective randomised placebo controlled trial with a‐tocoferol and atorvastatin in patients in hemo‐ and peritoneal dialysis [abstract]. Nephrology Dialysis Transplantation2001;16(6):A87. ">Diepeveen 2005</a>; <a href="./references#CD004289-bbs2-0009" title="Dornbrook‐LavenderKA , JoyMS , Denu‐CioccaCJ , ChinH , HoganSL , PieperJA . Effects of atorvastatin on low‐density lipoprotein cholesterol phenotype and C‐reactive protein levels in patients undergoing long‐term dialysis. Pharmacotherapy2005;25(3):335‐44. [MEDLINE: 15843280] JoyMS , Dornbrook‐LavenderKA , ChinH , HoganSL , Denu‐CioccaC . Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients. Annals of Pharmacotherapy2008;42(1):9‐15. [MEDLINE: 18000162] JoyMS , Dornbrook‐LavenderKA , ChinH , HoganSL , Denu‐CioccaCJ . Atorvastatin can safely and effectively improve cholesterol and contemporary measures of cardiovascular risks in hemodialysis patients [abstract]. Journal of the American Society of Nephrology2004;15(Oct):615A. ">Dornbrook‐Lavender 2005</a>; <a href="./references#CD004289-bbs2-0010" title="HanSH , KangEW , YoonSJ , LeeHC , YooTH , ChoiKH , et al. Combined vascular effects of HMG‐CoA reductase inhibitor and angiotensin receptor blocker in non‐diabetic patients undergoing peritoneal dialysis. Nephrology Dialysis Transplantation2011;26(11):3722‐8. [MEDLINE: 21385862] ">Han 2011</a>; <a href="./references#CD004289-bbs2-0011" title="HarrisKP , WheelerDC , ChongCC , Atorvastatin in CAPD Study Investigators. A placebo controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney International2002;61(4):1469‐74. [MEDLINE: 11918754] WheelerD , HarrisKP , UK CAPD Investigators. A placebo‐controlled trial examining the efficacy and safety of atorvastatin in dyslipidaemic patients undergoing CAPD [abstract]. Nephrology Dialysis Transplantation2001;16(6):A196. ">Harris 2002</a>; <a href="./references#CD004289-bbs2-0012" title="IchiharaA , HayashiM , RyuzakiM , HandaM , FurukawaT , SarutaT . Effects of fluvastatin on leg arterial stiffness in hemodialysis patients with type 2 diabetes mellitus [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):148A. IchiharaA , HayashiM , RyuzakiM , HandaM , FurukawaT , SarutaT . Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrology Dialysis Transplantation2002;17(8):1513‐7. [MEDLINE: 12147804] ">Ichihara 2002</a>; <a href="./references#CD004289-bbs2-0013" title="LinsRL , CarpentierYA , Clinical Investigators Study Group. Plasma lipids and liporoteins during atorvastatin (ATVS) up‐titration in hemodialysis patients with hyperlipidemia: a placebo‐controlled study [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):124. LinsRL , MatthysKE , BilliouwJM , DratwaM , DupontP , LameireNH , et al. Lipid and apoprotein changes during atorvastatin up‐titration in hemodialysis patients with hypercholesterolemia: a placebo‐controlled study. Clinical Nephrology2004;62(4):287‐94. [MEDLINE: 15524059] ">Lins 2004</a>; <a href="./references#CD004289-bbs2-0014" title="CollinsJF , RobsonR , MacMahonS , BaileyRR , PERFECT Study Group. Safety and efficacy of enalapril and simvastatin in dialysis patients [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5‐9; Hong Kong. 1995:144. RobsonR , CollinsJ , JohnsonR , KitchingR , SearleM , WalkerR , et al. Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. Journal of Nephrology1997;10(1):33‐40. [MEDLINE: 9241623] RobsonR , CollinsJ , KitchingsR , SearleM , WalkerR , SharpeN , et al. A randomized controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. Journal of the American Society of Nephrology1994;5(3):526. RobsonRA , CollinsJ , WalkerRJ , MacMahonS . A randomised controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid (Spain). 1995:530. WalkerRJ , SutherlandWH , WalkerH . Simvastatin and cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid (Spain). 1995:529. WalkerRJ , SutherlandWH , WalkerH , RobsonRA , MacMahonSA . The effects of simvastatin and enalapril on plasma cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5‐9; Hong Kong. 1995:28. WalkerRJ , SutherlandWH , WalkerHL , MacMahonS , RobsonRA . Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT Study Collaborative Group. Nephrology Dialysis Transplantation1997;12(1):87‐92. [MEDLINE: 9027779] ">PERFECT Study 1997</a>; <a href="./references#CD004289-bbs2-0015" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi HD 2002</a>‐<a href="./references#CD004289-bbs2-0016" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi PD 2002</a>; <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a>; <a href="./references#CD004289-bbs2-0019" title="HolmbergB , BrannstromM , BuchtB , CrougneauV , DimenyE , EkspongA , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):503‐10. [MEDLINE: 16303728] StegmayrBG , BrannstromM , BuchtS , DimenyE , EkspongA , GranrothB , et al. Safety and efficacy of atorvastatin in patients with impaired renal function [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna (Austria). 2001:134. StegmayrBG , BrännströmM , BuchtS , CrougneauV , DimenyE , EkspongA , et al. Low‐dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):489‐97. [MEDLINE: 18161210] StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GoschJ , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):161A. StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GranrothB , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):268A. ">Stegmayr 2005</a>; <a href="./references#CD004289-bbs2-0020" title="TseKC , YungS , TangCS , TamS , LaiKN , ChanTM . Atorvastatin at conventional dose did not reduce C‐reactive protein in patients on peritoneal dialysis. Journal of Nephrology2008;21(3):283. [MEDLINE: 18587714] ">Tse 2008</a>; <a href="./references#CD004289-bbs2-0021" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK‐HARP‐I) study: biochemical efficacy and safety of simvastatin and safety of low‐dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473‐84. [MEDLINE: 15754269] BaigentC , UK‐HARP Steering Committee. Efficacy and safety of simvastatin and safety of low‐dose aspirin among patients with chronic kidney disease: final results of the first UK‐heart and renal protection (UK‐HARP‐I) study [abstract]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. ">UK‐HARP‐I 2005</a>; <a href="./references#CD004289-bbs2-0023" title="VareesangthipK , LaouthaiwattanaP , HanlakornP , SuwannatonL , LarpkitkachornR , ChuawattanaD , et al. Effects of simvastatin on the kinetics of erythrocyte sodium lithium countertransport and C‐reactive protein in hemodialysis patients [abstract]. Journal of the American Society of Nephrology2005;16:276A. ">Vareesangthip 2005</a>; <a href="./references#CD004289-bbs2-0024" title="Velickovic‐RadovanovicR , AvramovicM , MalobabicZ , DjordjevicV , KosticS , MiticB . Therapeutic effects of simvastatin on hyperlipidemia in uraemic patients on CAPD [abstract]. Nephrology Dialysis Transplantation1997;12(9):A187. ">Velickovic 1997</a>; <a href="./references#CD004289-bbs2-0025" title="VernaglioneL , CristofanoC , MuscogiuriP , ChimientiS . Does atorvastatin influence serum C‐reactive protein levels in patients on long‐term hemodialysis?. American Journal of Kidney Diseases2004;43(3):471‐8. [MEDLINE: 14981605] VernaglioneL , CristofanoC , MuscogiuriP , PennacchiottiF , ChimientiS . Analysis of the impact of atorvastatin (ATO) on c‐reactive protein (CRP) levels in haemodialysis patients (HDP) [abstract]. Journal of the American Society of Nephrology2003;14(Nov):41A. VernaglioneL , CristofanoC , PennacchiottiF , MuscogiuriP , ChimientiS . Effects of atorvastatin (ATO) on C‐reactive protein (CRP) levels in haemodialysis patients (HDP) : a prospective study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):712‐3. ">Vernaglione 2003</a>;<a href="./references#CD004289-bbs2-0026" title="YuMH , LeeJH , MinWK , ChiHS , ChangJW , YangWS , et al. Effects of ezetimibe and ezetimibe plus simvastatin (Vytorin®) on markers for inflammation and thrombogenesis in end‐stage renal disease (ESRD) patients [abstract]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi322. ">Yu 2007</a>), and two (123 participants) directly compared two or more statins (<a href="./references#CD004289-bbs2-0018" title="SoliemaniA , NikoueinejadH , TabatabaizadeM , MianehsazE , TamadonM . Effect of hydroxymethylglutaryl‐CoA reductase inhibitors on low‐density lipoprotein cholesterol, interleukin‐6, and high‐sensitivity C‐reactive protein in end‐stage renal disease. Iranian journal of Kidney Diseases2011;5(1):29‐33. [MEDLINE: 21189431] ">Soliemani 2011</a>; <a href="./references#CD004289-bbs2-0022" title="van denAkkerJM , BredieSJ , DiepenveenSH , vanTitsLJ , StalenhoefAF , vanLeusenR . Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C‐reactive protein and in vivo oxidized LDL. Journal of Nephrology2003;16(2):238‐44. [MEDLINE: 12768071] ">van den Akker 2003</a>). </p> <section id="CD004289-sec-0059"> <h5 class="title">Study design</h5> <p>All included studies were RCTs; two were two‐by‐two factorial design with aspirin (<a href="./references#CD004289-bbs2-0021" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK‐HARP‐I) study: biochemical efficacy and safety of simvastatin and safety of low‐dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473‐84. [MEDLINE: 15754269] BaigentC , UK‐HARP Steering Committee. Efficacy and safety of simvastatin and safety of low‐dose aspirin among patients with chronic kidney disease: final results of the first UK‐heart and renal protection (UK‐HARP‐I) study [abstract]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. ">UK‐HARP‐I 2005</a>) and enalapril (<a href="./references#CD004289-bbs2-0014" title="CollinsJF , RobsonR , MacMahonS , BaileyRR , PERFECT Study Group. Safety and efficacy of enalapril and simvastatin in dialysis patients [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5‐9; Hong Kong. 1995:144. RobsonR , CollinsJ , JohnsonR , KitchingR , SearleM , WalkerR , et al. Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. Journal of Nephrology1997;10(1):33‐40. [MEDLINE: 9241623] RobsonR , CollinsJ , KitchingsR , SearleM , WalkerR , SharpeN , et al. A randomized controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. Journal of the American Society of Nephrology1994;5(3):526. RobsonRA , CollinsJ , WalkerRJ , MacMahonS . A randomised controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid (Spain). 1995:530. WalkerRJ , SutherlandWH , WalkerH . Simvastatin and cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid (Spain). 1995:529. WalkerRJ , SutherlandWH , WalkerH , RobsonRA , MacMahonSA . The effects of simvastatin and enalapril on plasma cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5‐9; Hong Kong. 1995:28. WalkerRJ , SutherlandWH , WalkerHL , MacMahonS , RobsonRA . Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT Study Collaborative Group. Nephrology Dialysis Transplantation1997;12(1):87‐92. [MEDLINE: 9027779] ">PERFECT Study 1997</a>). </p> </section> <section id="CD004289-sec-0060"> <h5 class="title">Participants</h5> <p>All participants were undergoing dialysis.</p> <p> <ul id="CD004289-list-0009"> <li> <p>Twelve studies only included participants undergoing haemodialysis (<a href="./references#CD004289-bbs2-0001" title="DrechslerC , KraneV , GrootendorstDC , RitzE , WinklerK , MarzW , et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrology Dialysis Transplantation2009;24(10):3151‐7. [MEDLINE: 19474272] DrechslerC , KraneV , RitzE , MarzW , WannerC . Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation2009;120(24):2421‐8. [MEDLINE: 19948978] DrechslerC , KraneV , WinklerK , DekkerFW , WannerC . Increasing adiponectin is associated with cardiovascular events and mortality in diabetic patients on hemodialysis [abstract]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):727A. KraneV , BergerM , LilienthalJ , WinklerK , SchambeckC , WannerC , et al. Antibodies to platelet factor 4‐heparin complex and outcome in hemodialysis patients with diabetes. Clinical Journal of The American Society of Nephrology: CJASN2010;5(5):874‐81. [MEDLINE: 20185595] KraneV , HeinrichF , MeesmannM , OlschewskiM , LilienthalJ , AngermannC , et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clinical Journal of The American Society of Nephrology: CJASN2009;4(2):394‐400. [MEDLINE: 19158371] KraneV , KrieterDH , OlschewskiM , MaerzW , MannJFE , RitzE , et al. Impact of dialyzer membrane characteristics on outcome in type 2 diabetic patients on maintenance hemodialysis: results of the 4D study [abstract]. Journal of the American Society of Nephrology2006;17(Abstracts):22A. KraneV , MaerzW , RufG , RitzE , WannerC . Atorvastatin in Type 2 diabetic patients on hemodialysis (4D‐study): baseline characteristics and 1st interim analysis [abstract]. Journal of the American Society of Nephrology2003;14(Nov):496A. KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. American Journal of Kidney Diseases2009;54(5):902‐11. [MEDLINE: 19781835] KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International2008;74(11):1461‐7. [MEDLINE: 18818679] MarzW , GenserB , DrechslerC , KraneV , GrammerTB , RitzE , et al. Atorvastatin and low‐density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN2011;6(6):1316‐25. [MEDLINE: 21493741] WannerC , KraneV , MarzW , OlschewskiM , AsmusHG , KramerW , et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney &amp; Blood Pressure Research2004;27(4):259‐66. [MEDLINE: 15316128] WannerC , KraneV , MärzW , OlschewskiM , MannJF , RufG , et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine2005;353(3):238‐48. [MEDLINE: 16034009] WannerC , KraneV , RufG , MarzW , RitzE . Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney International ‐ Supplement1999;56(Suppl 71):S222‐6. [MEDLINE: 10412782] ">4D Study 2004</a>; <a href="./references#CD004289-bbs2-0002" title="AhmadiFI , EslamiK , MaziarS , Lessan‐PezeshkiM , KhatamiMR , Mahdavi‐mazdehM , et al. Effect of lovastatin on high‐sensitivity C‐reactive protein and hemoglobin in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv229. AhmadiFL , EslamiK , MaziarS , Lessan‐PezeshkiM , Reza‐KhatamiM , Mahdavi‐mazdehM , et al. Effect of lovastatin on C‐reactive protein and hemoglobin in hemodialysis patients [abstract]. Nephrology2005;10(Suppl):A283‐4. ">Ahmadi 2005</a>; <a href="./references#CD004289-bbs2-0005" title="FellstromB , HoldaasH , JardineAG , RoseH , SchmiederR , WilpshaarW , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney &amp; Blood Pressure Research2007;30(5):314‐22. [MEDLINE: 17671394] FellstromB , HoldaasH , JardineAG , SchmiederRE , HolmeI , ZannadF . Normalisation of CRP and LDL‐C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:218a. FellstromB , JardineAG , HoldaasH , SchmiederR , GottlowM , JohnssonE , et al. Effect of rosuvastatin versus placebo on cardiovascular outcomes in patients with end‐stage renal disease on hemodialysis ‐ results of the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , ArmstrongJ , et al. A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events ‐ the AURORA study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):713. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , RoseH , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients ‐ Design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine2005;6:9. [EMBASE: 2005487466] FellstromBC , JardineAG , SchmiederRE , HoldaasH , BannisterK , BeutlerJ , et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine2009;360(14):1395‐407. [MEDLINE: 19332456] HoldaasH , FellstromB , HolmeI , SchmiederRE , ZannadF , JardineAG . Rosuvastatin and LDL cholesterol in diabetic patients receiving hemodialysis ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:12A. HoldaasH , HolmeI , SchmiederRE , JardineAG , ZannadF , NorbyGE , et al. Rosuvastatin in diabetic hemodialysis patients. Journal of the American Society of Nephrology2011;22(7):1335‐41. [MEDLINE: 21566054] HoldaasH , JardineAG , SchmiederR , GottlowM , JohnssonE , ZannadF , et al. Effect of rosuvastatin on cardiovascular outcomes in diabetic patients receiving hemodialysis ‐ results from the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. JardineAG , FellstromB , HoldaasH , GottlowM , JohnssonE , ZannadF , et al. Risk factors for cardiovascular events in patients receiving haemodialysis ‐ post hoc analyses of the AURORA study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. ">AURORA Study 2005</a>; <a href="./references#CD004289-bbs2-0006" title="BurmeisterJE , MiltersteinerDR , CamposBM . Rosuvastatin in hemodialysis: short‐term effects on lipids and C‐reactive protein. Journal of Nephrology2009;22(1):83‐89. [MEDLINE: 19229822] BurmeisterJE , MiltersteinerDR , CostaMG , CamposBM . Short‐term results of rosuvastatin therapy over lipid profile and hs‐C‐reactive protein in patients on regular hemodialysis [abstract]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv472. ">Burmeister 2006</a>; <a href="./references#CD004289-bbs2-0007" title="ChangJW , LeeMS , KinSB , YangWS , ParkSK , LeeSK , et al. Simvastatin decreased high‐sensitive c‐reactive protein (hs‐CRP) and increased serum albumin in hemodialysis (HD) patients [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):353A. ChangJW , YangWS , MinWK , LeeSK , ParkJS , KimSB . Effects of simvastatin on high‐sensitivity C‐reactive protein and serum albumin in hemodialysis patients. American Journal of Kidney Diseases2002;39(6):1213‐7. [MEDLINE: 12046033] ">Chang 2002</a>; <a href="./references#CD004289-bbs2-0009" title="Dornbrook‐LavenderKA , JoyMS , Denu‐CioccaCJ , ChinH , HoganSL , PieperJA . Effects of atorvastatin on low‐density lipoprotein cholesterol phenotype and C‐reactive protein levels in patients undergoing long‐term dialysis. Pharmacotherapy2005;25(3):335‐44. [MEDLINE: 15843280] JoyMS , Dornbrook‐LavenderKA , ChinH , HoganSL , Denu‐CioccaC . Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients. Annals of Pharmacotherapy2008;42(1):9‐15. [MEDLINE: 18000162] JoyMS , Dornbrook‐LavenderKA , ChinH , HoganSL , Denu‐CioccaCJ . Atorvastatin can safely and effectively improve cholesterol and contemporary measures of cardiovascular risks in hemodialysis patients [abstract]. Journal of the American Society of Nephrology2004;15(Oct):615A. ">Dornbrook‐Lavender 2005</a>; <a href="./references#CD004289-bbs2-0012" title="IchiharaA , HayashiM , RyuzakiM , HandaM , FurukawaT , SarutaT . Effects of fluvastatin on leg arterial stiffness in hemodialysis patients with type 2 diabetes mellitus [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):148A. IchiharaA , HayashiM , RyuzakiM , HandaM , FurukawaT , SarutaT . Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrology Dialysis Transplantation2002;17(8):1513‐7. [MEDLINE: 12147804] ">Ichihara 2002</a>; <a href="./references#CD004289-bbs2-0013" title="LinsRL , CarpentierYA , Clinical Investigators Study Group. Plasma lipids and liporoteins during atorvastatin (ATVS) up‐titration in hemodialysis patients with hyperlipidemia: a placebo‐controlled study [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):124. LinsRL , MatthysKE , BilliouwJM , DratwaM , DupontP , LameireNH , et al. Lipid and apoprotein changes during atorvastatin up‐titration in hemodialysis patients with hypercholesterolemia: a placebo‐controlled study. Clinical Nephrology2004;62(4):287‐94. [MEDLINE: 15524059] ">Lins 2004</a>; <a href="./references#CD004289-bbs2-0018" title="SoliemaniA , NikoueinejadH , TabatabaizadeM , MianehsazE , TamadonM . Effect of hydroxymethylglutaryl‐CoA reductase inhibitors on low‐density lipoprotein cholesterol, interleukin‐6, and high‐sensitivity C‐reactive protein in end‐stage renal disease. Iranian journal of Kidney Diseases2011;5(1):29‐33. [MEDLINE: 21189431] ">Soliemani 2011</a>; <a href="./references#CD004289-bbs2-0021" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK‐HARP‐I) study: biochemical efficacy and safety of simvastatin and safety of low‐dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473‐84. [MEDLINE: 15754269] BaigentC , UK‐HARP Steering Committee. Efficacy and safety of simvastatin and safety of low‐dose aspirin among patients with chronic kidney disease: final results of the first UK‐heart and renal protection (UK‐HARP‐I) study [abstract]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. ">UK‐HARP‐I 2005</a>; <a href="./references#CD004289-bbs2-0023" title="VareesangthipK , LaouthaiwattanaP , HanlakornP , SuwannatonL , LarpkitkachornR , ChuawattanaD , et al. Effects of simvastatin on the kinetics of erythrocyte sodium lithium countertransport and C‐reactive protein in hemodialysis patients [abstract]. Journal of the American Society of Nephrology2005;16:276A. ">Vareesangthip 2005</a>; <a href="./references#CD004289-bbs2-0025" title="VernaglioneL , CristofanoC , MuscogiuriP , ChimientiS . Does atorvastatin influence serum C‐reactive protein levels in patients on long‐term hemodialysis?. American Journal of Kidney Diseases2004;43(3):471‐8. [MEDLINE: 14981605] VernaglioneL , CristofanoC , MuscogiuriP , PennacchiottiF , ChimientiS . Analysis of the impact of atorvastatin (ATO) on c‐reactive protein (CRP) levels in haemodialysis patients (HDP) [abstract]. Journal of the American Society of Nephrology2003;14(Nov):41A. VernaglioneL , CristofanoC , PennacchiottiF , MuscogiuriP , ChimientiS . Effects of atorvastatin (ATO) on C‐reactive protein (CRP) levels in haemodialysis patients (HDP) : a prospective study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):712‐3. ">Vernaglione 2003</a>); </p> </li> <li> <p>Eight studies included participants treated with either haemodialysis or peritoneal dialysis (<a href="./references#CD004289-bbs2-0004" title="ArabulM , GulluluM , YilmazY , AkdagI , KahveciogluS , ErenMA , et al. Effect of fluvastatin on serum prohepcidin levels in patients with end‐stage renal disease. Clinical Biochemistry2008;41(13):1055‐8. [MEDLINE: 18571502] ">Arabul 2008</a>; <a href="./references#CD004289-bbs2-0008" title="BiloHJ , DiepeveenSJ , VerhoevenGH , van derPalenJ , DikkescheiBD , et al. Vitaestat 1: alpha‐tocopherol and atorvastatin in HD‐ and PD‐ patients: a short‐term, prospective randomised placebo‐controlled intervention trial [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):191A. DiepeveenSH , VerhoevenGH , van derPalenJ , DikkescheiLD , DenmackerPN , KolstersG , et al. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised‐controlled trial. Journal of Internal Medicine2005;257(5):438‐45. [MEDLINE: 15836660] DiepeveenSH , VerhoevenGH , van derPalenJ , DikkescheiLD , DenmackerPN , KolstersG , et al. Vitaestat 1: a prospective randomised placebo controlled trial with a‐tocoferol and atorvastatin in patients in hemo‐ and peritoneal dialysis [abstract]. Nephrology Dialysis Transplantation2001;16(6):A87. ">Diepeveen 2005</a>; <a href="./references#CD004289-bbs2-0021" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK‐HARP‐I) study: biochemical efficacy and safety of simvastatin and safety of low‐dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473‐84. [MEDLINE: 15754269] BaigentC , UK‐HARP Steering Committee. Efficacy and safety of simvastatin and safety of low‐dose aspirin among patients with chronic kidney disease: final results of the first UK‐heart and renal protection (UK‐HARP‐I) study [abstract]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. ">UK‐HARP‐I 2005</a>; <a href="./references#CD004289-bbs2-0014" title="CollinsJF , RobsonR , MacMahonS , BaileyRR , PERFECT Study Group. Safety and efficacy of enalapril and simvastatin in dialysis patients [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5‐9; Hong Kong. 1995:144. RobsonR , CollinsJ , JohnsonR , KitchingR , SearleM , WalkerR , et al. Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. Journal of Nephrology1997;10(1):33‐40. [MEDLINE: 9241623] RobsonR , CollinsJ , KitchingsR , SearleM , WalkerR , SharpeN , et al. A randomized controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. Journal of the American Society of Nephrology1994;5(3):526. RobsonRA , CollinsJ , WalkerRJ , MacMahonS . A randomised controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid (Spain). 1995:530. WalkerRJ , SutherlandWH , WalkerH . Simvastatin and cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid (Spain). 1995:529. WalkerRJ , SutherlandWH , WalkerH , RobsonRA , MacMahonSA . The effects of simvastatin and enalapril on plasma cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5‐9; Hong Kong. 1995:28. WalkerRJ , SutherlandWH , WalkerHL , MacMahonS , RobsonRA . Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT Study Collaborative Group. Nephrology Dialysis Transplantation1997;12(1):87‐92. [MEDLINE: 9027779] ">PERFECT Study 1997</a>; <a href="./references#CD004289-bbs2-0015" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi HD 2002</a>‐<a href="./references#CD004289-bbs2-0016" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi PD 2002</a>; <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a>; <a href="./references#CD004289-bbs2-0019" title="HolmbergB , BrannstromM , BuchtB , CrougneauV , DimenyE , EkspongA , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):503‐10. [MEDLINE: 16303728] StegmayrBG , BrannstromM , BuchtS , DimenyE , EkspongA , GranrothB , et al. Safety and efficacy of atorvastatin in patients with impaired renal function [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna (Austria). 2001:134. StegmayrBG , BrännströmM , BuchtS , CrougneauV , DimenyE , EkspongA , et al. Low‐dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):489‐97. [MEDLINE: 18161210] StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GoschJ , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):161A. StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GranrothB , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):268A. ">Stegmayr 2005</a>; <a href="./references#CD004289-bbs2-0026" title="YuMH , LeeJH , MinWK , ChiHS , ChangJW , YangWS , et al. Effects of ezetimibe and ezetimibe plus simvastatin (Vytorin®) on markers for inflammation and thrombogenesis in end‐stage renal disease (ESRD) patients [abstract]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi322. ">Yu 2007</a>) </p> </li> <li> <p>Five studies only included peritoneal dialysis patients (<a href="./references#CD004289-bbs2-0003" title="AngelJR , RojasE , delCampoFM , NavaD , Cueto‐ManzanoA . Effect of pravastatin on inflammatory status of CAPD patients: a randomized, double‐blinded, controlled and cross‐over clinical trial [abstract]. Journal of the American Society of Nephrology2007;18(Abstracts):270A. ZunigaJ , Rojas‐CamposE , delCampoFM , NavaD , Cueto‐ManzanoA . Effect of pravastatin on the inflammatory status of CAPD patients: a randomized, double‐blinded, controlled and cross‐over clinical trial [abstract]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi301. ">Angel 2007</a>; <a href="./references#CD004289-bbs2-0011" title="HarrisKP , WheelerDC , ChongCC , Atorvastatin in CAPD Study Investigators. A placebo controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney International2002;61(4):1469‐74. [MEDLINE: 11918754] WheelerD , HarrisKP , UK CAPD Investigators. A placebo‐controlled trial examining the efficacy and safety of atorvastatin in dyslipidaemic patients undergoing CAPD [abstract]. Nephrology Dialysis Transplantation2001;16(6):A196. ">Harris 2002</a>; <a href="./references#CD004289-bbs2-0010" title="HanSH , KangEW , YoonSJ , LeeHC , YooTH , ChoiKH , et al. Combined vascular effects of HMG‐CoA reductase inhibitor and angiotensin receptor blocker in non‐diabetic patients undergoing peritoneal dialysis. Nephrology Dialysis Transplantation2011;26(11):3722‐8. [MEDLINE: 21385862] ">Han 2011</a>; <a href="./references#CD004289-bbs2-0020" title="TseKC , YungS , TangCS , TamS , LaiKN , ChanTM . Atorvastatin at conventional dose did not reduce C‐reactive protein in patients on peritoneal dialysis. Journal of Nephrology2008;21(3):283. [MEDLINE: 18587714] ">Tse 2008</a>; <a href="./references#CD004289-bbs2-0024" title="Velickovic‐RadovanovicR , AvramovicM , MalobabicZ , DjordjevicV , KosticS , MiticB . Therapeutic effects of simvastatin on hyperlipidemia in uraemic patients on CAPD [abstract]. Nephrology Dialysis Transplantation1997;12(9):A187. ">Velickovic 1997</a>). </p> </li> <li> <p>Median baseline serum LDL cholesterol was 190 mg/dL (range 150 to 254 mg/dL).</p> </li> <li> <p>Two studies only included participants with diabetes at baseline (<a href="./references#CD004289-bbs2-0001" title="DrechslerC , KraneV , GrootendorstDC , RitzE , WinklerK , MarzW , et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrology Dialysis Transplantation2009;24(10):3151‐7. [MEDLINE: 19474272] DrechslerC , KraneV , RitzE , MarzW , WannerC . Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation2009;120(24):2421‐8. [MEDLINE: 19948978] DrechslerC , KraneV , WinklerK , DekkerFW , WannerC . Increasing adiponectin is associated with cardiovascular events and mortality in diabetic patients on hemodialysis [abstract]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):727A. KraneV , BergerM , LilienthalJ , WinklerK , SchambeckC , WannerC , et al. Antibodies to platelet factor 4‐heparin complex and outcome in hemodialysis patients with diabetes. Clinical Journal of The American Society of Nephrology: CJASN2010;5(5):874‐81. [MEDLINE: 20185595] KraneV , HeinrichF , MeesmannM , OlschewskiM , LilienthalJ , AngermannC , et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clinical Journal of The American Society of Nephrology: CJASN2009;4(2):394‐400. [MEDLINE: 19158371] KraneV , KrieterDH , OlschewskiM , MaerzW , MannJFE , RitzE , et al. Impact of dialyzer membrane characteristics on outcome in type 2 diabetic patients on maintenance hemodialysis: results of the 4D study [abstract]. Journal of the American Society of Nephrology2006;17(Abstracts):22A. KraneV , MaerzW , RufG , RitzE , WannerC . Atorvastatin in Type 2 diabetic patients on hemodialysis (4D‐study): baseline characteristics and 1st interim analysis [abstract]. Journal of the American Society of Nephrology2003;14(Nov):496A. KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. American Journal of Kidney Diseases2009;54(5):902‐11. [MEDLINE: 19781835] KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International2008;74(11):1461‐7. [MEDLINE: 18818679] MarzW , GenserB , DrechslerC , KraneV , GrammerTB , RitzE , et al. Atorvastatin and low‐density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN2011;6(6):1316‐25. [MEDLINE: 21493741] WannerC , KraneV , MarzW , OlschewskiM , AsmusHG , KramerW , et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney &amp; Blood Pressure Research2004;27(4):259‐66. [MEDLINE: 15316128] WannerC , KraneV , MärzW , OlschewskiM , MannJF , RufG , et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine2005;353(3):238‐48. [MEDLINE: 16034009] WannerC , KraneV , RufG , MarzW , RitzE . Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney International ‐ Supplement1999;56(Suppl 71):S222‐6. [MEDLINE: 10412782] ">4D Study 2004</a>; <a href="./references#CD004289-bbs2-0012" title="IchiharaA , HayashiM , RyuzakiM , HandaM , FurukawaT , SarutaT . Effects of fluvastatin on leg arterial stiffness in hemodialysis patients with type 2 diabetes mellitus [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):148A. IchiharaA , HayashiM , RyuzakiM , HandaM , FurukawaT , SarutaT . Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrology Dialysis Transplantation2002;17(8):1513‐7. [MEDLINE: 12147804] ">Ichihara 2002</a>). </p> </li> </ul> </p> </section> <section id="CD004289-sec-0061"> <h5 class="title">Interventions</h5> <p>Five studies reported follow‐up of more than six months (<a href="./references#CD004289-bbs2-0001" title="DrechslerC , KraneV , GrootendorstDC , RitzE , WinklerK , MarzW , et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrology Dialysis Transplantation2009;24(10):3151‐7. [MEDLINE: 19474272] DrechslerC , KraneV , RitzE , MarzW , WannerC . Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation2009;120(24):2421‐8. [MEDLINE: 19948978] DrechslerC , KraneV , WinklerK , DekkerFW , WannerC . Increasing adiponectin is associated with cardiovascular events and mortality in diabetic patients on hemodialysis [abstract]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):727A. KraneV , BergerM , LilienthalJ , WinklerK , SchambeckC , WannerC , et al. Antibodies to platelet factor 4‐heparin complex and outcome in hemodialysis patients with diabetes. Clinical Journal of The American Society of Nephrology: CJASN2010;5(5):874‐81. [MEDLINE: 20185595] KraneV , HeinrichF , MeesmannM , OlschewskiM , LilienthalJ , AngermannC , et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clinical Journal of The American Society of Nephrology: CJASN2009;4(2):394‐400. [MEDLINE: 19158371] KraneV , KrieterDH , OlschewskiM , MaerzW , MannJFE , RitzE , et al. Impact of dialyzer membrane characteristics on outcome in type 2 diabetic patients on maintenance hemodialysis: results of the 4D study [abstract]. Journal of the American Society of Nephrology2006;17(Abstracts):22A. KraneV , MaerzW , RufG , RitzE , WannerC . Atorvastatin in Type 2 diabetic patients on hemodialysis (4D‐study): baseline characteristics and 1st interim analysis [abstract]. Journal of the American Society of Nephrology2003;14(Nov):496A. KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. American Journal of Kidney Diseases2009;54(5):902‐11. [MEDLINE: 19781835] KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International2008;74(11):1461‐7. [MEDLINE: 18818679] MarzW , GenserB , DrechslerC , KraneV , GrammerTB , RitzE , et al. Atorvastatin and low‐density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN2011;6(6):1316‐25. [MEDLINE: 21493741] WannerC , KraneV , MarzW , OlschewskiM , AsmusHG , KramerW , et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney &amp; Blood Pressure Research2004;27(4):259‐66. [MEDLINE: 15316128] WannerC , KraneV , MärzW , OlschewskiM , MannJF , RufG , et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine2005;353(3):238‐48. [MEDLINE: 16034009] WannerC , KraneV , RufG , MarzW , RitzE . Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney International ‐ Supplement1999;56(Suppl 71):S222‐6. [MEDLINE: 10412782] ">4D Study 2004</a>; <a href="./references#CD004289-bbs2-0005" title="FellstromB , HoldaasH , JardineAG , RoseH , SchmiederR , WilpshaarW , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney &amp; Blood Pressure Research2007;30(5):314‐22. [MEDLINE: 17671394] FellstromB , HoldaasH , JardineAG , SchmiederRE , HolmeI , ZannadF . Normalisation of CRP and LDL‐C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:218a. FellstromB , JardineAG , HoldaasH , SchmiederR , GottlowM , JohnssonE , et al. Effect of rosuvastatin versus placebo on cardiovascular outcomes in patients with end‐stage renal disease on hemodialysis ‐ results of the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , ArmstrongJ , et al. A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events ‐ the AURORA study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):713. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , RoseH , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients ‐ Design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine2005;6:9. [EMBASE: 2005487466] FellstromBC , JardineAG , SchmiederRE , HoldaasH , BannisterK , BeutlerJ , et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine2009;360(14):1395‐407. [MEDLINE: 19332456] HoldaasH , FellstromB , HolmeI , SchmiederRE , ZannadF , JardineAG . Rosuvastatin and LDL cholesterol in diabetic patients receiving hemodialysis ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:12A. HoldaasH , HolmeI , SchmiederRE , JardineAG , ZannadF , NorbyGE , et al. Rosuvastatin in diabetic hemodialysis patients. Journal of the American Society of Nephrology2011;22(7):1335‐41. [MEDLINE: 21566054] HoldaasH , JardineAG , SchmiederR , GottlowM , JohnssonE , ZannadF , et al. Effect of rosuvastatin on cardiovascular outcomes in diabetic patients receiving hemodialysis ‐ results from the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. JardineAG , FellstromB , HoldaasH , GottlowM , JohnssonE , ZannadF , et al. Risk factors for cardiovascular events in patients receiving haemodialysis ‐ post hoc analyses of the AURORA study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. ">AURORA Study 2005</a>; <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a>; <a href="./references#CD004289-bbs2-0019" title="HolmbergB , BrannstromM , BuchtB , CrougneauV , DimenyE , EkspongA , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):503‐10. [MEDLINE: 16303728] StegmayrBG , BrannstromM , BuchtS , DimenyE , EkspongA , GranrothB , et al. Safety and efficacy of atorvastatin in patients with impaired renal function [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna (Austria). 2001:134. StegmayrBG , BrännströmM , BuchtS , CrougneauV , DimenyE , EkspongA , et al. Low‐dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):489‐97. [MEDLINE: 18161210] StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GoschJ , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):161A. StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GranrothB , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):268A. ">Stegmayr 2005</a>; <a href="./references#CD004289-bbs2-0021" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK‐HARP‐I) study: biochemical efficacy and safety of simvastatin and safety of low‐dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473‐84. [MEDLINE: 15754269] BaigentC , UK‐HARP Steering Committee. Efficacy and safety of simvastatin and safety of low‐dose aspirin among patients with chronic kidney disease: final results of the first UK‐heart and renal protection (UK‐HARP‐I) study [abstract]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. ">UK‐HARP‐I 2005</a>). Generally, studies were small (median 42 participants; range 13 to 3023 participants); three studies enrolled more than 1000 participants undergoing dialysis (<a href="./references#CD004289-bbs2-0001" title="DrechslerC , KraneV , GrootendorstDC , RitzE , WinklerK , MarzW , et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrology Dialysis Transplantation2009;24(10):3151‐7. [MEDLINE: 19474272] DrechslerC , KraneV , RitzE , MarzW , WannerC . Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation2009;120(24):2421‐8. [MEDLINE: 19948978] DrechslerC , KraneV , WinklerK , DekkerFW , WannerC . Increasing adiponectin is associated with cardiovascular events and mortality in diabetic patients on hemodialysis [abstract]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):727A. KraneV , BergerM , LilienthalJ , WinklerK , SchambeckC , WannerC , et al. Antibodies to platelet factor 4‐heparin complex and outcome in hemodialysis patients with diabetes. Clinical Journal of The American Society of Nephrology: CJASN2010;5(5):874‐81. [MEDLINE: 20185595] KraneV , HeinrichF , MeesmannM , OlschewskiM , LilienthalJ , AngermannC , et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clinical Journal of The American Society of Nephrology: CJASN2009;4(2):394‐400. [MEDLINE: 19158371] KraneV , KrieterDH , OlschewskiM , MaerzW , MannJFE , RitzE , et al. Impact of dialyzer membrane characteristics on outcome in type 2 diabetic patients on maintenance hemodialysis: results of the 4D study [abstract]. Journal of the American Society of Nephrology2006;17(Abstracts):22A. KraneV , MaerzW , RufG , RitzE , WannerC . Atorvastatin in Type 2 diabetic patients on hemodialysis (4D‐study): baseline characteristics and 1st interim analysis [abstract]. Journal of the American Society of Nephrology2003;14(Nov):496A. KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. American Journal of Kidney Diseases2009;54(5):902‐11. [MEDLINE: 19781835] KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International2008;74(11):1461‐7. [MEDLINE: 18818679] MarzW , GenserB , DrechslerC , KraneV , GrammerTB , RitzE , et al. Atorvastatin and low‐density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN2011;6(6):1316‐25. [MEDLINE: 21493741] WannerC , KraneV , MarzW , OlschewskiM , AsmusHG , KramerW , et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney &amp; Blood Pressure Research2004;27(4):259‐66. [MEDLINE: 15316128] WannerC , KraneV , MärzW , OlschewskiM , MannJF , RufG , et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine2005;353(3):238‐48. [MEDLINE: 16034009] WannerC , KraneV , RufG , MarzW , RitzE . Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney International ‐ Supplement1999;56(Suppl 71):S222‐6. [MEDLINE: 10412782] ">4D Study 2004</a>; <a href="./references#CD004289-bbs2-0005" title="FellstromB , HoldaasH , JardineAG , RoseH , SchmiederR , WilpshaarW , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney &amp; Blood Pressure Research2007;30(5):314‐22. [MEDLINE: 17671394] FellstromB , HoldaasH , JardineAG , SchmiederRE , HolmeI , ZannadF . Normalisation of CRP and LDL‐C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:218a. FellstromB , JardineAG , HoldaasH , SchmiederR , GottlowM , JohnssonE , et al. Effect of rosuvastatin versus placebo on cardiovascular outcomes in patients with end‐stage renal disease on hemodialysis ‐ results of the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , ArmstrongJ , et al. A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events ‐ the AURORA study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):713. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , RoseH , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients ‐ Design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine2005;6:9. [EMBASE: 2005487466] FellstromBC , JardineAG , SchmiederRE , HoldaasH , BannisterK , BeutlerJ , et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine2009;360(14):1395‐407. [MEDLINE: 19332456] HoldaasH , FellstromB , HolmeI , SchmiederRE , ZannadF , JardineAG . Rosuvastatin and LDL cholesterol in diabetic patients receiving hemodialysis ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:12A. HoldaasH , HolmeI , SchmiederRE , JardineAG , ZannadF , NorbyGE , et al. Rosuvastatin in diabetic hemodialysis patients. Journal of the American Society of Nephrology2011;22(7):1335‐41. [MEDLINE: 21566054] HoldaasH , JardineAG , SchmiederR , GottlowM , JohnssonE , ZannadF , et al. Effect of rosuvastatin on cardiovascular outcomes in diabetic patients receiving hemodialysis ‐ results from the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. JardineAG , FellstromB , HoldaasH , GottlowM , JohnssonE , ZannadF , et al. Risk factors for cardiovascular events in patients receiving haemodialysis ‐ post hoc analyses of the AURORA study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. ">AURORA Study 2005</a>; <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a>). </p> <p>Doses of statin (equivalent to simvastatin) were generally 20 mg (5 to 80 mg) with a median follow‐up of six months (2 to 59 months) including studies reporting mortality and cardiovascular events. Non‐randomised co‐interventions included diet in three comparisons (<a href="./references#CD004289-bbs2-0012" title="IchiharaA , HayashiM , RyuzakiM , HandaM , FurukawaT , SarutaT . Effects of fluvastatin on leg arterial stiffness in hemodialysis patients with type 2 diabetes mellitus [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):148A. IchiharaA , HayashiM , RyuzakiM , HandaM , FurukawaT , SarutaT . Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrology Dialysis Transplantation2002;17(8):1513‐7. [MEDLINE: 12147804] ">Ichihara 2002</a>; <a href="./references#CD004289-bbs2-0015" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi HD 2002</a>; <a href="./references#CD004289-bbs2-0016" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi PD 2002</a>). </p> </section> </section> <section id="CD004289-sec-0062"> <h4 class="title">Excluded studies</h4> <p>We excluded 28 studies: 13 were not randomised; seven did not include an appropriate intervention (other active treatment); one was a discontinued study; five were short durations (&lt; 8 weeks); two were not conducted in dialysis populations (see <a href="./references#CD004289-sec-0101" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD004289-sec-0063"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias in included studies is summarised in <a href="#CD004289-fig-0002">Figure 2</a> and <a href="#CD004289-fig-0003">Figure 3</a>. The risk of bias was high in many of the included studies. Random sequence generation and allocation concealment was reported in three (12%) and four studies (16%), respectively. Participants and personnel were blinded in 13 studies (52%), and outcome assessors were blinded in five studies (20%). Complete outcome reporting occurred in nine studies (36%). Adverse events were only reported in nine studies (36%); 11 studies (44%) reported industry funding.The risk of bias was high in many included studies. </p> <div class="figure" id="CD004289-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD004289-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD004289-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD004289-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD004289-sec-0064"> <h4 class="title">Allocation</h4> <section id="CD004289-sec-0065"> <h5 class="title">Random sequence generation</h5> <p>Random sequence generation was only reported in 3/25 studies (<a href="./references#CD004289-bbs2-0001" title="DrechslerC , KraneV , GrootendorstDC , RitzE , WinklerK , MarzW , et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrology Dialysis Transplantation2009;24(10):3151‐7. [MEDLINE: 19474272] DrechslerC , KraneV , RitzE , MarzW , WannerC . Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation2009;120(24):2421‐8. [MEDLINE: 19948978] DrechslerC , KraneV , WinklerK , DekkerFW , WannerC . Increasing adiponectin is associated with cardiovascular events and mortality in diabetic patients on hemodialysis [abstract]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):727A. KraneV , BergerM , LilienthalJ , WinklerK , SchambeckC , WannerC , et al. Antibodies to platelet factor 4‐heparin complex and outcome in hemodialysis patients with diabetes. Clinical Journal of The American Society of Nephrology: CJASN2010;5(5):874‐81. [MEDLINE: 20185595] KraneV , HeinrichF , MeesmannM , OlschewskiM , LilienthalJ , AngermannC , et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clinical Journal of The American Society of Nephrology: CJASN2009;4(2):394‐400. [MEDLINE: 19158371] KraneV , KrieterDH , OlschewskiM , MaerzW , MannJFE , RitzE , et al. Impact of dialyzer membrane characteristics on outcome in type 2 diabetic patients on maintenance hemodialysis: results of the 4D study [abstract]. Journal of the American Society of Nephrology2006;17(Abstracts):22A. KraneV , MaerzW , RufG , RitzE , WannerC . Atorvastatin in Type 2 diabetic patients on hemodialysis (4D‐study): baseline characteristics and 1st interim analysis [abstract]. Journal of the American Society of Nephrology2003;14(Nov):496A. KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. American Journal of Kidney Diseases2009;54(5):902‐11. [MEDLINE: 19781835] KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International2008;74(11):1461‐7. [MEDLINE: 18818679] MarzW , GenserB , DrechslerC , KraneV , GrammerTB , RitzE , et al. Atorvastatin and low‐density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN2011;6(6):1316‐25. [MEDLINE: 21493741] WannerC , KraneV , MarzW , OlschewskiM , AsmusHG , KramerW , et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney &amp; Blood Pressure Research2004;27(4):259‐66. [MEDLINE: 15316128] WannerC , KraneV , MärzW , OlschewskiM , MannJF , RufG , et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine2005;353(3):238‐48. [MEDLINE: 16034009] WannerC , KraneV , RufG , MarzW , RitzE . Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney International ‐ Supplement1999;56(Suppl 71):S222‐6. [MEDLINE: 10412782] ">4D Study 2004</a>; <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a>; <a href="./references#CD004289-bbs2-0021" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK‐HARP‐I) study: biochemical efficacy and safety of simvastatin and safety of low‐dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473‐84. [MEDLINE: 15754269] BaigentC , UK‐HARP Steering Committee. Efficacy and safety of simvastatin and safety of low‐dose aspirin among patients with chronic kidney disease: final results of the first UK‐heart and renal protection (UK‐HARP‐I) study [abstract]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. ">UK‐HARP‐I 2005</a>). </p> </section> <section id="CD004289-sec-0066"> <h5 class="title">Allocation concealment</h5> <p>Allocation to randomised groups was not reported adequately: only 4/25 included studies reported allocation methodology in detail (<a href="./references#CD004289-bbs2-0001" title="DrechslerC , KraneV , GrootendorstDC , RitzE , WinklerK , MarzW , et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrology Dialysis Transplantation2009;24(10):3151‐7. [MEDLINE: 19474272] DrechslerC , KraneV , RitzE , MarzW , WannerC . Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation2009;120(24):2421‐8. [MEDLINE: 19948978] DrechslerC , KraneV , WinklerK , DekkerFW , WannerC . Increasing adiponectin is associated with cardiovascular events and mortality in diabetic patients on hemodialysis [abstract]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):727A. KraneV , BergerM , LilienthalJ , WinklerK , SchambeckC , WannerC , et al. Antibodies to platelet factor 4‐heparin complex and outcome in hemodialysis patients with diabetes. Clinical Journal of The American Society of Nephrology: CJASN2010;5(5):874‐81. [MEDLINE: 20185595] KraneV , HeinrichF , MeesmannM , OlschewskiM , LilienthalJ , AngermannC , et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clinical Journal of The American Society of Nephrology: CJASN2009;4(2):394‐400. [MEDLINE: 19158371] KraneV , KrieterDH , OlschewskiM , MaerzW , MannJFE , RitzE , et al. Impact of dialyzer membrane characteristics on outcome in type 2 diabetic patients on maintenance hemodialysis: results of the 4D study [abstract]. Journal of the American Society of Nephrology2006;17(Abstracts):22A. KraneV , MaerzW , RufG , RitzE , WannerC . Atorvastatin in Type 2 diabetic patients on hemodialysis (4D‐study): baseline characteristics and 1st interim analysis [abstract]. Journal of the American Society of Nephrology2003;14(Nov):496A. KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. American Journal of Kidney Diseases2009;54(5):902‐11. [MEDLINE: 19781835] KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International2008;74(11):1461‐7. [MEDLINE: 18818679] MarzW , GenserB , DrechslerC , KraneV , GrammerTB , RitzE , et al. Atorvastatin and low‐density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN2011;6(6):1316‐25. [MEDLINE: 21493741] WannerC , KraneV , MarzW , OlschewskiM , AsmusHG , KramerW , et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney &amp; Blood Pressure Research2004;27(4):259‐66. [MEDLINE: 15316128] WannerC , KraneV , MärzW , OlschewskiM , MannJF , RufG , et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine2005;353(3):238‐48. [MEDLINE: 16034009] WannerC , KraneV , RufG , MarzW , RitzE . Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney International ‐ Supplement1999;56(Suppl 71):S222‐6. [MEDLINE: 10412782] ">4D Study 2004</a>; <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a>; <a href="./references#CD004289-bbs2-0019" title="HolmbergB , BrannstromM , BuchtB , CrougneauV , DimenyE , EkspongA , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):503‐10. [MEDLINE: 16303728] StegmayrBG , BrannstromM , BuchtS , DimenyE , EkspongA , GranrothB , et al. Safety and efficacy of atorvastatin in patients with impaired renal function [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna (Austria). 2001:134. StegmayrBG , BrännströmM , BuchtS , CrougneauV , DimenyE , EkspongA , et al. Low‐dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):489‐97. [MEDLINE: 18161210] StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GoschJ , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):161A. StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GranrothB , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):268A. ">Stegmayr 2005</a>; <a href="./references#CD004289-bbs2-0021" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK‐HARP‐I) study: biochemical efficacy and safety of simvastatin and safety of low‐dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473‐84. [MEDLINE: 15754269] BaigentC , UK‐HARP Steering Committee. Efficacy and safety of simvastatin and safety of low‐dose aspirin among patients with chronic kidney disease: final results of the first UK‐heart and renal protection (UK‐HARP‐I) study [abstract]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. ">UK‐HARP‐I 2005</a>). </p> </section> </section> <section id="CD004289-sec-0067"> <h4 class="title">Blinding</h4> <p>Blinding methodology was well reported: 13 provided adequate details (<a href="./references#CD004289-bbs2-0001" title="DrechslerC , KraneV , GrootendorstDC , RitzE , WinklerK , MarzW , et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrology Dialysis Transplantation2009;24(10):3151‐7. [MEDLINE: 19474272] DrechslerC , KraneV , RitzE , MarzW , WannerC . Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation2009;120(24):2421‐8. [MEDLINE: 19948978] DrechslerC , KraneV , WinklerK , DekkerFW , WannerC . Increasing adiponectin is associated with cardiovascular events and mortality in diabetic patients on hemodialysis [abstract]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):727A. KraneV , BergerM , LilienthalJ , WinklerK , SchambeckC , WannerC , et al. Antibodies to platelet factor 4‐heparin complex and outcome in hemodialysis patients with diabetes. Clinical Journal of The American Society of Nephrology: CJASN2010;5(5):874‐81. [MEDLINE: 20185595] KraneV , HeinrichF , MeesmannM , OlschewskiM , LilienthalJ , AngermannC , et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clinical Journal of The American Society of Nephrology: CJASN2009;4(2):394‐400. [MEDLINE: 19158371] KraneV , KrieterDH , OlschewskiM , MaerzW , MannJFE , RitzE , et al. Impact of dialyzer membrane characteristics on outcome in type 2 diabetic patients on maintenance hemodialysis: results of the 4D study [abstract]. Journal of the American Society of Nephrology2006;17(Abstracts):22A. KraneV , MaerzW , RufG , RitzE , WannerC . Atorvastatin in Type 2 diabetic patients on hemodialysis (4D‐study): baseline characteristics and 1st interim analysis [abstract]. Journal of the American Society of Nephrology2003;14(Nov):496A. KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. American Journal of Kidney Diseases2009;54(5):902‐11. [MEDLINE: 19781835] KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International2008;74(11):1461‐7. [MEDLINE: 18818679] MarzW , GenserB , DrechslerC , KraneV , GrammerTB , RitzE , et al. Atorvastatin and low‐density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN2011;6(6):1316‐25. [MEDLINE: 21493741] WannerC , KraneV , MarzW , OlschewskiM , AsmusHG , KramerW , et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney &amp; Blood Pressure Research2004;27(4):259‐66. [MEDLINE: 15316128] WannerC , KraneV , MärzW , OlschewskiM , MannJF , RufG , et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine2005;353(3):238‐48. [MEDLINE: 16034009] WannerC , KraneV , RufG , MarzW , RitzE . Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney International ‐ Supplement1999;56(Suppl 71):S222‐6. [MEDLINE: 10412782] ">4D Study 2004</a>; <a href="./references#CD004289-bbs2-0003" title="AngelJR , RojasE , delCampoFM , NavaD , Cueto‐ManzanoA . Effect of pravastatin on inflammatory status of CAPD patients: a randomized, double‐blinded, controlled and cross‐over clinical trial [abstract]. Journal of the American Society of Nephrology2007;18(Abstracts):270A. ZunigaJ , Rojas‐CamposE , delCampoFM , NavaD , Cueto‐ManzanoA . Effect of pravastatin on the inflammatory status of CAPD patients: a randomized, double‐blinded, controlled and cross‐over clinical trial [abstract]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi301. ">Angel 2007</a>; <a href="./references#CD004289-bbs2-0004" title="ArabulM , GulluluM , YilmazY , AkdagI , KahveciogluS , ErenMA , et al. Effect of fluvastatin on serum prohepcidin levels in patients with end‐stage renal disease. Clinical Biochemistry2008;41(13):1055‐8. [MEDLINE: 18571502] ">Arabul 2008</a>; <a href="./references#CD004289-bbs2-0005" title="FellstromB , HoldaasH , JardineAG , RoseH , SchmiederR , WilpshaarW , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney &amp; Blood Pressure Research2007;30(5):314‐22. [MEDLINE: 17671394] FellstromB , HoldaasH , JardineAG , SchmiederRE , HolmeI , ZannadF . Normalisation of CRP and LDL‐C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:218a. FellstromB , JardineAG , HoldaasH , SchmiederR , GottlowM , JohnssonE , et al. Effect of rosuvastatin versus placebo on cardiovascular outcomes in patients with end‐stage renal disease on hemodialysis ‐ results of the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , ArmstrongJ , et al. A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events ‐ the AURORA study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):713. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , RoseH , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients ‐ Design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine2005;6:9. [EMBASE: 2005487466] FellstromBC , JardineAG , SchmiederRE , HoldaasH , BannisterK , BeutlerJ , et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine2009;360(14):1395‐407. [MEDLINE: 19332456] HoldaasH , FellstromB , HolmeI , SchmiederRE , ZannadF , JardineAG . Rosuvastatin and LDL cholesterol in diabetic patients receiving hemodialysis ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:12A. HoldaasH , HolmeI , SchmiederRE , JardineAG , ZannadF , NorbyGE , et al. Rosuvastatin in diabetic hemodialysis patients. Journal of the American Society of Nephrology2011;22(7):1335‐41. [MEDLINE: 21566054] HoldaasH , JardineAG , SchmiederR , GottlowM , JohnssonE , ZannadF , et al. Effect of rosuvastatin on cardiovascular outcomes in diabetic patients receiving hemodialysis ‐ results from the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. JardineAG , FellstromB , HoldaasH , GottlowM , JohnssonE , ZannadF , et al. Risk factors for cardiovascular events in patients receiving haemodialysis ‐ post hoc analyses of the AURORA study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. ">AURORA Study 2005</a>; <a href="./references#CD004289-bbs2-0006" title="BurmeisterJE , MiltersteinerDR , CamposBM . Rosuvastatin in hemodialysis: short‐term effects on lipids and C‐reactive protein. Journal of Nephrology2009;22(1):83‐89. [MEDLINE: 19229822] BurmeisterJE , MiltersteinerDR , CostaMG , CamposBM . Short‐term results of rosuvastatin therapy over lipid profile and hs‐C‐reactive protein in patients on regular hemodialysis [abstract]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv472. ">Burmeister 2006</a>; <a href="./references#CD004289-bbs2-0008" title="BiloHJ , DiepeveenSJ , VerhoevenGH , van derPalenJ , DikkescheiBD , et al. Vitaestat 1: alpha‐tocopherol and atorvastatin in HD‐ and PD‐ patients: a short‐term, prospective randomised placebo‐controlled intervention trial [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):191A. DiepeveenSH , VerhoevenGH , van derPalenJ , DikkescheiLD , DenmackerPN , KolstersG , et al. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised‐controlled trial. Journal of Internal Medicine2005;257(5):438‐45. [MEDLINE: 15836660] DiepeveenSH , VerhoevenGH , van derPalenJ , DikkescheiLD , DenmackerPN , KolstersG , et al. Vitaestat 1: a prospective randomised placebo controlled trial with a‐tocoferol and atorvastatin in patients in hemo‐ and peritoneal dialysis [abstract]. Nephrology Dialysis Transplantation2001;16(6):A87. ">Diepeveen 2005</a>; <a href="./references#CD004289-bbs2-0011" title="HarrisKP , WheelerDC , ChongCC , Atorvastatin in CAPD Study Investigators. A placebo controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney International2002;61(4):1469‐74. [MEDLINE: 11918754] WheelerD , HarrisKP , UK CAPD Investigators. A placebo‐controlled trial examining the efficacy and safety of atorvastatin in dyslipidaemic patients undergoing CAPD [abstract]. Nephrology Dialysis Transplantation2001;16(6):A196. ">Harris 2002</a>; <a href="./references#CD004289-bbs2-0012" title="IchiharaA , HayashiM , RyuzakiM , HandaM , FurukawaT , SarutaT . Effects of fluvastatin on leg arterial stiffness in hemodialysis patients with type 2 diabetes mellitus [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):148A. IchiharaA , HayashiM , RyuzakiM , HandaM , FurukawaT , SarutaT . Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrology Dialysis Transplantation2002;17(8):1513‐7. [MEDLINE: 12147804] ">Ichihara 2002</a>; <a href="./references#CD004289-bbs2-0013" title="LinsRL , CarpentierYA , Clinical Investigators Study Group. Plasma lipids and liporoteins during atorvastatin (ATVS) up‐titration in hemodialysis patients with hyperlipidemia: a placebo‐controlled study [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):124. LinsRL , MatthysKE , BilliouwJM , DratwaM , DupontP , LameireNH , et al. Lipid and apoprotein changes during atorvastatin up‐titration in hemodialysis patients with hypercholesterolemia: a placebo‐controlled study. Clinical Nephrology2004;62(4):287‐94. [MEDLINE: 15524059] ">Lins 2004</a>; <a href="./references#CD004289-bbs2-0014" title="CollinsJF , RobsonR , MacMahonS , BaileyRR , PERFECT Study Group. Safety and efficacy of enalapril and simvastatin in dialysis patients [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5‐9; Hong Kong. 1995:144. RobsonR , CollinsJ , JohnsonR , KitchingR , SearleM , WalkerR , et al. Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. Journal of Nephrology1997;10(1):33‐40. [MEDLINE: 9241623] RobsonR , CollinsJ , KitchingsR , SearleM , WalkerR , SharpeN , et al. A randomized controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. Journal of the American Society of Nephrology1994;5(3):526. RobsonRA , CollinsJ , WalkerRJ , MacMahonS . A randomised controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid (Spain). 1995:530. WalkerRJ , SutherlandWH , WalkerH . Simvastatin and cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid (Spain). 1995:529. WalkerRJ , SutherlandWH , WalkerH , RobsonRA , MacMahonSA . The effects of simvastatin and enalapril on plasma cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5‐9; Hong Kong. 1995:28. WalkerRJ , SutherlandWH , WalkerHL , MacMahonS , RobsonRA . Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT Study Collaborative Group. Nephrology Dialysis Transplantation1997;12(1):87‐92. [MEDLINE: 9027779] ">PERFECT Study 1997</a>; <a href="./references#CD004289-bbs2-0015" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi HD 2002</a>‐<a href="./references#CD004289-bbs2-0016" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi PD 2002</a>; <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a>; <a href="./references#CD004289-bbs2-0021" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK‐HARP‐I) study: biochemical efficacy and safety of simvastatin and safety of low‐dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473‐84. [MEDLINE: 15754269] BaigentC , UK‐HARP Steering Committee. Efficacy and safety of simvastatin and safety of low‐dose aspirin among patients with chronic kidney disease: final results of the first UK‐heart and renal protection (UK‐HARP‐I) study [abstract]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. ">UK‐HARP‐I 2005</a>); six did not indicate blinding (<a href="./references#CD004289-bbs2-0010" title="HanSH , KangEW , YoonSJ , LeeHC , YooTH , ChoiKH , et al. Combined vascular effects of HMG‐CoA reductase inhibitor and angiotensin receptor blocker in non‐diabetic patients undergoing peritoneal dialysis. Nephrology Dialysis Transplantation2011;26(11):3722‐8. [MEDLINE: 21385862] ">Han 2011</a>; <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a>; <a href="./references#CD004289-bbs2-0020" title="TseKC , YungS , TangCS , TamS , LaiKN , ChanTM . Atorvastatin at conventional dose did not reduce C‐reactive protein in patients on peritoneal dialysis. Journal of Nephrology2008;21(3):283. [MEDLINE: 18587714] ">Tse 2008</a>; <a href="./references#CD004289-bbs2-0022" title="van denAkkerJM , BredieSJ , DiepenveenSH , vanTitsLJ , StalenhoefAF , vanLeusenR . Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C‐reactive protein and in vivo oxidized LDL. Journal of Nephrology2003;16(2):238‐44. [MEDLINE: 12768071] ">van den Akker 2003</a>; <a href="./references#CD004289-bbs2-0023" title="VareesangthipK , LaouthaiwattanaP , HanlakornP , SuwannatonL , LarpkitkachornR , ChuawattanaD , et al. Effects of simvastatin on the kinetics of erythrocyte sodium lithium countertransport and C‐reactive protein in hemodialysis patients [abstract]. Journal of the American Society of Nephrology2005;16:276A. ">Vareesangthip 2005</a>; <a href="./references#CD004289-bbs2-0025" title="VernaglioneL , CristofanoC , MuscogiuriP , ChimientiS . Does atorvastatin influence serum C‐reactive protein levels in patients on long‐term hemodialysis?. American Journal of Kidney Diseases2004;43(3):471‐8. [MEDLINE: 14981605] VernaglioneL , CristofanoC , MuscogiuriP , PennacchiottiF , ChimientiS . Analysis of the impact of atorvastatin (ATO) on c‐reactive protein (CRP) levels in haemodialysis patients (HDP) [abstract]. Journal of the American Society of Nephrology2003;14(Nov):41A. VernaglioneL , CristofanoC , PennacchiottiF , MuscogiuriP , ChimientiS . Effects of atorvastatin (ATO) on C‐reactive protein (CRP) levels in haemodialysis patients (HDP) : a prospective study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):712‐3. ">Vernaglione 2003</a>); and six did not blind participants (<a href="./references#CD004289-bbs2-0002" title="AhmadiFI , EslamiK , MaziarS , Lessan‐PezeshkiM , KhatamiMR , Mahdavi‐mazdehM , et al. Effect of lovastatin on high‐sensitivity C‐reactive protein and hemoglobin in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv229. AhmadiFL , EslamiK , MaziarS , Lessan‐PezeshkiM , Reza‐KhatamiM , Mahdavi‐mazdehM , et al. Effect of lovastatin on C‐reactive protein and hemoglobin in hemodialysis patients [abstract]. Nephrology2005;10(Suppl):A283‐4. ">Ahmadi 2005</a>; <a href="./references#CD004289-bbs2-0007" title="ChangJW , LeeMS , KinSB , YangWS , ParkSK , LeeSK , et al. Simvastatin decreased high‐sensitive c‐reactive protein (hs‐CRP) and increased serum albumin in hemodialysis (HD) patients [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):353A. ChangJW , YangWS , MinWK , LeeSK , ParkJS , KimSB . Effects of simvastatin on high‐sensitivity C‐reactive protein and serum albumin in hemodialysis patients. American Journal of Kidney Diseases2002;39(6):1213‐7. [MEDLINE: 12046033] ">Chang 2002</a>; <a href="./references#CD004289-bbs2-0009" title="Dornbrook‐LavenderKA , JoyMS , Denu‐CioccaCJ , ChinH , HoganSL , PieperJA . Effects of atorvastatin on low‐density lipoprotein cholesterol phenotype and C‐reactive protein levels in patients undergoing long‐term dialysis. Pharmacotherapy2005;25(3):335‐44. [MEDLINE: 15843280] JoyMS , Dornbrook‐LavenderKA , ChinH , HoganSL , Denu‐CioccaC . Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients. Annals of Pharmacotherapy2008;42(1):9‐15. [MEDLINE: 18000162] JoyMS , Dornbrook‐LavenderKA , ChinH , HoganSL , Denu‐CioccaCJ . Atorvastatin can safely and effectively improve cholesterol and contemporary measures of cardiovascular risks in hemodialysis patients [abstract]. Journal of the American Society of Nephrology2004;15(Oct):615A. ">Dornbrook‐Lavender 2005</a>; <a href="./references#CD004289-bbs2-0019" title="HolmbergB , BrannstromM , BuchtB , CrougneauV , DimenyE , EkspongA , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):503‐10. [MEDLINE: 16303728] StegmayrBG , BrannstromM , BuchtS , DimenyE , EkspongA , GranrothB , et al. Safety and efficacy of atorvastatin in patients with impaired renal function [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna (Austria). 2001:134. StegmayrBG , BrännströmM , BuchtS , CrougneauV , DimenyE , EkspongA , et al. Low‐dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):489‐97. [MEDLINE: 18161210] StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GoschJ , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):161A. StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GranrothB , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):268A. ">Stegmayr 2005</a>; <a href="./references#CD004289-bbs2-0024" title="Velickovic‐RadovanovicR , AvramovicM , MalobabicZ , DjordjevicV , KosticS , MiticB . Therapeutic effects of simvastatin on hyperlipidemia in uraemic patients on CAPD [abstract]. Nephrology Dialysis Transplantation1997;12(9):A187. ">Velickovic 1997</a>; <a href="./references#CD004289-bbs2-0026" title="YuMH , LeeJH , MinWK , ChiHS , ChangJW , YangWS , et al. Effects of ezetimibe and ezetimibe plus simvastatin (Vytorin®) on markers for inflammation and thrombogenesis in end‐stage renal disease (ESRD) patients [abstract]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi322. ">Yu 2007</a>). </p> </section> <section id="CD004289-sec-0068"> <h4 class="title">Incomplete outcome data</h4> <p>Drop‐outs and losses to follow‐up ranged for 0% to 32%. Seven studies were judged to be at low risk of bias (<a href="./references#CD004289-bbs2-0001" title="DrechslerC , KraneV , GrootendorstDC , RitzE , WinklerK , MarzW , et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrology Dialysis Transplantation2009;24(10):3151‐7. [MEDLINE: 19474272] DrechslerC , KraneV , RitzE , MarzW , WannerC . Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation2009;120(24):2421‐8. [MEDLINE: 19948978] DrechslerC , KraneV , WinklerK , DekkerFW , WannerC . Increasing adiponectin is associated with cardiovascular events and mortality in diabetic patients on hemodialysis [abstract]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):727A. KraneV , BergerM , LilienthalJ , WinklerK , SchambeckC , WannerC , et al. Antibodies to platelet factor 4‐heparin complex and outcome in hemodialysis patients with diabetes. Clinical Journal of The American Society of Nephrology: CJASN2010;5(5):874‐81. [MEDLINE: 20185595] KraneV , HeinrichF , MeesmannM , OlschewskiM , LilienthalJ , AngermannC , et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clinical Journal of The American Society of Nephrology: CJASN2009;4(2):394‐400. [MEDLINE: 19158371] KraneV , KrieterDH , OlschewskiM , MaerzW , MannJFE , RitzE , et al. Impact of dialyzer membrane characteristics on outcome in type 2 diabetic patients on maintenance hemodialysis: results of the 4D study [abstract]. Journal of the American Society of Nephrology2006;17(Abstracts):22A. KraneV , MaerzW , RufG , RitzE , WannerC . Atorvastatin in Type 2 diabetic patients on hemodialysis (4D‐study): baseline characteristics and 1st interim analysis [abstract]. Journal of the American Society of Nephrology2003;14(Nov):496A. KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. American Journal of Kidney Diseases2009;54(5):902‐11. [MEDLINE: 19781835] KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International2008;74(11):1461‐7. [MEDLINE: 18818679] MarzW , GenserB , DrechslerC , KraneV , GrammerTB , RitzE , et al. Atorvastatin and low‐density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN2011;6(6):1316‐25. [MEDLINE: 21493741] WannerC , KraneV , MarzW , OlschewskiM , AsmusHG , KramerW , et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney &amp; Blood Pressure Research2004;27(4):259‐66. [MEDLINE: 15316128] WannerC , KraneV , MärzW , OlschewskiM , MannJF , RufG , et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine2005;353(3):238‐48. [MEDLINE: 16034009] WannerC , KraneV , RufG , MarzW , RitzE . Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney International ‐ Supplement1999;56(Suppl 71):S222‐6. [MEDLINE: 10412782] ">4D Study 2004</a>; <a href="./references#CD004289-bbs2-0004" title="ArabulM , GulluluM , YilmazY , AkdagI , KahveciogluS , ErenMA , et al. Effect of fluvastatin on serum prohepcidin levels in patients with end‐stage renal disease. Clinical Biochemistry2008;41(13):1055‐8. [MEDLINE: 18571502] ">Arabul 2008</a>; <a href="./references#CD004289-bbs2-0005" title="FellstromB , HoldaasH , JardineAG , RoseH , SchmiederR , WilpshaarW , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney &amp; Blood Pressure Research2007;30(5):314‐22. [MEDLINE: 17671394] FellstromB , HoldaasH , JardineAG , SchmiederRE , HolmeI , ZannadF . Normalisation of CRP and LDL‐C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:218a. FellstromB , JardineAG , HoldaasH , SchmiederR , GottlowM , JohnssonE , et al. Effect of rosuvastatin versus placebo on cardiovascular outcomes in patients with end‐stage renal disease on hemodialysis ‐ results of the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , ArmstrongJ , et al. A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events ‐ the AURORA study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):713. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , RoseH , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients ‐ Design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine2005;6:9. [EMBASE: 2005487466] FellstromBC , JardineAG , SchmiederRE , HoldaasH , BannisterK , BeutlerJ , et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine2009;360(14):1395‐407. [MEDLINE: 19332456] HoldaasH , FellstromB , HolmeI , SchmiederRE , ZannadF , JardineAG . Rosuvastatin and LDL cholesterol in diabetic patients receiving hemodialysis ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:12A. HoldaasH , HolmeI , SchmiederRE , JardineAG , ZannadF , NorbyGE , et al. Rosuvastatin in diabetic hemodialysis patients. Journal of the American Society of Nephrology2011;22(7):1335‐41. [MEDLINE: 21566054] HoldaasH , JardineAG , SchmiederR , GottlowM , JohnssonE , ZannadF , et al. Effect of rosuvastatin on cardiovascular outcomes in diabetic patients receiving hemodialysis ‐ results from the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. JardineAG , FellstromB , HoldaasH , GottlowM , JohnssonE , ZannadF , et al. Risk factors for cardiovascular events in patients receiving haemodialysis ‐ post hoc analyses of the AURORA study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. ">AURORA Study 2005</a>; <a href="./references#CD004289-bbs2-0008" title="BiloHJ , DiepeveenSJ , VerhoevenGH , van derPalenJ , DikkescheiBD , et al. Vitaestat 1: alpha‐tocopherol and atorvastatin in HD‐ and PD‐ patients: a short‐term, prospective randomised placebo‐controlled intervention trial [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):191A. DiepeveenSH , VerhoevenGH , van derPalenJ , DikkescheiLD , DenmackerPN , KolstersG , et al. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised‐controlled trial. Journal of Internal Medicine2005;257(5):438‐45. [MEDLINE: 15836660] DiepeveenSH , VerhoevenGH , van derPalenJ , DikkescheiLD , DenmackerPN , KolstersG , et al. Vitaestat 1: a prospective randomised placebo controlled trial with a‐tocoferol and atorvastatin in patients in hemo‐ and peritoneal dialysis [abstract]. Nephrology Dialysis Transplantation2001;16(6):A87. ">Diepeveen 2005</a>; <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a>; <a href="./references#CD004289-bbs2-0019" title="HolmbergB , BrannstromM , BuchtB , CrougneauV , DimenyE , EkspongA , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):503‐10. [MEDLINE: 16303728] StegmayrBG , BrannstromM , BuchtS , DimenyE , EkspongA , GranrothB , et al. Safety and efficacy of atorvastatin in patients with impaired renal function [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna (Austria). 2001:134. StegmayrBG , BrännströmM , BuchtS , CrougneauV , DimenyE , EkspongA , et al. Low‐dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):489‐97. [MEDLINE: 18161210] StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GoschJ , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):161A. StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GranrothB , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):268A. ">Stegmayr 2005</a>; <a href="./references#CD004289-bbs2-0021" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK‐HARP‐I) study: biochemical efficacy and safety of simvastatin and safety of low‐dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473‐84. [MEDLINE: 15754269] BaigentC , UK‐HARP Steering Committee. Efficacy and safety of simvastatin and safety of low‐dose aspirin among patients with chronic kidney disease: final results of the first UK‐heart and renal protection (UK‐HARP‐I) study [abstract]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. ">UK‐HARP‐I 2005</a>), six were at high risk (<a href="./references#CD004289-bbs2-0006" title="BurmeisterJE , MiltersteinerDR , CamposBM . Rosuvastatin in hemodialysis: short‐term effects on lipids and C‐reactive protein. Journal of Nephrology2009;22(1):83‐89. [MEDLINE: 19229822] BurmeisterJE , MiltersteinerDR , CostaMG , CamposBM . Short‐term results of rosuvastatin therapy over lipid profile and hs‐C‐reactive protein in patients on regular hemodialysis [abstract]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv472. ">Burmeister 2006</a>; <a href="./references#CD004289-bbs2-0007" title="ChangJW , LeeMS , KinSB , YangWS , ParkSK , LeeSK , et al. Simvastatin decreased high‐sensitive c‐reactive protein (hs‐CRP) and increased serum albumin in hemodialysis (HD) patients [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):353A. ChangJW , YangWS , MinWK , LeeSK , ParkJS , KimSB . Effects of simvastatin on high‐sensitivity C‐reactive protein and serum albumin in hemodialysis patients. American Journal of Kidney Diseases2002;39(6):1213‐7. [MEDLINE: 12046033] ">Chang 2002</a>; <a href="./references#CD004289-bbs2-0009" title="Dornbrook‐LavenderKA , JoyMS , Denu‐CioccaCJ , ChinH , HoganSL , PieperJA . Effects of atorvastatin on low‐density lipoprotein cholesterol phenotype and C‐reactive protein levels in patients undergoing long‐term dialysis. Pharmacotherapy2005;25(3):335‐44. [MEDLINE: 15843280] JoyMS , Dornbrook‐LavenderKA , ChinH , HoganSL , Denu‐CioccaC . Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients. Annals of Pharmacotherapy2008;42(1):9‐15. [MEDLINE: 18000162] JoyMS , Dornbrook‐LavenderKA , ChinH , HoganSL , Denu‐CioccaCJ . Atorvastatin can safely and effectively improve cholesterol and contemporary measures of cardiovascular risks in hemodialysis patients [abstract]. Journal of the American Society of Nephrology2004;15(Oct):615A. ">Dornbrook‐Lavender 2005</a>; <a href="./references#CD004289-bbs2-0011" title="HarrisKP , WheelerDC , ChongCC , Atorvastatin in CAPD Study Investigators. A placebo controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney International2002;61(4):1469‐74. [MEDLINE: 11918754] WheelerD , HarrisKP , UK CAPD Investigators. A placebo‐controlled trial examining the efficacy and safety of atorvastatin in dyslipidaemic patients undergoing CAPD [abstract]. Nephrology Dialysis Transplantation2001;16(6):A196. ">Harris 2002</a>; <a href="./references#CD004289-bbs2-0015" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi HD 2002</a>‐<a href="./references#CD004289-bbs2-0016" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi PD 2002</a>; <a href="./references#CD004289-bbs2-0022" title="van denAkkerJM , BredieSJ , DiepenveenSH , vanTitsLJ , StalenhoefAF , vanLeusenR . Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C‐reactive protein and in vivo oxidized LDL. Journal of Nephrology2003;16(2):238‐44. [MEDLINE: 12768071] ">van den Akker 2003</a>), and the remaining 12 studies were unclear. </p> </section> <section id="CD004289-sec-0069"> <h4 class="title">Selective reporting</h4> <p>Overall, nine studies (36%) reported all expected outcomes (<a href="./references#CD004289-bbs2-0001" title="DrechslerC , KraneV , GrootendorstDC , RitzE , WinklerK , MarzW , et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrology Dialysis Transplantation2009;24(10):3151‐7. [MEDLINE: 19474272] DrechslerC , KraneV , RitzE , MarzW , WannerC . Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation2009;120(24):2421‐8. [MEDLINE: 19948978] DrechslerC , KraneV , WinklerK , DekkerFW , WannerC . Increasing adiponectin is associated with cardiovascular events and mortality in diabetic patients on hemodialysis [abstract]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):727A. KraneV , BergerM , LilienthalJ , WinklerK , SchambeckC , WannerC , et al. Antibodies to platelet factor 4‐heparin complex and outcome in hemodialysis patients with diabetes. Clinical Journal of The American Society of Nephrology: CJASN2010;5(5):874‐81. [MEDLINE: 20185595] KraneV , HeinrichF , MeesmannM , OlschewskiM , LilienthalJ , AngermannC , et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clinical Journal of The American Society of Nephrology: CJASN2009;4(2):394‐400. [MEDLINE: 19158371] KraneV , KrieterDH , OlschewskiM , MaerzW , MannJFE , RitzE , et al. Impact of dialyzer membrane characteristics on outcome in type 2 diabetic patients on maintenance hemodialysis: results of the 4D study [abstract]. Journal of the American Society of Nephrology2006;17(Abstracts):22A. KraneV , MaerzW , RufG , RitzE , WannerC . Atorvastatin in Type 2 diabetic patients on hemodialysis (4D‐study): baseline characteristics and 1st interim analysis [abstract]. Journal of the American Society of Nephrology2003;14(Nov):496A. KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. American Journal of Kidney Diseases2009;54(5):902‐11. [MEDLINE: 19781835] KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International2008;74(11):1461‐7. [MEDLINE: 18818679] MarzW , GenserB , DrechslerC , KraneV , GrammerTB , RitzE , et al. Atorvastatin and low‐density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN2011;6(6):1316‐25. [MEDLINE: 21493741] WannerC , KraneV , MarzW , OlschewskiM , AsmusHG , KramerW , et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney &amp; Blood Pressure Research2004;27(4):259‐66. [MEDLINE: 15316128] WannerC , KraneV , MärzW , OlschewskiM , MannJF , RufG , et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine2005;353(3):238‐48. [MEDLINE: 16034009] WannerC , KraneV , RufG , MarzW , RitzE . Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney International ‐ Supplement1999;56(Suppl 71):S222‐6. [MEDLINE: 10412782] ">4D Study 2004</a>; <a href="./references#CD004289-bbs2-0004" title="ArabulM , GulluluM , YilmazY , AkdagI , KahveciogluS , ErenMA , et al. Effect of fluvastatin on serum prohepcidin levels in patients with end‐stage renal disease. Clinical Biochemistry2008;41(13):1055‐8. [MEDLINE: 18571502] ">Arabul 2008</a>; <a href="./references#CD004289-bbs2-0005" title="FellstromB , HoldaasH , JardineAG , RoseH , SchmiederR , WilpshaarW , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney &amp; Blood Pressure Research2007;30(5):314‐22. [MEDLINE: 17671394] FellstromB , HoldaasH , JardineAG , SchmiederRE , HolmeI , ZannadF . Normalisation of CRP and LDL‐C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:218a. FellstromB , JardineAG , HoldaasH , SchmiederR , GottlowM , JohnssonE , et al. Effect of rosuvastatin versus placebo on cardiovascular outcomes in patients with end‐stage renal disease on hemodialysis ‐ results of the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , ArmstrongJ , et al. A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events ‐ the AURORA study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):713. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , RoseH , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients ‐ Design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine2005;6:9. [EMBASE: 2005487466] FellstromBC , JardineAG , SchmiederRE , HoldaasH , BannisterK , BeutlerJ , et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine2009;360(14):1395‐407. [MEDLINE: 19332456] HoldaasH , FellstromB , HolmeI , SchmiederRE , ZannadF , JardineAG . Rosuvastatin and LDL cholesterol in diabetic patients receiving hemodialysis ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:12A. HoldaasH , HolmeI , SchmiederRE , JardineAG , ZannadF , NorbyGE , et al. Rosuvastatin in diabetic hemodialysis patients. Journal of the American Society of Nephrology2011;22(7):1335‐41. [MEDLINE: 21566054] HoldaasH , JardineAG , SchmiederR , GottlowM , JohnssonE , ZannadF , et al. Effect of rosuvastatin on cardiovascular outcomes in diabetic patients receiving hemodialysis ‐ results from the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. JardineAG , FellstromB , HoldaasH , GottlowM , JohnssonE , ZannadF , et al. Risk factors for cardiovascular events in patients receiving haemodialysis ‐ post hoc analyses of the AURORA study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. ">AURORA Study 2005</a>; <a href="./references#CD004289-bbs2-0006" title="BurmeisterJE , MiltersteinerDR , CamposBM . Rosuvastatin in hemodialysis: short‐term effects on lipids and C‐reactive protein. Journal of Nephrology2009;22(1):83‐89. [MEDLINE: 19229822] BurmeisterJE , MiltersteinerDR , CostaMG , CamposBM . Short‐term results of rosuvastatin therapy over lipid profile and hs‐C‐reactive protein in patients on regular hemodialysis [abstract]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv472. ">Burmeister 2006</a>; <a href="./references#CD004289-bbs2-0013" title="LinsRL , CarpentierYA , Clinical Investigators Study Group. Plasma lipids and liporoteins during atorvastatin (ATVS) up‐titration in hemodialysis patients with hyperlipidemia: a placebo‐controlled study [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):124. LinsRL , MatthysKE , BilliouwJM , DratwaM , DupontP , LameireNH , et al. Lipid and apoprotein changes during atorvastatin up‐titration in hemodialysis patients with hypercholesterolemia: a placebo‐controlled study. Clinical Nephrology2004;62(4):287‐94. [MEDLINE: 15524059] ">Lins 2004</a>; <a href="./references#CD004289-bbs2-0015" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi HD 2002</a>‐<a href="./references#CD004289-bbs2-0016" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi PD 2002</a>; <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a>; <a href="./references#CD004289-bbs2-0019" title="HolmbergB , BrannstromM , BuchtB , CrougneauV , DimenyE , EkspongA , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):503‐10. [MEDLINE: 16303728] StegmayrBG , BrannstromM , BuchtS , DimenyE , EkspongA , GranrothB , et al. Safety and efficacy of atorvastatin in patients with impaired renal function [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna (Austria). 2001:134. StegmayrBG , BrännströmM , BuchtS , CrougneauV , DimenyE , EkspongA , et al. Low‐dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):489‐97. [MEDLINE: 18161210] StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GoschJ , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):161A. StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GranrothB , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):268A. ">Stegmayr 2005</a>; <a href="./references#CD004289-bbs2-0021" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK‐HARP‐I) study: biochemical efficacy and safety of simvastatin and safety of low‐dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473‐84. [MEDLINE: 15754269] BaigentC , UK‐HARP Steering Committee. Efficacy and safety of simvastatin and safety of low‐dose aspirin among patients with chronic kidney disease: final results of the first UK‐heart and renal protection (UK‐HARP‐I) study [abstract]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. ">UK‐HARP‐I 2005</a>). </p> </section> <section id="CD004289-sec-0070"> <h4 class="title">Other potential sources of bias</h4> <p>Eleven studies (44%) reported industry funding (<a href="./references#CD004289-bbs2-0001" title="DrechslerC , KraneV , GrootendorstDC , RitzE , WinklerK , MarzW , et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrology Dialysis Transplantation2009;24(10):3151‐7. [MEDLINE: 19474272] DrechslerC , KraneV , RitzE , MarzW , WannerC . Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation2009;120(24):2421‐8. [MEDLINE: 19948978] DrechslerC , KraneV , WinklerK , DekkerFW , WannerC . Increasing adiponectin is associated with cardiovascular events and mortality in diabetic patients on hemodialysis [abstract]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):727A. KraneV , BergerM , LilienthalJ , WinklerK , SchambeckC , WannerC , et al. Antibodies to platelet factor 4‐heparin complex and outcome in hemodialysis patients with diabetes. Clinical Journal of The American Society of Nephrology: CJASN2010;5(5):874‐81. [MEDLINE: 20185595] KraneV , HeinrichF , MeesmannM , OlschewskiM , LilienthalJ , AngermannC , et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clinical Journal of The American Society of Nephrology: CJASN2009;4(2):394‐400. [MEDLINE: 19158371] KraneV , KrieterDH , OlschewskiM , MaerzW , MannJFE , RitzE , et al. Impact of dialyzer membrane characteristics on outcome in type 2 diabetic patients on maintenance hemodialysis: results of the 4D study [abstract]. Journal of the American Society of Nephrology2006;17(Abstracts):22A. KraneV , MaerzW , RufG , RitzE , WannerC . Atorvastatin in Type 2 diabetic patients on hemodialysis (4D‐study): baseline characteristics and 1st interim analysis [abstract]. Journal of the American Society of Nephrology2003;14(Nov):496A. KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. American Journal of Kidney Diseases2009;54(5):902‐11. [MEDLINE: 19781835] KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International2008;74(11):1461‐7. [MEDLINE: 18818679] MarzW , GenserB , DrechslerC , KraneV , GrammerTB , RitzE , et al. Atorvastatin and low‐density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN2011;6(6):1316‐25. [MEDLINE: 21493741] WannerC , KraneV , MarzW , OlschewskiM , AsmusHG , KramerW , et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney &amp; Blood Pressure Research2004;27(4):259‐66. [MEDLINE: 15316128] WannerC , KraneV , MärzW , OlschewskiM , MannJF , RufG , et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine2005;353(3):238‐48. [MEDLINE: 16034009] WannerC , KraneV , RufG , MarzW , RitzE . Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney International ‐ Supplement1999;56(Suppl 71):S222‐6. [MEDLINE: 10412782] ">4D Study 2004</a>; <a href="./references#CD004289-bbs2-0005" title="FellstromB , HoldaasH , JardineAG , RoseH , SchmiederR , WilpshaarW , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney &amp; Blood Pressure Research2007;30(5):314‐22. [MEDLINE: 17671394] FellstromB , HoldaasH , JardineAG , SchmiederRE , HolmeI , ZannadF . Normalisation of CRP and LDL‐C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:218a. FellstromB , JardineAG , HoldaasH , SchmiederR , GottlowM , JohnssonE , et al. Effect of rosuvastatin versus placebo on cardiovascular outcomes in patients with end‐stage renal disease on hemodialysis ‐ results of the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , ArmstrongJ , et al. A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events ‐ the AURORA study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):713. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , RoseH , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients ‐ Design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine2005;6:9. [EMBASE: 2005487466] FellstromBC , JardineAG , SchmiederRE , HoldaasH , BannisterK , BeutlerJ , et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine2009;360(14):1395‐407. [MEDLINE: 19332456] HoldaasH , FellstromB , HolmeI , SchmiederRE , ZannadF , JardineAG . Rosuvastatin and LDL cholesterol in diabetic patients receiving hemodialysis ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:12A. HoldaasH , HolmeI , SchmiederRE , JardineAG , ZannadF , NorbyGE , et al. Rosuvastatin in diabetic hemodialysis patients. Journal of the American Society of Nephrology2011;22(7):1335‐41. [MEDLINE: 21566054] HoldaasH , JardineAG , SchmiederR , GottlowM , JohnssonE , ZannadF , et al. Effect of rosuvastatin on cardiovascular outcomes in diabetic patients receiving hemodialysis ‐ results from the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. JardineAG , FellstromB , HoldaasH , GottlowM , JohnssonE , ZannadF , et al. Risk factors for cardiovascular events in patients receiving haemodialysis ‐ post hoc analyses of the AURORA study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. ">AURORA Study 2005</a>; <a href="./references#CD004289-bbs2-0006" title="BurmeisterJE , MiltersteinerDR , CamposBM . Rosuvastatin in hemodialysis: short‐term effects on lipids and C‐reactive protein. Journal of Nephrology2009;22(1):83‐89. [MEDLINE: 19229822] BurmeisterJE , MiltersteinerDR , CostaMG , CamposBM . Short‐term results of rosuvastatin therapy over lipid profile and hs‐C‐reactive protein in patients on regular hemodialysis [abstract]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv472. ">Burmeister 2006</a>; <a href="./references#CD004289-bbs2-0007" title="ChangJW , LeeMS , KinSB , YangWS , ParkSK , LeeSK , et al. Simvastatin decreased high‐sensitive c‐reactive protein (hs‐CRP) and increased serum albumin in hemodialysis (HD) patients [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):353A. ChangJW , YangWS , MinWK , LeeSK , ParkJS , KimSB . Effects of simvastatin on high‐sensitivity C‐reactive protein and serum albumin in hemodialysis patients. American Journal of Kidney Diseases2002;39(6):1213‐7. [MEDLINE: 12046033] ">Chang 2002</a>; <a href="./references#CD004289-bbs2-0008" title="BiloHJ , DiepeveenSJ , VerhoevenGH , van derPalenJ , DikkescheiBD , et al. Vitaestat 1: alpha‐tocopherol and atorvastatin in HD‐ and PD‐ patients: a short‐term, prospective randomised placebo‐controlled intervention trial [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):191A. DiepeveenSH , VerhoevenGH , van derPalenJ , DikkescheiLD , DenmackerPN , KolstersG , et al. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised‐controlled trial. Journal of Internal Medicine2005;257(5):438‐45. [MEDLINE: 15836660] DiepeveenSH , VerhoevenGH , van derPalenJ , DikkescheiLD , DenmackerPN , KolstersG , et al. Vitaestat 1: a prospective randomised placebo controlled trial with a‐tocoferol and atorvastatin in patients in hemo‐ and peritoneal dialysis [abstract]. Nephrology Dialysis Transplantation2001;16(6):A87. ">Diepeveen 2005</a>; <a href="./references#CD004289-bbs2-0009" title="Dornbrook‐LavenderKA , JoyMS , Denu‐CioccaCJ , ChinH , HoganSL , PieperJA . Effects of atorvastatin on low‐density lipoprotein cholesterol phenotype and C‐reactive protein levels in patients undergoing long‐term dialysis. Pharmacotherapy2005;25(3):335‐44. [MEDLINE: 15843280] JoyMS , Dornbrook‐LavenderKA , ChinH , HoganSL , Denu‐CioccaC . Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients. Annals of Pharmacotherapy2008;42(1):9‐15. [MEDLINE: 18000162] JoyMS , Dornbrook‐LavenderKA , ChinH , HoganSL , Denu‐CioccaCJ . Atorvastatin can safely and effectively improve cholesterol and contemporary measures of cardiovascular risks in hemodialysis patients [abstract]. Journal of the American Society of Nephrology2004;15(Oct):615A. ">Dornbrook‐Lavender 2005</a>; <a href="./references#CD004289-bbs2-0013" title="LinsRL , CarpentierYA , Clinical Investigators Study Group. Plasma lipids and liporoteins during atorvastatin (ATVS) up‐titration in hemodialysis patients with hyperlipidemia: a placebo‐controlled study [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):124. LinsRL , MatthysKE , BilliouwJM , DratwaM , DupontP , LameireNH , et al. Lipid and apoprotein changes during atorvastatin up‐titration in hemodialysis patients with hypercholesterolemia: a placebo‐controlled study. Clinical Nephrology2004;62(4):287‐94. [MEDLINE: 15524059] ">Lins 2004</a>; <a href="./references#CD004289-bbs2-0014" title="CollinsJF , RobsonR , MacMahonS , BaileyRR , PERFECT Study Group. Safety and efficacy of enalapril and simvastatin in dialysis patients [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5‐9; Hong Kong. 1995:144. RobsonR , CollinsJ , JohnsonR , KitchingR , SearleM , WalkerR , et al. Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. Journal of Nephrology1997;10(1):33‐40. [MEDLINE: 9241623] RobsonR , CollinsJ , KitchingsR , SearleM , WalkerR , SharpeN , et al. A randomized controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. Journal of the American Society of Nephrology1994;5(3):526. RobsonRA , CollinsJ , WalkerRJ , MacMahonS . A randomised controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid (Spain). 1995:530. WalkerRJ , SutherlandWH , WalkerH . Simvastatin and cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid (Spain). 1995:529. WalkerRJ , SutherlandWH , WalkerH , RobsonRA , MacMahonSA . The effects of simvastatin and enalapril on plasma cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5‐9; Hong Kong. 1995:28. WalkerRJ , SutherlandWH , WalkerHL , MacMahonS , RobsonRA . Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT Study Collaborative Group. Nephrology Dialysis Transplantation1997;12(1):87‐92. [MEDLINE: 9027779] ">PERFECT Study 1997</a>; <a href="./references#CD004289-bbs2-0015" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi HD 2002</a>‐<a href="./references#CD004289-bbs2-0016" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi PD 2002</a>; <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a>; <a href="./references#CD004289-bbs2-0021" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al. First United Kingdom Heart and Renal Protection (UK‐HARP‐I) study: biochemical efficacy and safety of simvastatin and safety of low‐dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473‐84. [MEDLINE: 15754269] BaigentC , UK‐HARP Steering Committee. Efficacy and safety of simvastatin and safety of low‐dose aspirin among patients with chronic kidney disease: final results of the first UK‐heart and renal protection (UK‐HARP‐I) study [abstract]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. ">UK‐HARP‐I 2005</a>) </p> </section> </section> <section id="CD004289-sec-0071"> <h3 class="title" id="CD004289-sec-0071">Effects of interventions</h3> <p>See: <a href="./full#CD004289-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <section id="CD004289-sec-0072"> <h4 class="title">Statins versus placebo or no treatment</h4> <p>We found moderate‐to‐high quality evidence to indicate that statin therapy had little or no effect on risks of major cardiovascular events (<a href="./references#CD004289-fig-0004" title="">Analysis 1.1</a> (4 studies, 7084 participants): RR 0.95, 95% CI 0.88 to 1.03), all‐cause mortality (<a href="./references#CD004289-fig-0005" title="">Analysis 1.2</a> (13 studies, 4705 participants): RR 0.96, 95% CI 0.90 to 1.02) and cardiovascular mortality (<a href="./references#CD004289-fig-0006" title="">Analysis 1.3</a> (13 studies, 4627 participants): RR 0.94, 95% CI 0.84 to 1.06) (<a href="./full#CD004289-tbl-0001">summary of findings Table for the main comparison</a>). Statins had little or no effect on risks of fatal or non‐fatal myocardial infarction (<a href="./references#CD004289-fig-0007" title="">Analysis 1.4</a> (3 studies, 4047 participants): RR 0.87, 95% CI 0.71 to 1.07) and had uncertain effects on fatal or non‐fatal stroke (<a href="./references#CD004289-fig-0008" title="">Analysis 1.5</a> (2 studies, 4018 participants): RR 1.29, 95% CI 0.96 to 1.72). There was no evidence of heterogeneity in these analyses (I² = 0%). </p> <p>Statins had uncertain effects on adverse events, including elevation of creatine kinase (<a href="./references#CD004289-fig-0009" title="">Analysis 1.6</a> (5 studies, 3067 participants): RR 1.25, 95% CI 0.55 to 2.83), elevated liver enzymes (<a href="./references#CD004289-fig-0010" title="">Analysis 1.7</a> (4 studies, 3044 participants): RR 1.09, 95% CI 0.41 to 2.91), withdrawal due to adverse events (<a href="./references#CD004289-fig-0011" title="">Analysis 1.8</a> (9 studies, 1832 participants): RR 1.04, 95% CI 0.87 to 1.25) and cancer (<a href="./references#CD004289-fig-0012" title="">Analysis 1.9</a> (2 studies, 4012 participants): RR 0.90, 95% CI 0.72 to 1.11) (<a href="./full#CD004289-tbl-0001">summary of findings Table for the main comparison</a>). There was no evidence of heterogeneity in these analyses (I² = 0%). </p> <p>Statins significantly reduced total cholesterol (<a href="./references#CD004289-fig-0013" title="">Analysis 1.10</a> (14 studies, 1803 participants): MD ‐44.86 mg/dL, 95% CI ‐55.19 to ‐34.53), LDL cholesterol (<a href="./references#CD004289-fig-0014" title="">Analysis 1.11</a> (12 studies, 1747 participants): MD ‐39.99 mg/dL, 95% CI ‐52.46 to ‐27.52) and triglycerides (<a href="./references#CD004289-fig-0015" title="">Analysis 1.12</a> (13 studies, 1692 participants): MD ‐18.02 mg/dL, 95% CI ‐33.00 to ‐3.04), but had uncertain effects on HDL cholesterol (<a href="./references#CD004289-fig-0016" title="">Analysis 1.13</a> (13 studies, 1769 participants): MD 2.57 mg/dL, 95% CI ‐0.39 to 5.52). </p> </section> <section id="CD004289-sec-0073"> <h4 class="title">Analysis of heterogeneity</h4> <p>We did not identify any sources of heterogeneity in the analyses for total or LDL cholesterol using prespecified subgroup analyses (dialysis type or statin type or dose, age, proportion with diabetes, baseline serum cholesterol, risk of bias (allocation concealment)). The lack of specific populations with or without cardiovascular disease at baseline in the available studies prevented subgroup analysis for the effect of statins by the presence or absence of cardiovascular disease. </p> </section> <section id="CD004289-sec-0074"> <h4 class="title">Statin versus other statin</h4> <p><a href="./references#CD004289-bbs2-0022" title="van denAkkerJM , BredieSJ , DiepenveenSH , vanTitsLJ , StalenhoefAF , vanLeusenR . Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C‐reactive protein and in vivo oxidized LDL. Journal of Nephrology2003;16(2):238‐44. [MEDLINE: 12768071] ">van den Akker 2003</a> (28 participants) compared atorvastatin (10 to 40 mg/d) with simvastatin (10 to 40 mg/d), and <a href="./references#CD004289-bbs2-0018" title="SoliemaniA , NikoueinejadH , TabatabaizadeM , MianehsazE , TamadonM . Effect of hydroxymethylglutaryl‐CoA reductase inhibitors on low‐density lipoprotein cholesterol, interleukin‐6, and high‐sensitivity C‐reactive protein in end‐stage renal disease. Iranian journal of Kidney Diseases2011;5(1):29‐33. [MEDLINE: 21189431] ">Soliemani 2011</a> compared atorvastatin, simvastatin and lovastatin directly (95 participants). Compared to simvastatin, atorvastatin treatment had uncertain effects on elevation of liver enzymes (<a href="./references#CD004289-fig-0017" title="">Analysis 2.1</a> (1 study, 28 participants): RR 5.71, 95% CI 0.30 to 109.22), withdrawal from treatment due to adverse events (<a href="./references#CD004289-fig-0018" title="">Analysis 2.2</a> (1 study, 63 participants): RR 2.06, 95% CI 0.20 to 21.63), total cholesterol (<a href="./references#CD004289-fig-0019" title="">Analysis 2.3</a> (1 study, 28 participants): MD 0.23 mg/dL, 95% CI ‐0.35 to 0.81), LDL cholesterol (<a href="./references#CD004289-fig-0020" title="">Analysis 2.4</a> (1 study, 28 participants): MD 0.06 mg/dL, 95% CI ‐0.40 to 0.52), triglycerides (<a href="./references#CD004289-fig-0021" title="">Analysis 2.5</a> ((1 study, 28 participants): MD ‐0.02 mg/dL, 95% CI ‐0.58 to 0.54), and HDL cholesterol (<a href="./references#CD004289-fig-0022" title="">Analysis 2.6</a> (1 study, 28 participants): 0.10 mg/dL, 95% CI ‐0.13 to 0.33). Data for other outcomes were not available in extractable format. </p> </section> <section id="CD004289-sec-0075"> <h4 class="title">Sensitivity analyses</h4> <p>When analyses were restricted to studies in which follow‐up data were provided for six months or more, the results were unchanged (major cardiovascular events, unchanged from primary result; all‐cause mortality (7 studies, 4328 participants): RR 0.96, 95% CI 0.90 to 1.02) (<a href="./references#CD004289-bbs2-0001" title="DrechslerC , KraneV , GrootendorstDC , RitzE , WinklerK , MarzW , et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrology Dialysis Transplantation2009;24(10):3151‐7. [MEDLINE: 19474272] DrechslerC , KraneV , RitzE , MarzW , WannerC . Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation2009;120(24):2421‐8. [MEDLINE: 19948978] DrechslerC , KraneV , WinklerK , DekkerFW , WannerC . Increasing adiponectin is associated with cardiovascular events and mortality in diabetic patients on hemodialysis [abstract]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):727A. KraneV , BergerM , LilienthalJ , WinklerK , SchambeckC , WannerC , et al. Antibodies to platelet factor 4‐heparin complex and outcome in hemodialysis patients with diabetes. Clinical Journal of The American Society of Nephrology: CJASN2010;5(5):874‐81. [MEDLINE: 20185595] KraneV , HeinrichF , MeesmannM , OlschewskiM , LilienthalJ , AngermannC , et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clinical Journal of The American Society of Nephrology: CJASN2009;4(2):394‐400. [MEDLINE: 19158371] KraneV , KrieterDH , OlschewskiM , MaerzW , MannJFE , RitzE , et al. Impact of dialyzer membrane characteristics on outcome in type 2 diabetic patients on maintenance hemodialysis: results of the 4D study [abstract]. Journal of the American Society of Nephrology2006;17(Abstracts):22A. KraneV , MaerzW , RufG , RitzE , WannerC . Atorvastatin in Type 2 diabetic patients on hemodialysis (4D‐study): baseline characteristics and 1st interim analysis [abstract]. Journal of the American Society of Nephrology2003;14(Nov):496A. KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. American Journal of Kidney Diseases2009;54(5):902‐11. [MEDLINE: 19781835] KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International2008;74(11):1461‐7. [MEDLINE: 18818679] MarzW , GenserB , DrechslerC , KraneV , GrammerTB , RitzE , et al. Atorvastatin and low‐density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN2011;6(6):1316‐25. [MEDLINE: 21493741] WannerC , KraneV , MarzW , OlschewskiM , AsmusHG , KramerW , et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney &amp; Blood Pressure Research2004;27(4):259‐66. [MEDLINE: 15316128] WannerC , KraneV , MärzW , OlschewskiM , MannJF , RufG , et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine2005;353(3):238‐48. [MEDLINE: 16034009] WannerC , KraneV , RufG , MarzW , RitzE . Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney International ‐ Supplement1999;56(Suppl 71):S222‐6. [MEDLINE: 10412782] ">4D Study 2004</a>; <a href="./references#CD004289-bbs2-0005" title="FellstromB , HoldaasH , JardineAG , RoseH , SchmiederR , WilpshaarW , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney &amp; Blood Pressure Research2007;30(5):314‐22. [MEDLINE: 17671394] FellstromB , HoldaasH , JardineAG , SchmiederRE , HolmeI , ZannadF . Normalisation of CRP and LDL‐C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:218a. FellstromB , JardineAG , HoldaasH , SchmiederR , GottlowM , JohnssonE , et al. Effect of rosuvastatin versus placebo on cardiovascular outcomes in patients with end‐stage renal disease on hemodialysis ‐ results of the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , ArmstrongJ , et al. A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events ‐ the AURORA study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):713. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , RoseH , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients ‐ Design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine2005;6:9. [EMBASE: 2005487466] FellstromBC , JardineAG , SchmiederRE , HoldaasH , BannisterK , BeutlerJ , et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine2009;360(14):1395‐407. [MEDLINE: 19332456] HoldaasH , FellstromB , HolmeI , SchmiederRE , ZannadF , JardineAG . Rosuvastatin and LDL cholesterol in diabetic patients receiving hemodialysis ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:12A. HoldaasH , HolmeI , SchmiederRE , JardineAG , ZannadF , NorbyGE , et al. Rosuvastatin in diabetic hemodialysis patients. Journal of the American Society of Nephrology2011;22(7):1335‐41. [MEDLINE: 21566054] HoldaasH , JardineAG , SchmiederR , GottlowM , JohnssonE , ZannadF , et al. Effect of rosuvastatin on cardiovascular outcomes in diabetic patients receiving hemodialysis ‐ results from the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. JardineAG , FellstromB , HoldaasH , GottlowM , JohnssonE , ZannadF , et al. Risk factors for cardiovascular events in patients receiving haemodialysis ‐ post hoc analyses of the AURORA study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. ">AURORA Study 2005</a>; <a href="./references#CD004289-bbs2-0012" title="IchiharaA , HayashiM , RyuzakiM , HandaM , FurukawaT , SarutaT . Effects of fluvastatin on leg arterial stiffness in hemodialysis patients with type 2 diabetes mellitus [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):148A. IchiharaA , HayashiM , RyuzakiM , HandaM , FurukawaT , SarutaT . Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrology Dialysis Transplantation2002;17(8):1513‐7. [MEDLINE: 12147804] ">Ichihara 2002</a>; <a href="./references#CD004289-bbs2-0010" title="HanSH , KangEW , YoonSJ , LeeHC , YooTH , ChoiKH , et al. Combined vascular effects of HMG‐CoA reductase inhibitor and angiotensin receptor blocker in non‐diabetic patients undergoing peritoneal dialysis. Nephrology Dialysis Transplantation2011;26(11):3722‐8. [MEDLINE: 21385862] ">Han 2011</a>; <a href="./references#CD004289-bbs2-0014" title="CollinsJF , RobsonR , MacMahonS , BaileyRR , PERFECT Study Group. Safety and efficacy of enalapril and simvastatin in dialysis patients [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5‐9; Hong Kong. 1995:144. RobsonR , CollinsJ , JohnsonR , KitchingR , SearleM , WalkerR , et al. Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. Journal of Nephrology1997;10(1):33‐40. [MEDLINE: 9241623] RobsonR , CollinsJ , KitchingsR , SearleM , WalkerR , SharpeN , et al. A randomized controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. Journal of the American Society of Nephrology1994;5(3):526. RobsonRA , CollinsJ , WalkerRJ , MacMahonS . A randomised controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid (Spain). 1995:530. WalkerRJ , SutherlandWH , WalkerH . Simvastatin and cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid (Spain). 1995:529. WalkerRJ , SutherlandWH , WalkerH , RobsonRA , MacMahonSA . The effects of simvastatin and enalapril on plasma cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5‐9; Hong Kong. 1995:28. WalkerRJ , SutherlandWH , WalkerHL , MacMahonS , RobsonRA . Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT Study Collaborative Group. Nephrology Dialysis Transplantation1997;12(1):87‐92. [MEDLINE: 9027779] ">PERFECT Study 1997</a>; <a href="./references#CD004289-bbs2-0015" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi HD 2002</a>‐<a href="./references#CD004289-bbs2-0016" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi PD 2002</a>); cardiovascular mortality ((7 studies, 4247 participants): RR 0.94, 95% CI 0.84 to 1.06) (<a href="./references#CD004289-bbs2-0001" title="DrechslerC , KraneV , GrootendorstDC , RitzE , WinklerK , MarzW , et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrology Dialysis Transplantation2009;24(10):3151‐7. [MEDLINE: 19474272] DrechslerC , KraneV , RitzE , MarzW , WannerC . Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation2009;120(24):2421‐8. [MEDLINE: 19948978] DrechslerC , KraneV , WinklerK , DekkerFW , WannerC . Increasing adiponectin is associated with cardiovascular events and mortality in diabetic patients on hemodialysis [abstract]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):727A. KraneV , BergerM , LilienthalJ , WinklerK , SchambeckC , WannerC , et al. Antibodies to platelet factor 4‐heparin complex and outcome in hemodialysis patients with diabetes. Clinical Journal of The American Society of Nephrology: CJASN2010;5(5):874‐81. [MEDLINE: 20185595] KraneV , HeinrichF , MeesmannM , OlschewskiM , LilienthalJ , AngermannC , et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clinical Journal of The American Society of Nephrology: CJASN2009;4(2):394‐400. [MEDLINE: 19158371] KraneV , KrieterDH , OlschewskiM , MaerzW , MannJFE , RitzE , et al. Impact of dialyzer membrane characteristics on outcome in type 2 diabetic patients on maintenance hemodialysis: results of the 4D study [abstract]. Journal of the American Society of Nephrology2006;17(Abstracts):22A. KraneV , MaerzW , RufG , RitzE , WannerC . Atorvastatin in Type 2 diabetic patients on hemodialysis (4D‐study): baseline characteristics and 1st interim analysis [abstract]. Journal of the American Society of Nephrology2003;14(Nov):496A. KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. American Journal of Kidney Diseases2009;54(5):902‐11. [MEDLINE: 19781835] KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International2008;74(11):1461‐7. [MEDLINE: 18818679] MarzW , GenserB , DrechslerC , KraneV , GrammerTB , RitzE , et al. Atorvastatin and low‐density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN2011;6(6):1316‐25. [MEDLINE: 21493741] WannerC , KraneV , MarzW , OlschewskiM , AsmusHG , KramerW , et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney &amp; Blood Pressure Research2004;27(4):259‐66. [MEDLINE: 15316128] WannerC , KraneV , MärzW , OlschewskiM , MannJF , RufG , et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine2005;353(3):238‐48. [MEDLINE: 16034009] WannerC , KraneV , RufG , MarzW , RitzE . Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney International ‐ Supplement1999;56(Suppl 71):S222‐6. [MEDLINE: 10412782] ">4D Study 2004</a>; <a href="./references#CD004289-bbs2-0005" title="FellstromB , HoldaasH , JardineAG , RoseH , SchmiederR , WilpshaarW , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney &amp; Blood Pressure Research2007;30(5):314‐22. [MEDLINE: 17671394] FellstromB , HoldaasH , JardineAG , SchmiederRE , HolmeI , ZannadF . Normalisation of CRP and LDL‐C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:218a. FellstromB , JardineAG , HoldaasH , SchmiederR , GottlowM , JohnssonE , et al. Effect of rosuvastatin versus placebo on cardiovascular outcomes in patients with end‐stage renal disease on hemodialysis ‐ results of the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , ArmstrongJ , et al. A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events ‐ the AURORA study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):713. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , RoseH , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients ‐ Design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine2005;6:9. [EMBASE: 2005487466] FellstromBC , JardineAG , SchmiederRE , HoldaasH , BannisterK , BeutlerJ , et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine2009;360(14):1395‐407. [MEDLINE: 19332456] HoldaasH , FellstromB , HolmeI , SchmiederRE , ZannadF , JardineAG . Rosuvastatin and LDL cholesterol in diabetic patients receiving hemodialysis ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:12A. HoldaasH , HolmeI , SchmiederRE , JardineAG , ZannadF , NorbyGE , et al. Rosuvastatin in diabetic hemodialysis patients. Journal of the American Society of Nephrology2011;22(7):1335‐41. [MEDLINE: 21566054] HoldaasH , JardineAG , SchmiederR , GottlowM , JohnssonE , ZannadF , et al. Effect of rosuvastatin on cardiovascular outcomes in diabetic patients receiving hemodialysis ‐ results from the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. JardineAG , FellstromB , HoldaasH , GottlowM , JohnssonE , ZannadF , et al. Risk factors for cardiovascular events in patients receiving haemodialysis ‐ post hoc analyses of the AURORA study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. ">AURORA Study 2005</a>; <a href="./references#CD004289-bbs2-0012" title="IchiharaA , HayashiM , RyuzakiM , HandaM , FurukawaT , SarutaT . Effects of fluvastatin on leg arterial stiffness in hemodialysis patients with type 2 diabetes mellitus [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):148A. IchiharaA , HayashiM , RyuzakiM , HandaM , FurukawaT , SarutaT . Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrology Dialysis Transplantation2002;17(8):1513‐7. [MEDLINE: 12147804] ">Ichihara 2002</a>; <a href="./references#CD004289-bbs2-0010" title="HanSH , KangEW , YoonSJ , LeeHC , YooTH , ChoiKH , et al. Combined vascular effects of HMG‐CoA reductase inhibitor and angiotensin receptor blocker in non‐diabetic patients undergoing peritoneal dialysis. Nephrology Dialysis Transplantation2011;26(11):3722‐8. [MEDLINE: 21385862] ">Han 2011</a>; <a href="./references#CD004289-bbs2-0014" title="CollinsJF , RobsonR , MacMahonS , BaileyRR , PERFECT Study Group. Safety and efficacy of enalapril and simvastatin in dialysis patients [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5‐9; Hong Kong. 1995:144. RobsonR , CollinsJ , JohnsonR , KitchingR , SearleM , WalkerR , et al. Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. Journal of Nephrology1997;10(1):33‐40. [MEDLINE: 9241623] RobsonR , CollinsJ , KitchingsR , SearleM , WalkerR , SharpeN , et al. A randomized controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. Journal of the American Society of Nephrology1994;5(3):526. RobsonRA , CollinsJ , WalkerRJ , MacMahonS . A randomised controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid (Spain). 1995:530. WalkerRJ , SutherlandWH , WalkerH . Simvastatin and cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid (Spain). 1995:529. WalkerRJ , SutherlandWH , WalkerH , RobsonRA , MacMahonSA . The effects of simvastatin and enalapril on plasma cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5‐9; Hong Kong. 1995:28. WalkerRJ , SutherlandWH , WalkerHL , MacMahonS , RobsonRA . Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT Study Collaborative Group. Nephrology Dialysis Transplantation1997;12(1):87‐92. [MEDLINE: 9027779] ">PERFECT Study 1997</a>; <a href="./references#CD004289-bbs2-0015" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi HD 2002</a>‐<a href="./references#CD004289-bbs2-0016" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi PD 2002</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004289-sec-0076" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004289-sec-0076"></div> <section id="CD004289-sec-0077"> <h3 class="title" id="CD004289-sec-0077">Summary of main results</h3> <p>This review update on the benefits and harms of statins in people treated with dialysis found that data for mortality and cardiovascular events were generally moderate‐to‐high quality. Statin therapy (generally at doses equivalent to 20 mg of simvastatin) reduced total serum cholesterol levels by 46 mg/dL (1.2 mmol/L) in adult dialysis patients, but had little or no effect on major cardiovascular events or mortality. Statins were found to have little or no effect on myocardial infarction and uncertain effects on the risk of stroke. Statins were also found to have uncertain effects on risks of liver dysfunction, muscle damage or cancer in people on dialysis; and toxicity data were limited by a lack of systematic reporting in half the studies. Few data were available for people treated with peritoneal dialysis. Direct head‐to‐head studies of different statin agents were rare and estimated effects of atorvastatin versus simvastatin were imprecise. </p> </section> <section id="CD004289-sec-0078"> <h3 class="title" id="CD004289-sec-0078">Overall completeness and applicability of evidence</h3> <p>Three large and well‐conducted studies provided moderate‐to‐high quality data that showed consistent effects of statins on cardiovascular events in people treated with dialysis (<a href="./references#CD004289-bbs2-0001" title="DrechslerC , KraneV , GrootendorstDC , RitzE , WinklerK , MarzW , et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrology Dialysis Transplantation2009;24(10):3151‐7. [MEDLINE: 19474272] DrechslerC , KraneV , RitzE , MarzW , WannerC . Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation2009;120(24):2421‐8. [MEDLINE: 19948978] DrechslerC , KraneV , WinklerK , DekkerFW , WannerC . Increasing adiponectin is associated with cardiovascular events and mortality in diabetic patients on hemodialysis [abstract]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):727A. KraneV , BergerM , LilienthalJ , WinklerK , SchambeckC , WannerC , et al. Antibodies to platelet factor 4‐heparin complex and outcome in hemodialysis patients with diabetes. Clinical Journal of The American Society of Nephrology: CJASN2010;5(5):874‐81. [MEDLINE: 20185595] KraneV , HeinrichF , MeesmannM , OlschewskiM , LilienthalJ , AngermannC , et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clinical Journal of The American Society of Nephrology: CJASN2009;4(2):394‐400. [MEDLINE: 19158371] KraneV , KrieterDH , OlschewskiM , MaerzW , MannJFE , RitzE , et al. Impact of dialyzer membrane characteristics on outcome in type 2 diabetic patients on maintenance hemodialysis: results of the 4D study [abstract]. Journal of the American Society of Nephrology2006;17(Abstracts):22A. KraneV , MaerzW , RufG , RitzE , WannerC . Atorvastatin in Type 2 diabetic patients on hemodialysis (4D‐study): baseline characteristics and 1st interim analysis [abstract]. Journal of the American Society of Nephrology2003;14(Nov):496A. KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. American Journal of Kidney Diseases2009;54(5):902‐11. [MEDLINE: 19781835] KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International2008;74(11):1461‐7. [MEDLINE: 18818679] MarzW , GenserB , DrechslerC , KraneV , GrammerTB , RitzE , et al. Atorvastatin and low‐density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN2011;6(6):1316‐25. [MEDLINE: 21493741] WannerC , KraneV , MarzW , OlschewskiM , AsmusHG , KramerW , et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney &amp; Blood Pressure Research2004;27(4):259‐66. [MEDLINE: 15316128] WannerC , KraneV , MärzW , OlschewskiM , MannJF , RufG , et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine2005;353(3):238‐48. [MEDLINE: 16034009] WannerC , KraneV , RufG , MarzW , RitzE . Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney International ‐ Supplement1999;56(Suppl 71):S222‐6. [MEDLINE: 10412782] ">4D Study 2004</a>; <a href="./references#CD004289-bbs2-0005" title="FellstromB , HoldaasH , JardineAG , RoseH , SchmiederR , WilpshaarW , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney &amp; Blood Pressure Research2007;30(5):314‐22. [MEDLINE: 17671394] FellstromB , HoldaasH , JardineAG , SchmiederRE , HolmeI , ZannadF . Normalisation of CRP and LDL‐C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:218a. FellstromB , JardineAG , HoldaasH , SchmiederR , GottlowM , JohnssonE , et al. Effect of rosuvastatin versus placebo on cardiovascular outcomes in patients with end‐stage renal disease on hemodialysis ‐ results of the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , ArmstrongJ , et al. A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events ‐ the AURORA study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):713. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , RoseH , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients ‐ Design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine2005;6:9. [EMBASE: 2005487466] FellstromBC , JardineAG , SchmiederRE , HoldaasH , BannisterK , BeutlerJ , et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine2009;360(14):1395‐407. [MEDLINE: 19332456] HoldaasH , FellstromB , HolmeI , SchmiederRE , ZannadF , JardineAG . Rosuvastatin and LDL cholesterol in diabetic patients receiving hemodialysis ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:12A. HoldaasH , HolmeI , SchmiederRE , JardineAG , ZannadF , NorbyGE , et al. Rosuvastatin in diabetic hemodialysis patients. Journal of the American Society of Nephrology2011;22(7):1335‐41. [MEDLINE: 21566054] HoldaasH , JardineAG , SchmiederR , GottlowM , JohnssonE , ZannadF , et al. Effect of rosuvastatin on cardiovascular outcomes in diabetic patients receiving hemodialysis ‐ results from the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. JardineAG , FellstromB , HoldaasH , GottlowM , JohnssonE , ZannadF , et al. Risk factors for cardiovascular events in patients receiving haemodialysis ‐ post hoc analyses of the AURORA study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. ">AURORA Study 2005</a>; <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a>). Mortality data were assessed as moderate quality because information from <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a> could not be included as these were not reported in the published study separately for dialysis patients and could not be obtained from the authors on request. </p> <p>The strengths of this review include consistent results for primary outcomes among studies (no evidence of heterogeneity), comprehensive systematic searching for eligible studies, rigid inclusion criteria for RCTs, and data extraction and analysis by two independent investigators. Furthermore, the possibility of publication bias was minimised by including both published and unpublished studies (such as abstracts from meetings), although we could not formally test for evidence of publication bias or small study effects due to the small numbers of available studies. </p> <p>Despite comprehensive inclusion of available studies, the current evidence for statins in people treated with dialysis has some significant limitations. Studies were generally small (median number of participants was 42) and, with the exception of three large well‐conducted studies (<a href="./references#CD004289-bbs2-0001" title="DrechslerC , KraneV , GrootendorstDC , RitzE , WinklerK , MarzW , et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrology Dialysis Transplantation2009;24(10):3151‐7. [MEDLINE: 19474272] DrechslerC , KraneV , RitzE , MarzW , WannerC . Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation2009;120(24):2421‐8. [MEDLINE: 19948978] DrechslerC , KraneV , WinklerK , DekkerFW , WannerC . Increasing adiponectin is associated with cardiovascular events and mortality in diabetic patients on hemodialysis [abstract]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):727A. KraneV , BergerM , LilienthalJ , WinklerK , SchambeckC , WannerC , et al. Antibodies to platelet factor 4‐heparin complex and outcome in hemodialysis patients with diabetes. Clinical Journal of The American Society of Nephrology: CJASN2010;5(5):874‐81. [MEDLINE: 20185595] KraneV , HeinrichF , MeesmannM , OlschewskiM , LilienthalJ , AngermannC , et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clinical Journal of The American Society of Nephrology: CJASN2009;4(2):394‐400. [MEDLINE: 19158371] KraneV , KrieterDH , OlschewskiM , MaerzW , MannJFE , RitzE , et al. Impact of dialyzer membrane characteristics on outcome in type 2 diabetic patients on maintenance hemodialysis: results of the 4D study [abstract]. Journal of the American Society of Nephrology2006;17(Abstracts):22A. KraneV , MaerzW , RufG , RitzE , WannerC . Atorvastatin in Type 2 diabetic patients on hemodialysis (4D‐study): baseline characteristics and 1st interim analysis [abstract]. Journal of the American Society of Nephrology2003;14(Nov):496A. KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. American Journal of Kidney Diseases2009;54(5):902‐11. [MEDLINE: 19781835] KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International2008;74(11):1461‐7. [MEDLINE: 18818679] MarzW , GenserB , DrechslerC , KraneV , GrammerTB , RitzE , et al. Atorvastatin and low‐density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN2011;6(6):1316‐25. [MEDLINE: 21493741] WannerC , KraneV , MarzW , OlschewskiM , AsmusHG , KramerW , et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney &amp; Blood Pressure Research2004;27(4):259‐66. [MEDLINE: 15316128] WannerC , KraneV , MärzW , OlschewskiM , MannJF , RufG , et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine2005;353(3):238‐48. [MEDLINE: 16034009] WannerC , KraneV , RufG , MarzW , RitzE . Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney International ‐ Supplement1999;56(Suppl 71):S222‐6. [MEDLINE: 10412782] ">4D Study 2004</a>; <a href="./references#CD004289-bbs2-0005" title="FellstromB , HoldaasH , JardineAG , RoseH , SchmiederR , WilpshaarW , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney &amp; Blood Pressure Research2007;30(5):314‐22. [MEDLINE: 17671394] FellstromB , HoldaasH , JardineAG , SchmiederRE , HolmeI , ZannadF . Normalisation of CRP and LDL‐C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:218a. FellstromB , JardineAG , HoldaasH , SchmiederR , GottlowM , JohnssonE , et al. Effect of rosuvastatin versus placebo on cardiovascular outcomes in patients with end‐stage renal disease on hemodialysis ‐ results of the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , ArmstrongJ , et al. A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events ‐ the AURORA study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):713. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , RoseH , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients ‐ Design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine2005;6:9. [EMBASE: 2005487466] FellstromBC , JardineAG , SchmiederRE , HoldaasH , BannisterK , BeutlerJ , et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine2009;360(14):1395‐407. [MEDLINE: 19332456] HoldaasH , FellstromB , HolmeI , SchmiederRE , ZannadF , JardineAG . Rosuvastatin and LDL cholesterol in diabetic patients receiving hemodialysis ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:12A. HoldaasH , HolmeI , SchmiederRE , JardineAG , ZannadF , NorbyGE , et al. Rosuvastatin in diabetic hemodialysis patients. Journal of the American Society of Nephrology2011;22(7):1335‐41. [MEDLINE: 21566054] HoldaasH , JardineAG , SchmiederR , GottlowM , JohnssonE , ZannadF , et al. Effect of rosuvastatin on cardiovascular outcomes in diabetic patients receiving hemodialysis ‐ results from the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. JardineAG , FellstromB , HoldaasH , GottlowM , JohnssonE , ZannadF , et al. Risk factors for cardiovascular events in patients receiving haemodialysis ‐ post hoc analyses of the AURORA study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. ">AURORA Study 2005</a>; <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a>), were assessed to be at high risk of bias. Studies were also generally of short duration (six months) and may not have been sufficiently powered to identify the effects of statins on clinical end points such as mortality (<a href="./references#CD004289-bbs2-0061" title="BrielM , SchwartzGG , ThompsonPL , deLemosJA , BlazingMA , vanEsGA , et al. Effects of early treatment with statins on short‐term clinical outcomes in acute coronary syndromes: a meta‐analysis of randomized controlled trials. JAMA2006;295(17):2046‐56. [MEDLINE: 16670413] ">Briel 2006</a>) (although the larger studies that dominated analyses provided outcome data for three to five years of treatment). </p> <p>Limited data were available for adverse events, which were not systematically captured in over half of the included studies, such that potential toxicities of statins in this population remain incompletely characterised. We were unable to determine whether treatment effects were different in people on peritoneal dialysis compared with those on haemodialysis. Eight studies enrolled both haemodialysis and peritoneal dialysis patients and only one presented separate outcome data for these two populations (<a href="./references#CD004289-bbs2-0015" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi HD 2002</a>‐<a href="./references#CD004289-bbs2-0016" title="SaltissiD , MorganC , RigbyRJ , WesthuyzenJ . Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases2002;39(2):283‐90. [MEDLINE: 11840368] WesthuyzenJ , SaltissiC , MorganC , RigbyRJ . Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]. Nephrology2002;7(Suppl 3):A38. ">Saltissi PD 2002</a>). In addition, the small number of available studies meant that we were unable to explore other sources of heterogeneity in the treatment effects among studies on serum cholesterol levels, although this was a secondary (and surrogate) outcome. We could not identify whether treatment effects differed between men and women. Furthermore, we were unable to analyse the relative benefits of primary versus secondary prevention of cardiovascular events in people on dialysis, because there were too few studies specifically designed to address this question. <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a> evaluated a combination of simvastatin and ezetimibe, but it remains unclear whether there was an important difference in treatment effects compared with a statin alone, although it is unlikely because treatment effects were consistent among all studies for major cardiovascular events irrespective of the treatment used. </p> <p>It was noteworthy that adverse mortality and cardiovascular events were not clearly prevented by statins in the dialysis population, despite clinically significant lowering of serum lipid levels. This finding is inconsistent with data from people with earlier stages of kidney disease not treated with dialysis, for which statins clearly reduce risks of death and major cardiovascular events (<a href="./references#CD004289-bbs2-0076" title="PalmerSC , NavaneethanSD , CraigJC , JohnsonDW , PerkovicV , HegbrantJ , et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews2013, Issue in press. ">Palmer 2013a</a>). It was possible that a lack of power in available studies for dialysis resulted in the small or no effects on all‐cause mortality and cardiovascular events, although the inclusion of nearly 2000 events in each analysis makes this unlikely. It has previously been suggested that the choice of endpoints for major cardiovascular events in <a href="./references#CD004289-bbs2-0005" title="FellstromB , HoldaasH , JardineAG , RoseH , SchmiederR , WilpshaarW , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney &amp; Blood Pressure Research2007;30(5):314‐22. [MEDLINE: 17671394] FellstromB , HoldaasH , JardineAG , SchmiederRE , HolmeI , ZannadF . Normalisation of CRP and LDL‐C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:218a. FellstromB , JardineAG , HoldaasH , SchmiederR , GottlowM , JohnssonE , et al. Effect of rosuvastatin versus placebo on cardiovascular outcomes in patients with end‐stage renal disease on hemodialysis ‐ results of the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , ArmstrongJ , et al. A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events ‐ the AURORA study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):713. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , RoseH , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients ‐ Design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine2005;6:9. [EMBASE: 2005487466] FellstromBC , JardineAG , SchmiederRE , HoldaasH , BannisterK , BeutlerJ , et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine2009;360(14):1395‐407. [MEDLINE: 19332456] HoldaasH , FellstromB , HolmeI , SchmiederRE , ZannadF , JardineAG . Rosuvastatin and LDL cholesterol in diabetic patients receiving hemodialysis ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:12A. HoldaasH , HolmeI , SchmiederRE , JardineAG , ZannadF , NorbyGE , et al. Rosuvastatin in diabetic hemodialysis patients. Journal of the American Society of Nephrology2011;22(7):1335‐41. [MEDLINE: 21566054] HoldaasH , JardineAG , SchmiederR , GottlowM , JohnssonE , ZannadF , et al. Effect of rosuvastatin on cardiovascular outcomes in diabetic patients receiving hemodialysis ‐ results from the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. JardineAG , FellstromB , HoldaasH , GottlowM , JohnssonE , ZannadF , et al. Risk factors for cardiovascular events in patients receiving haemodialysis ‐ post hoc analyses of the AURORA study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. ">AURORA Study 2005</a> and <a href="./references#CD004289-bbs2-0001" title="DrechslerC , KraneV , GrootendorstDC , RitzE , WinklerK , MarzW , et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrology Dialysis Transplantation2009;24(10):3151‐7. [MEDLINE: 19474272] DrechslerC , KraneV , RitzE , MarzW , WannerC . Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation2009;120(24):2421‐8. [MEDLINE: 19948978] DrechslerC , KraneV , WinklerK , DekkerFW , WannerC . Increasing adiponectin is associated with cardiovascular events and mortality in diabetic patients on hemodialysis [abstract]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):727A. KraneV , BergerM , LilienthalJ , WinklerK , SchambeckC , WannerC , et al. Antibodies to platelet factor 4‐heparin complex and outcome in hemodialysis patients with diabetes. Clinical Journal of The American Society of Nephrology: CJASN2010;5(5):874‐81. [MEDLINE: 20185595] KraneV , HeinrichF , MeesmannM , OlschewskiM , LilienthalJ , AngermannC , et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clinical Journal of The American Society of Nephrology: CJASN2009;4(2):394‐400. [MEDLINE: 19158371] KraneV , KrieterDH , OlschewskiM , MaerzW , MannJFE , RitzE , et al. Impact of dialyzer membrane characteristics on outcome in type 2 diabetic patients on maintenance hemodialysis: results of the 4D study [abstract]. Journal of the American Society of Nephrology2006;17(Abstracts):22A. KraneV , MaerzW , RufG , RitzE , WannerC . Atorvastatin in Type 2 diabetic patients on hemodialysis (4D‐study): baseline characteristics and 1st interim analysis [abstract]. Journal of the American Society of Nephrology2003;14(Nov):496A. KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. American Journal of Kidney Diseases2009;54(5):902‐11. [MEDLINE: 19781835] KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International2008;74(11):1461‐7. [MEDLINE: 18818679] MarzW , GenserB , DrechslerC , KraneV , GrammerTB , RitzE , et al. Atorvastatin and low‐density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN2011;6(6):1316‐25. [MEDLINE: 21493741] WannerC , KraneV , MarzW , OlschewskiM , AsmusHG , KramerW , et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney &amp; Blood Pressure Research2004;27(4):259‐66. [MEDLINE: 15316128] WannerC , KraneV , MärzW , OlschewskiM , MannJF , RufG , et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine2005;353(3):238‐48. [MEDLINE: 16034009] WannerC , KraneV , RufG , MarzW , RitzE . Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney International ‐ Supplement1999;56(Suppl 71):S222‐6. [MEDLINE: 10412782] ">4D Study 2004</a> (both showing no statistical effect on cardiovascular events) were a reason for negative studies of statins in dialysis, because definitions of endpoints included a smaller proportion of modifiable vascular events. While this is possible, even with the inclusion of <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a> (in which cardiovascular events were predominantly occlusive vascular outcomes including revascularisation procedures), statins had little or no effect on cardiovascular outcomes. Finally, data comparing a statin with another statin regimen (different drug or different dose) were sparse for people treated with dialysis. </p> </section> <section id="CD004289-sec-0079"> <h3 class="title" id="CD004289-sec-0079">Quality of the evidence</h3> <p>Overall, data evaluating the effects of statins on mortality and cardiovascular outcomes for dialysis patients is of moderate to high quality and suggests that additional studies are unlikely to change our confidence in the estimates of effect or our confidence in these results. The estimates of treatment effect for mortality, cardiovascular mortality and major cardiovascular events are derived from studies at generally low risks of bias, are consistent between studies, are precise, and are generalisable to dialysis populations outside the RCTs. Direct head‐to‐head data for different statin agents are sparse and inconclusive. </p> </section> <section id="CD004289-sec-0080"> <h3 class="title" id="CD004289-sec-0080">Potential biases in the review process</h3> <p>Although this review was conducted by two or more independent authors, used a comprehensive search of the literature designed by a specialist librarian that included grey literature, and examined all potentially relevant clinical outcomes, potential biases exist in the review process. </p> <p>We were unable to include data for people treated with dialysis from <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a> or <a href="./references#CD004289-bbs2-0019" title="HolmbergB , BrannstromM , BuchtB , CrougneauV , DimenyE , EkspongA , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):503‐10. [MEDLINE: 16303728] StegmayrBG , BrannstromM , BuchtS , DimenyE , EkspongA , GranrothB , et al. Safety and efficacy of atorvastatin in patients with impaired renal function [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna (Austria). 2001:134. StegmayrBG , BrännströmM , BuchtS , CrougneauV , DimenyE , EkspongA , et al. Low‐dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scandinavian Journal of Urology &amp; Nephrology2005;39(6):489‐97. [MEDLINE: 18161210] StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GoschJ , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):161A. StegmayrBG , NasstromBG , BrannstromM , BuchtS , DimenyE , GranrothB , et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):268A. ">Stegmayr 2005</a> for all‐cause and cardiovascular mortality because reported data combined results for dialysis with earlier stages of kidney disease not treated with dialysis; separate unpublished data for dialysis populations were not available. </p> <p>Many studies did not systematically report clinical outcomes: all but two either did not report or reported very few mortality events. Similarly, although meta‐analyses for mortality and cardiovascular events had no discernible heterogeneity, effects of statins on serum cholesterol levels were markedly different among studies. Subgroup analyses did not identify reasons for differences, including type of dialysis or baseline serum cholesterol. </p> <p>Adverse events and stroke data were limited by wider confidence intervals and treatment effects were uncertain. </p> </section> <section id="CD004289-sec-0081"> <h3 class="title" id="CD004289-sec-0081">Agreements and disagreements with other studies or reviews</h3> <p>This review analysed current evidence on statin therapy in adults treated with dialysis, updating evidence from its previous two iterations in 2004 and 2009 (<a href="./references#CD004289-bbs2-0084" title="NavaneethanSD , ShrivastavaR . HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD004289.pub2] ">Navaneethan 2004</a>; <a href="./references#CD004289-bbs2-0085" title="NavaneethanSD , NigwekarSU , PerkovicV , JohnsonDW , CraigJC , StrippoliGF . HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD004289.pub4] ">Navaneethan 2009a</a>). This update included 23 studies of statins versus placebo or no treatment in 8166 participants treated with dialysis and two head‐to‐head studies comparing two different statins. </p> <p>Data from <a href="./references#CD004289-bbs2-0005" title="FellstromB , HoldaasH , JardineAG , RoseH , SchmiederR , WilpshaarW , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney &amp; Blood Pressure Research2007;30(5):314‐22. [MEDLINE: 17671394] FellstromB , HoldaasH , JardineAG , SchmiederRE , HolmeI , ZannadF . Normalisation of CRP and LDL‐C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:218a. FellstromB , JardineAG , HoldaasH , SchmiederR , GottlowM , JohnssonE , et al. Effect of rosuvastatin versus placebo on cardiovascular outcomes in patients with end‐stage renal disease on hemodialysis ‐ results of the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , ArmstrongJ , et al. A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events ‐ the AURORA study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):713. FellstromB , ZannadF , SchmiederR , HoldaasH , JardineA , RoseH , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients ‐ Design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine2005;6:9. [EMBASE: 2005487466] FellstromBC , JardineAG , SchmiederRE , HoldaasH , BannisterK , BeutlerJ , et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine2009;360(14):1395‐407. [MEDLINE: 19332456] HoldaasH , FellstromB , HolmeI , SchmiederRE , ZannadF , JardineAG . Rosuvastatin and LDL cholesterol in diabetic patients receiving hemodialysis ‐ a posthoc analysis of the AURORA trial [abstract]. Journal of the American Society of Nephrology2010;21:12A. HoldaasH , HolmeI , SchmiederRE , JardineAG , ZannadF , NorbyGE , et al. Rosuvastatin in diabetic hemodialysis patients. Journal of the American Society of Nephrology2011;22(7):1335‐41. [MEDLINE: 21566054] HoldaasH , JardineAG , SchmiederR , GottlowM , JohnssonE , ZannadF , et al. Effect of rosuvastatin on cardiovascular outcomes in diabetic patients receiving hemodialysis ‐ results from the Aurora Study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. JardineAG , FellstromB , HoldaasH , GottlowM , JohnssonE , ZannadF , et al. Risk factors for cardiovascular events in patients receiving haemodialysis ‐ post hoc analyses of the AURORA study [abstract]. World Congress of Nephrology; 2009 May 22‐26; Milan (Italy). 2009. ">AURORA Study 2005</a> were included in analyses for mortality and major cardiovascular events, and data from <a href="./references#CD004289-bbs2-0017" title="Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/˜sharp/download_protocol_en_v5.pdf (accessed 23 July 2013). BaigentC , LandryM . Study of Heart and Renal Protection (SHARP). Kidney International ‐ Supplement2003;63(Suppl 84):S207‐10. [MEDLINE: 12694346] BaigentC , ReithC , EmbersonJ , WheelerDC , TomsonCR , WannerC , et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‐controlled trial. Lancet2011;377(9784):2181‐92. [MEDLINE: 21663949] SHARP Collaborative Group. SHARP: an international randomized placebo‐controlled trial of lipid‐lowering in chronic kidney disease. 1‐year safety and efficacy experience [abstract no: SU‐PO1044]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):817A. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‐density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal2010;160(5):785‐94. [MEDLINE: 21095263] ">SHARP Study 2010</a> informed analyses of major cardiovascular events. The effect estimates for statins on mortality and adverse events in this review were largely similar to our 2009 review (<a href="./references#CD004289-bbs2-0085" title="NavaneethanSD , NigwekarSU , PerkovicV , JohnsonDW , CraigJC , StrippoliGF . HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD004289.pub4] ">Navaneethan 2009a</a>), finding little or no effect from statins among people treated with dialysis. The possible benefit from statins on non‐fatal cardiovascular events in our 2009 review (which included one study of 1255 participants, <a href="./references#CD004289-bbs2-0001" title="DrechslerC , KraneV , GrootendorstDC , RitzE , WinklerK , MarzW , et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrology Dialysis Transplantation2009;24(10):3151‐7. [MEDLINE: 19474272] DrechslerC , KraneV , RitzE , MarzW , WannerC . Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation2009;120(24):2421‐8. [MEDLINE: 19948978] DrechslerC , KraneV , WinklerK , DekkerFW , WannerC . Increasing adiponectin is associated with cardiovascular events and mortality in diabetic patients on hemodialysis [abstract]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):727A. KraneV , BergerM , LilienthalJ , WinklerK , SchambeckC , WannerC , et al. Antibodies to platelet factor 4‐heparin complex and outcome in hemodialysis patients with diabetes. Clinical Journal of The American Society of Nephrology: CJASN2010;5(5):874‐81. [MEDLINE: 20185595] KraneV , HeinrichF , MeesmannM , OlschewskiM , LilienthalJ , AngermannC , et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clinical Journal of The American Society of Nephrology: CJASN2009;4(2):394‐400. [MEDLINE: 19158371] KraneV , KrieterDH , OlschewskiM , MaerzW , MannJFE , RitzE , et al. Impact of dialyzer membrane characteristics on outcome in type 2 diabetic patients on maintenance hemodialysis: results of the 4D study [abstract]. Journal of the American Society of Nephrology2006;17(Abstracts):22A. KraneV , MaerzW , RufG , RitzE , WannerC . Atorvastatin in Type 2 diabetic patients on hemodialysis (4D‐study): baseline characteristics and 1st interim analysis [abstract]. Journal of the American Society of Nephrology2003;14(Nov):496A. KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. American Journal of Kidney Diseases2009;54(5):902‐11. [MEDLINE: 19781835] KraneV , WinklerK , DrechslerC , LilienthalJ , MarzW , WannerC , et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International2008;74(11):1461‐7. [MEDLINE: 18818679] MarzW , GenserB , DrechslerC , KraneV , GrammerTB , RitzE , et al. Atorvastatin and low‐density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN2011;6(6):1316‐25. [MEDLINE: 21493741] WannerC , KraneV , MarzW , OlschewskiM , AsmusHG , KramerW , et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney &amp; Blood Pressure Research2004;27(4):259‐66. [MEDLINE: 15316128] WannerC , KraneV , MärzW , OlschewskiM , MannJF , RufG , et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine2005;353(3):238‐48. [MEDLINE: 16034009] WannerC , KraneV , RufG , MarzW , RitzE . Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney International ‐ Supplement1999;56(Suppl 71):S222‐6. [MEDLINE: 10412782] ">4D Study 2004</a>) was not confirmed following inclusion of three additional studies and more than 5000 participants. </p> <p>The finding that statins had little or no effect on mortality and cardiovascular outcomes in people treated with dialysis contrasts with a similar systematic review and meta‐analysis of studies in people with earlier stages of CKD (<a href="./references#CD004289-bbs2-0076" title="PalmerSC , NavaneethanSD , CraigJC , JohnsonDW , PerkovicV , HegbrantJ , et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews2013, Issue in press. ">Palmer 2013a</a>) and a prospective meta‐analysis of data of more general populations <a href="./references#CD004289-bbs2-0060" title="BaigentC , KeechA , KearneyPM , BlackwellL , BuckG , PollicinoC , et al. Efficacy and safety of cholesterol‐lowering treatment: prospective meta‐analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet2005;366(9493):1267‐78. [MEDLINE: 16214597] ">Baigent 2005</a>. Statin therapy in people with less severe kidney disease proportionally reduced major cardiovascular events by 25% (RR 0.72, 95% CI 0.66 to 0.79) and all‐cause mortality by 20% (RR 0.79, 95% CI 0.69 to 0.91) (<a href="./references#CD004289-bbs2-0076" title="PalmerSC , NavaneethanSD , CraigJC , JohnsonDW , PerkovicV , HegbrantJ , et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews2013, Issue in press. ">Palmer 2013a</a>), and similarly reduced vascular events (RR 0.79, 95% CI 0.77 to 0.81) and all‐cause mortality (RR 0.88, 95% CI 0.84 to 0.91) in people with or at risk of cardiovascular disease in the general population (<a href="./references#CD004289-bbs2-0060" title="BaigentC , KeechA , KearneyPM , BlackwellL , BuckG , PollicinoC , et al. Efficacy and safety of cholesterol‐lowering treatment: prospective meta‐analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet2005;366(9493):1267‐78. [MEDLINE: 16214597] ">Baigent 2005</a>). </p> <p>In a recent analysis using the current data we showed that treatment effects of statins on mortality and cardiovascular events differ significantly based on stage of kidney disease (data not shown; <a href="./references#CD004289-bbs2-0075" title="PalmerSC , CraigJC , NavaneethanSD , TonelliM , PellegriniF , StrippoliGF . Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta‐analysis. Annals of Internal Medicine2012;157(4):263‐75. [MEDLINE: 22910937] ">Palmer 2012</a>). Although it is unclear why, despite equivalent lowering of serum cholesterol, statins have less effect in people treated with dialysis, reasons may relate to the competing causes of cardiovascular morbidity (known and unknown) in people treated with dialysis that cannot be modified significantly by the lipid‐lowering or other pleiotropic effects of statins. </p> <p>The smaller risk reductions from statins on death and cardiovascular disease in people treated with dialysis may reflect the competing mechanisms of cardiovascular disease in dialysis patients for whom vascular disease is dominated by vascular calcification, cardiomyopathy, hyperkalaemia, and sudden death, which might be modified to a lesser extent by statin therapy (<a href="./references#CD004289-bbs2-0059" title="Australia , New Zealand Transplant Registry(ANZDATA) . The 32nd Annual Report 2009 Report ‐ Data to 2008. http://www.anzdata.org.au/v1/report_2009.html (accessed 24 July 2013). ">ANZDATA 2009</a>). We note that reductions in mortality were small in this meta‐analysis despite end of treatment LDL cholesterol lowering by 41 mg/dL (1.1 mmol/L) on average. This small relative effect of lipid‐lowering contrasts with a 12% risk reduction (95% CI 9% to 16%) for each 1 mmol/L reduction in LDL cholesterol in a meta‐analysis of studies in the general population (<a href="./references#CD004289-bbs2-0060" title="BaigentC , KeechA , KearneyPM , BlackwellL , BuckG , PollicinoC , et al. Efficacy and safety of cholesterol‐lowering treatment: prospective meta‐analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet2005;366(9493):1267‐78. [MEDLINE: 16214597] ">Baigent 2005</a>). However, because few studies in the current meta‐analysis provided data for both all‐cause mortality and end of treatment lipid levels, we could not be certain if larger reductions in cholesterol levels might reduce mortality to a greater extent in the dialysis population or whether more aggressive lipid‐lowering approaches can be safely achieved with statin therapy. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004289-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study selection flow diagram" data-id="CD004289-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study selection flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/full#CD004289-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004289-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD004289-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/full#CD004289-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004289-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD004289-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/full#CD004289-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004289-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo or no treatment, Outcome 1 Major cardiovascular events." data-id="CD004289-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo or no treatment, Outcome 1 Major cardiovascular events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#CD004289-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004289-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo or no treatment, Outcome 2 All‐cause mortality." data-id="CD004289-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo or no treatment, Outcome 2 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#CD004289-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004289-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo or no treatment, Outcome 3 Cardiovascular mortality." data-id="CD004289-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo or no treatment, Outcome 3 Cardiovascular mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#CD004289-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004289-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo or no treatment, Outcome 4 Fatal and non‐fatal myocardial infarction." data-id="CD004289-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo or no treatment, Outcome 4 Fatal and non‐fatal myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#CD004289-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004289-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo or no treatment, Outcome 5 Fatal and non‐fatal stroke." data-id="CD004289-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo or no treatment, Outcome 5 Fatal and non‐fatal stroke. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#CD004289-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004289-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo or no treatment, Outcome 6 Elevated creatine kinase." data-id="CD004289-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo or no treatment, Outcome 6 Elevated creatine kinase.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#CD004289-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004289-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo or no treatment, Outcome 7 Elevated liver function enzymes." data-id="CD004289-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo or no treatment, Outcome 7 Elevated liver function enzymes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#CD004289-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004289-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo or no treatment, Outcome 8 Withdrawal due to adverse events." data-id="CD004289-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo or no treatment, Outcome 8 Withdrawal due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#CD004289-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004289-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo or no treatment, Outcome 9 Cancer." data-id="CD004289-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo or no treatment, Outcome 9 Cancer.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#CD004289-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004289-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo or no treatment, Outcome 10 Total cholesterol." data-id="CD004289-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo or no treatment, Outcome 10 Total cholesterol.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#CD004289-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004289-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo or no treatment, Outcome 11 LDL cholesterol." data-id="CD004289-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo or no treatment, Outcome 11 LDL cholesterol.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#CD004289-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004289-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo or no treatment, Outcome 12 Triglycerides." data-id="CD004289-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo or no treatment, Outcome 12 Triglycerides.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#CD004289-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004289-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo or no treatment, Outcome 13 HDL cholesterol." data-id="CD004289-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo or no treatment, Outcome 13 HDL cholesterol.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#CD004289-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004289-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Statin versus another statin, Outcome 1 Elevated liver function enzymes." data-id="CD004289-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Statin versus another statin, Outcome 1 Elevated liver function enzymes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#CD004289-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004289-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Statin versus another statin, Outcome 2 Withdrawal due to adverse events." data-id="CD004289-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Statin versus another statin, Outcome 2 Withdrawal due to adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#CD004289-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004289-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Statin versus another statin, Outcome 3 Total cholesterol." data-id="CD004289-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Statin versus another statin, Outcome 3 Total cholesterol.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#CD004289-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004289-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Statin versus another statin, Outcome 4 LDL cholesterol." data-id="CD004289-fig-0020" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Statin versus another statin, Outcome 4 LDL cholesterol.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#CD004289-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004289-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Statin versus another statin, Outcome 5 Triglycerides." data-id="CD004289-fig-0021" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Statin versus another statin, Outcome 5 Triglycerides.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#CD004289-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004289-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/urn:x-wiley:14651858:media:CD004289:CD004289-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_t/tCD004289-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Statin versus another statin, Outcome 6 HDL cholesterol." data-id="CD004289-fig-0022" src="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Statin versus another statin, Outcome 6 HDL cholesterol.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#CD004289-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/media/CDSR/CD004289/image_n/nCD004289-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004289-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Statin versus placebo or no treatment for dialysis patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with chronic kidney disease </p> <p><b>Settings:</b> dialysis </p> <p><b>Intervention:</b> statin therapy </p> <p><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk/year/1000 treated</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk/year/1000 treated</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Statin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major cardiovascular events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000 (7 fewer)</b> <br/> (132 to 155) (18 fewer to 5 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> (0.88 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7804 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>192 per 1000 (8 fewer)</b> <br/> (176 to 208) (24 fewer to 8 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> (0.90 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4705 (13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕</p> <p><b>moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>94 per 1000 (6 fewer)</b> <br/> (82 to 105) (18 fewer to 5 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> (0.84 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4627 (13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕<br/> <b>moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Absolute approximate events rates of outcomes per year were derived from previously observational cohort studies. Absolute numbers of people on dialysis with cardiovascular or mortality events avoided or incurred per 1000 treated were estimated using these assumed risks together with the estimated relative risks and 95% confidence intervals (<a href="./references#CD004289-bbs2-0066" title="HerzogC A , MaJ Z , CollinsA J . Poor long‐term survival after acute myocardial infarction among patients on long‐term dialysis. New England Journal of Medicine1998;339(12):799‐805. [MEDLINE: 9738087] ">Herzog 1998</a>; <a href="./references#CD004289-bbs2-0079" title="TrivediH , XiangQ , KleinJ P . Risk factors for non‐fatal myocardial infarction and cardiac death in incident dialysis patients. Nephrology Dialysis Transplantation2009;24(1):258‐66. [MEDLINE: 18682489] ">Trivedi 2009</a>; <a href="./references#CD004289-bbs2-0081" title="WeinerD E , TabatabaiS , TighiouartH , ElsayedE , BansalN , GriffithJ , et al. Cardiovascular outcomes and all‐cause mortality: exploring the interaction between CKD and cardiovascular disease. American Journal of Kidney Diseases2006;48(3):392‐401. [MEDLINE: 16931212] ">Weiner 2006</a>; <a href="./references#CD004289-bbs2-0082" title="WetmoreJB , ShiremanTI . The ABCs of cardioprotection in dialysis patients: a systematic review. American Journal of Kidney Diseases2009;53(3):457‐66. [MEDLINE: 19022545] ">Wetmore 2009</a>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/full#CD004289-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004289-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Statin versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Major cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7084</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.90, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4627</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.84, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Fatal and non‐fatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4047</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.71, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Fatal and non‐fatal stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.96, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Elevated creatine kinase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3067</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.55, 2.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Elevated liver function enzymes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.41, 2.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1832</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.87, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.72, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Total cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐44.86 [‐55.19, ‐34.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 LDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐39.99 [‐52.46, ‐27.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Triglycerides <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1692</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐18.02 [‐31.00, ‐3.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 HDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [‐0.39, 5.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Statin versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#CD004289-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004289-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Statin versus another statin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Elevated liver function enzymes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Total cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 LDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Triglycerides <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 HDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Statin versus another statin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004289.pub5/references#CD004289-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004289.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD004289-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD004289-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004289-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD004289-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD004289-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD004289-note-0002">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004289\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004289\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004289\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004289\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004289\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004289\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004289\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004289\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004289\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004289\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004289\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004289\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004289\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004289\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004289\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004289\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004289\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004289\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=bzu3XIhG&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004289.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004289.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004289.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004289.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004289.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727599327"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004289.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727599331"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004289.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eafff8bcb936d',t:'MTc0MDcyNzU5OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 